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Abstract 
 
Carbon-nitrogen bond formation reaqctions are ubitquous throughout modern synthetic 
methods, although amide C-N bond forming reactions have only recently begun to be explored. 
A Pd-catalyzed amide coupling reaction was utilized in a facile synthesis of imidazo[4,5-
b]pyridines and -pyrazines. This reaction provides quick access to products with substitution at 
N1 and C2. A model system relevant to the natural product pentosidine has been demonstrated, 
as well as the total synthesis of the mutagen 1-Me-5-PhIP. This reaction was then further 
explored to utilize more readily available catalytic components and to increase the substrate and 
amide scope. 
The C2 amination of imidazo[4,5-b]pyridines was accomplished through C2 halogenation 
followed by substitution (SNAr) with functionalized primary and secondary amines. This 
regioselective sequence is operationally simple and provides an easy access to derivatives of 
protected imidazo[4,5-b]pyridines. 
 Pentosidine, a biologically important advanced glycation endproduct, has been accessed 
in a rapid, high-yielding manner. The synthesis was accomplished via a six-step sequence 
starting with 3-amino-2-chloropyridine and features a palladium-catalyzed tandem cross-
coupling/cyclization to construct the imidazo[4,5-b]pyridine core. 
 A copper catalyzed amidation of Boc protected 4-chloro-3-aminopyridine was 
accomplished to produce a number of aryl and heteroaryl 4-chloro-3-aminopyridines. These 
pyridines were used to synthesize regioselectively substituted imidazo[4,5-c]pyridines using a 
Pd-catalyzed amide coupling reaction. 
  
 A regioselective palladium-catalyzed amidation of polychlorinated 
aminopyridines was accomplished to provide chlorinated imidazo[4,5-b]pyridines. A preliminary 
optimization of these reaction conditions is described herein. 
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PREFACE 
This thesis has been adapted from the following published articles co-written by the author: 
 
“Synthesis of Imidazo[4,5-b]pyridines and  Imidazo[4,5-b]pyrazines by Palladium Catalyzed 
Amidation of 2-Chloro-3-amino-heterocycles” Rosenberg, A. J.; Zhao, J.; Clark, D. A.  Org. 
Lett. 2012, 14(7), 1764-1767. 
 
“Total Synthesis of Pentosidine” Rosenberg, A. J.; Clark, D. A. Org. Lett. 2012, 14(17), 4678-
461. 
 
“Synthesis of  2-amino-imidazo[4,5-b]pyridines” Rosenberg, A. J.; Williams, T. M.; Jordan, A.;  
Clark, D.A. Org. Biomol. Chem. 2013, 11(18), 3064-3072 
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1.0  INTRODUCTION 
Transition-metal catalyzed bond formation has revolutionalized organic synthesis and 
allows straightforward access to molecules that were previously either difficult or impossible to 
prepare. In 2010, the Noble prize in chemistry was awarded to Heck, Negishi, and Suzuki for 
their pioneering work in “palladium-catalyzed cross couplings in organic synthesis.”1 However, 
these reactions, while extremely powerful, all focus on carbon-carbon bond formation. Carbon-
nitrogen bond forming reactions have also been developed and widely used in organic synthesis 
almost since their inception; and have been widely reviewed.
2-6
 Palladium catalyzed C-N 
couplings have become an increasingly important tool in heterocycle synthesis.
7-9
 One facet of 
C-N cross-coupling reactions which have not been explored to as great a degree, is the use of 
more problematic coupling partners such as amides, sulfonamides, carbamates and ureas. These 
moieties present special challenges due to their poor nucleophilicily, potential for additional 
coordination to the metal catalyst, and potential deleterious side-reactions (homocoupling, 
reduction) under the reaction conditions. However, despite these difficulties cross-coupling 
conditions for these substrates have been developed and widely utilized. Some examples of 
palladium catalyzed amidation include the synthesis of Taranabant (3)
10
 (Scheme 1) and the 
preparation of new antibiotics.
11
 (Scheme 2)  
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Scheme 1: Pd-Catalyzed Amidation for Taranabant 
 
Scheme 2: Pd-Catalyzed Amidation of a Carbamate 
 
Metal catalyzed coupling reactions offer an attractive alternative to C-N bond formation 
due to the potential for high functional group tolerance, mild conditions, and minimization of 
side products.
12
 In 1906, Goldberg published the first aryl amidation conditions with a copper 
catalyst.
13
 This method required harsh conditions, with temperatures above 200 C, and provided 
moderate yields of the desired products.  At times, stoichiometric copper was required to effect 
these transformations.  From both a cost-efficiency and environmental standpoint, stoichiometric 
copper reduces the attractiveness of this method especially for industry and pharmaceutical 
applications.  In addition, the high temperature and long reaction times limited the utility of this 
method.  Schotten-Bauman conditions allow for the preparation of amides from acyl halides and 
amines in the presence of base.  While this is a straightforward and useful method to prepare 
amides, it is limited to simple substrates that are resistant to hydrolysis.
14
 Additionally, amides 
are often synthesized from amines and carboxylic acids, but these reactions require 
stoichiometric coupling reagents.
15
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As previously mentioned, amides present a special challenge when used as a coupling 
partner for palladium catalysis. Their poor nucleophilicity serves to create a slow ligand 
exchange (transmetallation step) step in the catalytic cycle, allowing for a number of other 
potential processes to occur. More problamatic is the potential for the formation of a κ-2 bound 
amide complex. (Figure 1) 
 
Figure 1: κ-2 Amidate 
 
In 1996, the Buchwald group published the first successful amidation reactions using aryl 
halides with tethered acetamide substrates.
16
 (Scheme 3).  This method required high catalyst 
loadings and was slower than the analogous amine reactions; however, high yields could be 
obtained using select substrates.  Optimal success was obtained when forming five-membered 
rings (4, 5); six-membered rings (6) could also be formed, albeit in low yield.  Of note, no 
detectable product formation was observed when seven-membered ring formation was 
attempted.  Efforts to apply these conditions to intermolecular coupling were unsuccessful.   
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Scheme 3: Intramolecular Amidation 
 
In 1999, Shakespeare et al. expanded palladium catalyzed amidation reactions to the 
more challenging intermolecular reaction.
17
 They obtained poor to excellent yields, with 
variations based upon the size of the lactam employed, as well as the electronics of the aryl 
halide. Unfortunately, they were unsuccessful in incorporating non-cyclic amides under these 
reaction conditions. (Scheme 4) 
 
Scheme 4: Shakespeare’s Amide Coupling 
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The Hartwig group applied a similar strategy to the formation of carbamates to form Boc-
protected aniline derivatives using P(t-Bu)3 and Pd2(dba)3.
18
 Using tri-tert-butylphosphine, they 
were able to consistently obtain good yields, while also incorporating aryl chlorides and electron-
rich aryl bromides. (Scheme 5) 
 
Scheme 5: Hartwig’s Palladium Catalyzed Amidation 
a
 2% Pd2(dba)3 and 8% P(t-Bu)3 used 
 
 The Buchwald group described the first general intermolecular amidation reactions 
between aryl halides and amides in 2000.  Utilizing the bidentate ligand Xantphos, the reaction 
demonstrated high functional group tolerance and good to excellent yields.
19
 Significantly, 
Buchwald and co-workers were able to utilize acyclic amides under these conditions. 
Aryl chlorides are more attractive for cross-coupling reactions, since they are the least 
expensive, most readily available, and most stable aryl halide or psudeohalide coupling partners.  
However, they have proved to be the most challenging substrates for cross coupling chemistry.
18, 
20, 21
 The difference in reactivity between various halides can be advantageous for selective 
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coupling.
22
 The Buchwald group also designed an effective ligand for the amidation of aryl 
chlorides based on several mechanistic observations.
23
 
Palladium catalyzed amidation has also been utilized as part of a two-step one-pot 
reaction sequence to synthesize heterocycles through dehydration onto the resulting N-
substituted amide. In 2008 Faul and co-workers reported the preparation of 4-quinolones using a 
palladium-catalyzed amidation on a 2’-bromoacetophenone, followed, by a subsequent Camps 
cyclization to give the resulting 4-quinolone.
24
 (Scheme 6) 
 
 
Scheme 6: Faul’s Synthesis of 4-Quinolones 
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2.0  SYNTHESIS OF IMIDAZO[4,5-B]PYRIDINES & PYRAZINES BY PALLADIUM 
CATALYZED AMIDATION OF 2-CHLORO-3-AMINO-HETEROCYCLES 
2.1 INTRODUCTION 
Efficient catalytic methods for the synthesis of imidazo[4,5-b]pyridines, especially those 
bearing N1 substitution, are in demand. Imidazo[4,5-b]pyridine derived structures are of growing 
interest due to their ability to function as biological mimics of the well-explored and highly 
developed benzimidazole core-structure.
25-27
 Imidazo[4,5-b]pyridine derived molecules possess 
diverse pharmacological properties,
28
 including anticancer,
29, 30
 antiviral
31, 32
 and other important 
biological activities.
33-40
 
 
 
Figure 2: Imidazopyridine Containing Structures 
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Despite the importance of these structures, imidazo[4,5-b]pyridines are difficult to 
prepare in a regioselective manner, especially with substitution at the N1-position. (Fig. 2)  
Alkylation of the unsubstituted imidazo[4,5-b]pyridine is remarkably unselective.  For example, 
with sodium hydride and benzylbromide a 1:3.6:1.6 (21:22:23) ratio of products has been 
observed.
41
 (Scheme 7) 
 
 
Scheme 7: Alkylation of Imidazo[4,5-b]pyridine 
 
 The same problem exists for benzimidazole, as regioisomers are generally observed 
when the aryl moiety is substituted.
42
  Thus, a practical and selective method for the formation of 
N1 substituted imidazo[4,5-b]pyridines was sought.  A modular route that could grant access to 
analogues with substitution of hydrogen, carbon, halogens, and heteroatoms at C2 was highly 
desirable.  
Many attempts have been made to address the challenges associated with the synthesis of 
imidazo[4,5-b]pyridines.  In 1994 Senanayake and co-workers reported a multi-step sequence 
utilizing 1,3-diketones, malonamamidine salts and carboxylic acids to give 2-alkyl substituted 
imidazo[4,5-b]pyridines, however, no substitution at N1 or N3 was reported.
43
 (Scheme 8)  Other 
methods usually require the use of expensive 2,3-diaminopyridines as a starting material and/or 
proceed in moderate yield.
42
 As such, we choose to explore a metal-catalyzed cross-coupling 
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route. This would allow greater product diversity and the use of the readily available and 
monetarily beneficial 2-chloro-3-aminopyridine. 
 
Scheme 8: Senanayake’s Approach 
 
Recently Buchwald
44
 and Ma
45
 independently developed complementary syntheses of 
imidazo[4,5-b]pyridines using 2-halo-3-acylaminopyridines and amines to give N3-substituted 
products, with alkyl substitution at C2. However, these approaches did not allow substitution at 
N1 or heteroatom substitution at C2.  Additionally, alkyl amines performed poorly in this 
reaction due to facile β-hydride elimination of the Pd(II) intermediates.44  Buchwald and Zheng 
subsequently demonstrated that benzimidazole formation tolerated alkylamines with copper 
catalysis.
46
 Ma’s approach similarly utilized proline-bound copper which produced N3-
substituted imidazo[4,5-b]pyridines.
45,47
 (Figure 3) 
Our interest in imidazo[4,5-b]pyridines originated from our work toward the total 
synthesis of pentosidine. (Figure 2) We desired an economical method to produce imidazo[4,5-
b]pyridines with an electron-donating group at the N1 position
48
 and an amine at the 2 position.  
Our approach is conceptually distinct from those of Buchwald and Ma as we couple a 
protected 2-chloro-3-aminopyridine with a primary amide, followed by subsequent in situ 
cyclization and dehydration to provide the imidazo[4,5-b]pyridine core in a single reaction 
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vessel.
9, 49
 (Figure 3) Protected 3-amino-2-chloropyridines are easily generated on a multigram 
scale by reductive amination of the chloro-aminopyridines.
50
 
 
Figure 3: Imidazo[4,5-b]pyridine Approaches 
 
We began our studies with known chloropyridine 24a.  This compound is highly 
crystalline and the product possessed the electron-withdrawing-group at N1 which we desired for 
the synthesis of pentosidine. 
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2.2 FIRST GENERATION CONDITIONS 
Initial efforts to couple pyridine 24a and formamide with standard phosphine ligands 
(Table 1, entries 1–5) did not show the desired reactivity, presumably due to κ2 coordination of 
the formamide to the palladium center.
51,52
  Next we explored ligands which have recently been 
shown to be effective in coupling aryl halides with amides.  Both Me4-tBu-XPhos
51
 (entry 8) and 
t-BuBrettPhos
53
 (entry 9) gave the desired product 25a in excellent yield and can be used 
interchangeably.  The Bippyphos ligand
54
 gave only moderate yield of 25a (entry 7). Control 
experiments indicated there was no reaction in the absence of palladium; the absence of ligand 
also afforded no product.  Additionally, no SNAr products were obtained in the absence of both 
palladium and ligand.  When taken together, these experiments lend evidence to a metal 
catalyzed cross-coupling mechanism operating under the reaction conditions (entries 10–12).  
Potassium phosphate base and tert-butanol solvent have been previously used for coupling 
amides and aryl halides;
51
 they performed well here, granting the desired products in ≤ 4 hours in 
all cases under the optimized conditions. (Entries 8 & 9) 
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Figure 4: Ligands 
 
 
entry Pd source ligand yield (%)b 
1 Pd2(dba)3·CHCl3 (+/-)BINAP NR 
2 Pd2(dba)3·CHCl3 XantPhos NR 
3 Pd2(dba)3·CHCl3 P(tBu)3HBF4 NR 
4 Pd2(dba)3·CHCl3 CatacXium A < 5% Conv 
5 Pd2(dba)3·CHCl3 RuPhos NR 
6 Pd2(dba)3·CHCl3 Brettphos 65% 
7 Pd2(dba)3·CHCl3 BippyPhos 59% 
8 Pd2(dba)3·CHCl3 L1 85-90% 
9 Pd2(dba)3·CHCl3 L2 86% 
10 Pd2(dba)3·CHCl3 - NR 
11 - L1 NR 
12 - - NR 
Table 1: Reaction Optimization
a
 
a Reaction Conditions: 24a (0.4 mmol), Pd (0.004 mmol, 1 mol %), ligand (0.02 mmol, 5 mol %), 2 mL t-BuOH (0.2 M), 110 °C, 
4 h. b Yields are of isolated products. 
 
With optimized reaction conditions in hand, we explored the reaction scope. As shown in 
Table 2 the reaction produces the desired imidazo[4,5-b]pyridines in good to excellent yields 
with substituted benzyl derivatives (entries 1–4).  Importantly, an aryl chloride (i.e. 2-
chlorobenzyl) was tolerated under the reaction conditions (entry 5).  Pyridine substitution was 
well tolerated at N1 despite pyridine’s known ability act as a ligand on palladium (entry 6).55, 56  
Alkyl substitution was also well tolerated and no β-hydride elimination was encountered in this 
  
13 
 
reaction (entries 7–12).  Excellent yields were obtained for both branched and unbranched alkyl 
groups.  Compatibility of chiral substitution at the 1-position was also demonstrated (entries 13 
& 14), and the products were isolated without racemization of either 25m or 25n.
57
 Chiral 
substrates 24m and 24n were prepared through known Buchwald-Hartwig coupling of  3-iodo-2-
chloropyridine with the desired amine.
58
 Both phenyl and 4-methoxyphenyl aryl substitution 
were well tolerated (entries 15 & 16).  Aryl substitution at N1 was installed by Chan-Lam 
coupling with the corresponding arylboronic acids.
59-61
 
 
 
entry R ligand yield (%)b product 
1 CH2(4-OMeC6H4)  24a L1 85 25a 
2 CH2Ph 24b L1 85 25b 
3 CH2(2,4-OMeC6H4) 24c L1 82 25c 
4 CH2(3-FC6H4) 24d L2 90 25d 
5 CH2(2-ClC6H4) 24e L2 51 25e 
6 CH2(2-Pyr) 24f L1 95 25f 
7 Cy 24g L2 90 25g 
8 i-Pr 24h L2 91 25h 
9 CH2C(CH3)3 24i L2 75 25i 
10 Cypc 24j L2 85 25j 
11 CH2(C6H11) 24k L2 84 25k 
12 CH3 24l L1 89 25l 
13 (R)-CH(CH3)Ph 24m L2 77 25m 
14 (S)-CH(CH3)Ph 24n L2 79 25n 
15 Ph 24o L2 90 25o 
16 4-OMeC6H4 24p L2 91 25p 
Table 2: Reaction Scope
a
 
a Reaction Conditions: 24 (0.4 mmol), Pd (0.004 mmol, 1 mol %), ligand (0.02 mmol, 5 mol %), 2 mL t-BuOH (0.2 M), 110 °C, 
4 h. b Yields are of isolated products. c Cyp = Cyclopentyl 
 
 
 
Although alkyl or aryl substitution at the 2 position of the imidazo[4,5-b]pyridine was not 
our primary objective, the reaction performs well when the formamide was exchanged for either 
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benzamide or acetamide to give the phenyl (30) and methyl (31) substituted products 
respectively. (Scheme 9) Other substituted amides such as cyclohexanecarboxamide coupled in 
89% but failed to undergo the dehydrative cyclization, while cinnamamide gave a 3:1 mixture of 
uncyclized to cyclized products in 92% yield.
62
 Substitution at both the 4 and 6 positions of the 
pyridine was well tolerated and afforded 32 and 33 in excellent yield. Pyrazines performed 
particularly well under the standard reaction conditions, the desired imidazo[4,5-b]pyrazines 34 
and 25 were isolated in excellent yield with the reaction taking place up to eight-fold faster. 
(Scheme 9) We ascribe the rate enhancement to faster oxidative addition with the electron-
deficient pyrazine moiety. Traditionally imidazo[4,5-b]pyrazines are prepared with a series of 
SNAr reactions and cyclization with a carboxcyclic acid deriviative.
63
 
 
 
Scheme 9: Reaction Scope
a,b 
a Reaction Conditions: Pyr (0.4 mmol), Pd (0.004 mmol, 1 mol%), ligand (0.02 mmol, 5 mol %), 2 mL t-BuOH (0.2 M), 110 °C, 
4 h. b Yields are of isolated products. c L2 was used. d L1 was used. e 2 h. f 0.5 h. 
 
One advantage of this method is that C2 can be easily functionalized.  The 2-position can 
be selectively deprotonated with LDA at low temperature, and subsequently quenched with 
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electrophiles.
64
 (Scheme 10, eq. 1) We choose iodine as an electrophile to demonstrate the 
potential of this reaction which produced 36 in 84% yield.  Further functionalization of 36 by 
SNAr with amines as the nucleophiles illustrates the utility of our methodology for the synthesis 
of pentosidine (eq. 2).
65, 66
 Alternatively, direct functionalization via Chichibabin amination
67, 68
 
was also performed to provide known mutagen 1-Me-5-PhIP 38
69
 from 33 in 95%. This route 
represents a short and high yielding synthesis of this naturally occurring N1 substituted 
imidazo[4,5-b]pyridine. 
 
Scheme 10: Product Functionalization 
 
In summary, we have developed a regioselective palladium catalyzed method for the 
synthesis of imidazo[4,5-b]pyridines and imidazo[4,5-b]pyrazines. The current protocol is 
completely selective, and offers a high yielding route to regioisomers that are difficult to obtain 
using established methods.  The present method is complementary to those developed by 
Buchwald
44
 and Ma,
45
 because N1 substituted isomers can now be obtained through metal 
catalyzed coupling.  
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2.3 SECOND GENERATION CONDITIONS 
Imidazopyridines are a class of structures commonly used for pharmaceuticals and other 
uses.
37-39, 43, 70-73
 One powerful method of preparing these structures is the palladium catalyzed 
coupling of an amide and a 3-amino-2-chloropyridine.
74
 (vida supra) This method of preparing 
imidazo[4,5-b]pyridines and their derivatives, while useful, did not achieve all of our goals for 
their preparation. The goals of new catalytic reaction development are many; however, some of 
the more important are: high yield, low catalyst loadings, and readily available starting materials, 
including, the catalyst and ligands.
75, 76
 In our quest to develop new reactions to produce 
imidazopyridines, we have achieved the first two objectives but the last remained elusive. Our 
previously published methodology to form imidazo[4,5-b]pyridines utilizes cheap and easily 
accessed 3-amino-2-chloropyridines, amides, with Pd2(dba)3·CHCl3 as our precatalyst of 
choice.
74
 However, the biaryl phosphine ligands used remained the limiting factor in scaling-up 
the reaction, creating logistical difficulties when this methodology was applied to the synthesis 
of pentosidine.
77
 While significant progress has been achieved in addressing this problem;
78, 79
 
we nevertheless desired alternate reaction conditions that could make use of more readily 
available components, while retaining the high yields, ease of operation, and low catalyst 
loadings. Additionally, we desired to expand the reaction scope with regard to substrates and 
amide coupling partners. 
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In our initial report, we screened various ligands and observed that only biaryl ligands 
showed acceptable reactivity.
74
 The non-proprietary ligand BippyPhos gave only a moderate 
yield; and the related 4-MeBippyPhos gave comparable yields to the biaryl ligands. However, 
the difficulty of preparing the 4-methylpyrazole, needed for the synthesis of the 4-MeBippyPhos, 
led us to explore other options. A survey of the literature revealed that Pd catalyzed C-N amide 
bond formation has been accomplished using Xantphos under in non-protic solvents.
19, 80-84
 
Further scrutiny of the literature revelaed an interesting trend, alcoholic solvents were best when 
ancillary ligands bearing a biarylphosphine motif were utilized; conversely, bidentate phosphine 
ligands required the use of aprotic solvents to have a positive outcome; with little to no 
conversion observed in alcoholic solvents.
9, 49, 51, 53, 74, 85
 A reexamination of the reaction revealed 
that XantPhos and DPEPhos in aprotic solvents produced the desired cyclization product 25a 
along with the reduced product 39. (Entries 1-5, Table 3) This was confirmed by independently 
synthesizing the reduced product from 3-aminopyridine. Since 39 was not observed utilizing the 
biaryl ligands in tert-butanol we screened solvents to determine what, if any, affect the solvent 
had on the ratio of 25a to 39. No reaction was observed using DMF or NMP (Entries 6 and 7); 
while the reaction in diglyme showed moderate conversion, with no reduction observed.  (Entries 
8 & 9) These results combined with our previous success using tert-butanol suggested a protic 
solvent was critical to avoid or minimize formation of pyridine 39.  However, based on our 
previous data protic solvents interfered with the active palladium/ligand complex when bidentate 
ligands were utilized. To overcome these difficulties, we examined mixed solvent systems using 
an aprotic solvent and tert-amyl alcohol (t-AmOH).
86, 87, 88
 The choice of alcohol was determined 
based on our previous results, and literature precedent demonstrating the effectiveness of a 
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binary solvent system.
54, 87, 89
 First, mixtures of toluene and t-AmOH were examined.  While 
excellent conversion was obtained in a 10:1 mixture, the reduced pyridine being the primary 
product. (Entries 10 & 11) Switching to the more polar 1,4-dioxane, which demonstrated 
promise as the sole solvent, we immediately observed positive a result. (Entries 12-14) In a 1:1 
solvent mixture, XantPhos showed little change from solely 1,4-dioxane in entry 3; DPEPhos in 
a 10:1 mixture also displayed little change from entry 4. However, using XantPhos in a 10:1 
solvent system we obtained a 93% yield in only six hours (Entry 14), as opposed to eighteen 
hours in solely 1,4-dioxane. (Entry 3) We also explored using BINAP under these solvent 
conditions, however after eighteen hours only 40% conversion was observed. (Entry 15) Other 
bidentate ligands, with bite angles similar to XantPhos (111°), such as dppb (99°) or dppf (96°) 
also proved inferior.
90
 (Entries 16 & 17) 
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Entry Ligand Solvent 
Yield 
(Reduced)b 
Cnv.b Rxn Time 
1 XantPhos t-BuOH NR - 18h 
2 XantPhos Toluene 22 (42) 79 18h 
3 XantPhos 1,4-Dioxane 83 (15) 100 18h 
4 DPEPhos 1,4-Dioxane 37 (46) 87 18h 
5 XantPhos DME 22 (31) 53 18h 
6 XantPhos DMF NR - 18h 
7 XantPhos NMP NR - 18h 
8 DPEPhos Diglyme 36 (0) 56 18h 
9 XantPhos Diglyme 33 (0) 51 18h 
10 XantPhos Toluene/t-AmOH (10:1) 11 (79) 100 6h 
11 XantPhos Toluene/t-AmOH (1:1) 13 (29) 42 6h 
12 XantPhos Dioxane/t-AmOH (1:1) 84 (0) 85 18h 
13 DPEPhos Dioxane/t-AmOH (10:1) 27 (35) 71 18h 
14 XantPhos Dioxane/t-AmOH (10:1) 93%
c 100 6h 
15 Rac-BINAP Dioxane/t-AmOH (10:1) 4 (36) 40 18h 
16 dppb Dioxane/t-AmOH (10:1) Trace (45) 48 18h 
17 dppf Dioxane/t-AmOH (10:1) 23 (19) 50 18h 
Table 3 Reaction Optimization
a
 
a Reaction Conditions: 24a (0.4 mmol), Pd2(dba)3·CHCl3 (0.004 mmol, 1 mol %), ligand (0.02 mmol, 5 mol %), formamide (0.6 
mmol), K3PO4 (0.6 mmol), solvent (0.2 M), 110 °C. 
bUsing mesitylene as an internal standard. cIsolated Yield. 
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With the ligand and solvent mixture chosen, we explored alternatives to tert-amyl alcohol 
as the co-solvent to determine the effect on the reaction. (Table 4) Water resulted in rapid 
consumption of 25a, however, soley the reduced pyridine 39 was observed. (Entry 2) Altering 
the co-solvent to methanol, provided some of desired imidazo[4,5-b]pyridine 25a, but at greatly 
reduced conversion. (Entry 3) Swiching to the more hindered isobutanol and isopropanol offered 
a higher degree of conversion. (Entries 4 & 5) Isobutanol gave a 30% yield of 25a with 20% 39; 
while isopropanol provided 69% of 25a, albeit at 78% conversion after 24h. Based upon these 
results, we posit that the reaction requires a sterically hindered protic co-solvent to give both 
high conversion of 24a and to provide a high yield of the desired 25a, while avoiding the 
formation of 39. 
 
 
Entry Co-Solvent Yield (Reduced)b Conversion of 24a (%)b 
1 t-AmOH 93 (0) 100 
2 H2O 0 (74) 100 
3 MeOH 13 (18) 31 
4 i-BuOH 30 (20) 84 
5 i-PrOH 69 (0) 78 
Table 4: Co-Solvent Screen
a 
a Reaction Conditions: 24a (0.4 mmol), Pd2(dba)3·CHCl3 (0.004 mmol, 1 mol %), ligand (0.02 mmol, 5 mol %), formamide (0.6 
mmol), K3PO4 (0.6 mmol), solvent (0.2 M), 110 °C, 24h. 
bUsing mesitylene as an internal standard. 
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Mechanisticially, we believe there are a number of pathways operating under the reaction 
conditions. Our mechanisitic proposal begins with oxidative insertion of the zero-valent 
palladium into the pyridine-chlorine bond of 24 to give palladium (II) species 40. (Scheme 11). 
Once this occurs, 40 can follow one of three distinct pathways, shown in scheme 12 as cycles A, 
B & C. Pathways A & C provide reduced pyridne 39, while pathway B provides the desired 
imidazo[4,5-b]pyridine 25. Since formamide is known to produce ammonium formate under 
aqueous conditions,
91, 92
 we believe that pathway A is responsible for the reduction of pyridine 
24a when water was employed as the co-solvent. This distinct pathway would explain why 39 
was the sole product when using water as a cosolvent. Formamide is also known to undergo 
dehydration to hygrogen cyanide and water, thereby providing a source of H2O for non-aqueous 
conditions. Alternatively, advantageous water would explain the formation of 39 in some cases. 
Pathways B & C, share the first step of ligand exchange to substitute the chlorine for 
formamide under base mediated conditions. Following this exchange, palladium (II) species can 
either undergo reductive-elimination to provide 42, or β-hydride elimination to provide 43 and 
isocyanate. While uncommon, this β-hydride elimination is precedented at temperatures similar 
to our reaction conditions.
93, 94
 Judging by the results of our optimization, there is a clear solvent 
effect for pathways B & C, although the exact mechanistic nature of this effect remains elusive. 
The ligand is also an important component, given the observed variation of 25 & 39 with 
alterations in the ancillary ligand. With conformationally constrained bulky ligands, such as the 
Buchwald ligands, the palladium may be unable to adopt the geometry for the β-hydride 
elimination process, thereby favoring pathway B. 
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In support of pathways A & C for the production of 25, no reduced product was observed 
when amides other than formamide are used; suggesting that the hydride is derived from 
formamide. An experiment that could be conducted to support this hypothesis would be to utilize 
formamide-1-d1, and observe if the deuterium is incorportated into the 2-position of 39. 
 
 
 
Scheme 11: Initiation & Ammonium Formation Production 
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Scheme 12: Mechanistic Hypothesis 
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With the new conditions in hand, we set out to explore the reaction scope. As 
shown in table 5, the new reaction conditions provided the desired imidazo[4,5-
b]pyridines in good to excellent yields with substituted benzylic derivatives. (Entries 1-
12) Electron-donating substituents (Entries 1-4) as well as halogenated substrates (Entries 
5 & 6) performed well, giving 81 - 94% yields. Notably, under our previous conditions 
utilzing biaryl ligands, the o-chlorobenzyl subtrate was selectively coupled, but the p-
chlorobenzyl system did not selectively couple. We observed multiple coupling events 
and a high degree of decomposition under previous conditions with the p-chlorobenzyl 
substrate. Under these modified conditions both the ortho and para chloro moities 
underwent clean cyclization giving 79 and 94% yield respectively. (Entries 7 & 8) 
Electron-neutral benzyl and biphenyl substrates were also well tolerated under the 
reaction conditions, and the chiral subtrate 25m showed no racemization in addition to 
giving excellent yield. (Entries 9-11) One major improvement over the previous 
conditions was that electron deficient groups were tolerated under these more selective 
conditions, with 24t giving a 95% yield, and the m-nitrobenzyl 24u giving 57%. (Entries 
12 & 13). Under the previously reported conditions, nitro groups proved deleterious 
giving decomposition and extremely poor yields. Aryl subsituents such as 24o gave 94% 
yield. (Entry 14) N-Alkyl substrates performed well; although the more sterically bulky 
cyclohexylmethyl 24k and cyclohexyl 24g gave moderate 77% and 63% yields, 
respectively, while isopropyl gave 91%. (Entries 15 – 18) 
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Entry R Yield (%)b Product 
1 CH2(4-OMeC6H4) 24a 93 25a 
2 CH2(2,4-OMeC6H3) 24c 81 25c 
3 CH2(2,5-OMeC6H3) 24q 85 25q 
4 CH2(4-Me2NC6H4) 24r 94 25r 
5 CH2(3-FC6H4) 24d 94 25d 
6 CH2(4-FC6H4) 24v 96 25v 
7 CH2(2-ClC6H4) 24e 79 25e 
8 CH2(4-ClC6H4) 24s 94 25s 
9 CH2(4-PhC6H4) 24w 70 25w 
10 CH2Ph 24b 85 25b 
11 (R)-CH(CH3)Ph 24m 96 25m 
12 CH2(4-CF3C6H4) 24t 95 25t 
13 CH2(3-NO2C6H4) 24u 57 25u 
14 Ph 24o 94 24o 
15 CH2(C6H11) 24k 77 25k 
16 Cy 24g 63 25g 
17 Cyp 24j 85 25j 
18 i-Pr 24h 91 25h 
Table 5: Substrate Scope
a
 
a Reaction Conditions: 24 (0.4 mmol), Pd2(dba)3·CHCl3 (0.004 mmol, 1 mol %), XantPhos (0.02 mmol, 5 mol %), formamide 
(0.6 mmol), K3PO4 (0.6 mmol), solvent (0.2 M), 110 °C, 6.5h. 
b Isolated Yields. 
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One of our goals for the improvement of the reaction was to broaden the scope of amide 
coupling partners. Under our previous conditions we were able to utilize only benzamide and 
acetamide gave the desired imidazo[4,5-b]pyridines in 65% and 60% respectively. Using the new 
protocol 30 and 31 were obtained 78%, and 83% respectively. Previously no reaction or 
incomplete conversion was observed with cyclohexanecarboxamide and trans-cinnamide; 
however, 44% of 47 and 97% of 48 was acheived. 2-Furanamide also performs well, providing 
46 in 97% yield. In contrast to the previously conditions, substitution at the four position of the 
pyridine slows the reaction, nevertheless, 32 was obtained in 70% yield. In agreement with our 
previous report, pyrazines performed well, giving 34 in 83% and 35 in 95% yield; again with 
reduced reaction times. 
 
 
Scheme 13: Substrate Scope II
a
 
a Reaction Conditions: Pyr (0.4 mmol), Pd2(dba)3·CHCl3 (0.004 mmol, 1 mol %), ligand (0.02 mmol, 5 mol %), Amide (0.6 
mmol), K3PO4 (0.6 mmol), solvent (0.2 M), 110 °C. 
b Isolated as a mixture of 47 and Cyclohexanecarboxamide 
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In summary, we have developed conditions for the regioselective palladium-catalyzed 
synthesis of imidazo[4,5-b]pyridines and imidazo[4,5-b]pyrazines using XantPhos as a ligand. 
Additionally these conditions allow for the regioselective coupling of multiple-chlorinated 
substrates as well as electron-poor aryl functionality including a nitro-group. We were also able 
to utilize an expanded amide coupling-partner scope which can grant access to a large selection 
of C2 substituted imidazo[4,5-b]pyridines. We are currently working to expand this methodology 
to regioselectively couple polychlorinated aminopyridines. 
  
29 
 
3.0  SYNTHESIS OF 2-AMINO-IMIDAZO[4,5-B]PYRIDINES 
3.1 INTRODUCTION 
Guanidine containing molecules such as 2-aminobenzimidazole derivatives are an important 
class of heterocyclic compounds (Fig. 1).
95, 96
 They have been utilized as organocatalysts for a 
variety of transformations including aldol
97
 and Michael addition reactions.
98
 These moieties also 
display a wide range of biological activities, most notably against multidrug-resistant bacteria.
99-
104
 
 
Figure 5: Biologically Active 2-Aminobenzimidazole/Azabenzimidazole 
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While the majority of these biological explorations have been carried out with 2-
aminobenzimidazoles, Cheng and co-workers reported in 2009 that altering this scaffold from a 
benzimidazole to an imidazo[4,5-b]pyridine (4-azabenzimidazole) brings about a significant 
increase in biological activity.
105
 Altering the benzene portion of benzimidazole by replacement 
with pyridine has profound effects on how these compounds interact with their environment. One 
of the more critical effects of this variation is increasing aqueous solubility, a major factor in 
determining how well a molecule can perform as a drug candidate.
106
 
 
Introduction of an amino moiety at C2 is well precedented for benzimidazoles with 
several principal strategies for functionalization (Scheme 14). The simplest strategy is a direct 
nucleophilic aromatic substitution (SNAr) of the corresponding halogenated benzimidazole.
107-110
 
Alternatively, the harsh conditions required for this transformation can in some cases be avoided 
through the use of palladium-catalyzed amination chemistry.
110-113
 Finally a C-H activation 
strategy has been employed using selected nitrogen coupling partners.
114-117
 However, 
application of these conditions to the corresponding imidazo[4,5-b]pyridine proved to be 
challenging.
77, 118
 
 
 
Scheme 14: Functionalization Strategies 
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The copper catalyzed C-H activation conditions previously employed with 
benzimidazoles proved to be completely ineffective with imidazo[4,5-b]pyridines;
114-117
 likely 
due to the strong coordination of N3 and N4 to copper.
119
 Furthermore, palladium catalyzed 
methods resulted in poor to moderate yields of the desired product.
77
 As shown in figure 6, 
imidazo[4,5-b]pyridines possess three electrophilic positions (HE) that are difficult to 
regioselectively functionalize; but only one acidic site (HA) which allows for selective 
derivatization.
120
 
 
 
Figure 6: Reactive Sites on an Imidazo[4,5-b]pyridine 
 Failure of the aforementioned methods led us to pursue a more robust nucleophilic 
aromatic substitution strategy for introducing amine functionality at the imidazo[4,5-b]pyridine 
C2 position.
121-123
 Chloroazoles were pursued as electrophiles because they have previously 
displayed superior reactivity compared to the corresponding iodoazoles.
77, 124, 125
 The 
chloroazoles were conveniently prepared by deprotonation using LDA and quenching the anion 
with hexachloroethane to provide the 2-chloroazoles.
126, 127
  This method allows for complete 
regioselective functionalization of the imidazo[4,5-b]pyridine and avoids the extremely harsh 
conditions and regioselectivity problems associated with the Chichibabin reaction or similar 
methodologies.
128, 129
  
 
  
32 
 
3.2 REACTION DEVELOPMENT 
Optimization of the reaction parameters was conducted with 2,4-dimethoxybenyl 
substrate (49a) which has previously prepared in multigram batches.
77
  A base screen was 
conducted with morpholine utilized as the nucleophile due to its availability, low volatility and 
known nucleophillicity. Inorganic bases such as sodium carbonate, sodium bicarbonate and 
potassium carbonate gave greater than 90% yields; sodium bases were found optimal giving 
yields of 97% (Table 1).  Potassium bicarbonate gave a slightly inferior yield of 79%, while the 
less basic sodium acetate afforded only 55% of 50a. Use of the soluble organic bases such as 
Hünigs base gave a moderate 73% yield 50a and incomplete conversion.
109, 118
 
 
 
Entry Base Yield (%)b Conversion (%)b 
1 Na2CO3 97 100 
2 NaHCO3 97 100 
3 K2CO3 90 100 
4 KHCO3 79 80 
5 NaOAc 55 95 
6 EtNi-Pr2 73 84 
Table 6: Base Screen
a 
a Reaction conditions: 49a (0.33 mmol), morpholine (0.40 mmol), Base (0.50 mmol), 0.66 mL n-BuOH, 120 °C, 16h b Using 
Mesitylene as an internal standard 
 
 
 
 
 
 
A solvent screen was conducted in an attempt to optimize the reaction time (Table 2). 
Alcoholic solvents performed well with n-butanol being optimal with a reaction time of 16 
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hours.  We found that lower boiling solvents (ethanol and isopropanol) were effective for the 
reaction giving greater than 90% yield of 50a, but required 36 hours to reach completion (entries 
2 and 3).  Changing to 2-methoxyethanol gave 84% yield of 50a.  Ethereal solvents such as 1,2-
dimethoxyethane (DME) and 1,4-dioxane gave 59% and 52% of 50a respectively, although the 
reaction was incomplete even after 36 hours. Attempting to avoid the use of an additional base, 
we explored pyridine as both the base and the solvent; however, this gave an inferior yield and a 
large amount of decomposition was observed.  
 
 
Entry Solvent Yield 
(%)b  
Reaction Time 
(h) 
Conversion 
(%)b 
1 n-BuOH 97 16 100 
2 EtOH 91 36 96 
3 i-PrOH 90 36 90 
4 2-Methoxyethanol  84 16 100 
5 DME 59 36 91 
6 1,4-Dioxane 52 36 90 
7 Pyridinec 45 16 100 
Table 7: Solvent Optimization
a 
 
a 49a (0.33 mmol), morpholine (0.40 mmol), Na2CO3 (0.50 mmol), 0.66 mL solvent
  b using Mesitylene as an internal 
standard. c Reaction run without Na2CO3 
 
 
 
  With the optimized conditions in hand we explored the scope of this reaction with regard 
to the amino nucleophile (Table 8). In addition to morpholine, secondary amines such as 
piperidine, N,N-diethylamine and N,N-methylbenzylamine gave excellent yields: 94%, 85%, and 
90% respectively (entries 2-4). Primary amines such as benzylamine (90%) and n-butylamine 
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(96%) also gave excellent yields (entries 5 and 6). As expected the reaction was sensitive to 
steric hindrance on the nucleophile.  The bulky isopropylamine (entry 7) required 36 hours to 
reach full conversion and gave a 92% yield of 50g; whereas tert-butylamine (entry 8) gave no 
conversion to 50h even with extended reaction times. These trends are similar to those found in 
the fluoride mediated
107
 and high-pressure SNAr reactions
109
 for the analogous benzimidazoles. 
When allyl amine was utilized, we obtained 50j in 72% yield and no isomerisation of the olefin 
was observed in the crude proton NMR (entry 10). Chiral amines could also be utilized as shown 
in entries 11 and 12.  No racemization was observed by chiral HPLC; although the increased 
steric environment on the nucleophile mandated a 24 hour reaction time for these substrates. 
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Entry Amine Yield (%) b Product 
1 
 
97 50a 
2 
 
94 50b 
3c 
 
85 50c 
4 
 
90 50d 
5 
 
90 50e 
6 
 
96 50f 
7c 
 
92 50g 
8 c 
 
NR 50h 
9 
 
51 50i 
10 
 
72 50j 
11d 
 
62 50k 
12d 
 
65 50l 
Table 8: Amine Scope 
a 
a Reaction conditions unless otherwise noted: 49a (0.33 mmol), amine (0.40 mmol), Na2CO3 (0.50 mmol), 0.66 mL n-BuOH, 120 
°C, 16h b Isolated yields c Reaction time: 36h. d Reaction time: 24h 
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The scope of N1 substitution on the azole was then explored to probe the effect on the 
SNAr reaction (Table 4). Altering the dimethoxybenzyl moiety to p-methoxybenzyl or benzyl 
gave 51 and 52 in 86% and 74% yield, respectively (entries 2 and 3).  Interestingly the p-
fluorobenzyl system also gave a 77% yield of 53, and no observable SNAr chemisty occured on 
the benzyl group (entry 4).
130
  Alkyl groups also performed well with cyclohexylmethyl (88%), 
isopropyl (79%), and neopentyl (62%) moieties giving the desired product in good to excellent 
yields (entries 5-7). The diminished yield of 56 is likely due to the close proximity of the 
neopentyl group to the reactive carbon which could impede formation of the tetrahedral 
Meisenheimer complex.  The N-phenyl group was also well tolerated under the reaction 
conditions giving 57 in 82% yield (entry 8). 
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Entry R Yield (%) b Product 
1 
 
97 50a 
2 
 
86 51 
3 
 
74 52 
4 
 
77 53 
5 
 
88 54 
6 
 
79 55 
7 
 
62 56 
8 
 
82 57 
Table 9: Azole Scope 
a 
a Reaction conditions unless otherwise noted: Azole (0.33 mmol), morpholine (0.40 mmol), Na2CO3 (0.50 mmol), 0.66 mL n-
BuOH, 120 °C, 16h. b Isolated yields. 
 
3.3 CONCLUSIONS 
In summary, we have developed a facile and selective method for the amination of 
imidazo[4,5-b]pyridines which affords substituted 2-amino-imidazo[4,5-b]pyridines.  This 
protocol is completely regioselective, procedurally simple, and provides rapid access to these 
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previously difficult to access moieties.  Using this protocol both primary and secondary amines 
can be used as nucleophiles.  2-Chloro-imidazo[4,5-b]pyridines substituted at N1 with aryl, 
alkyl, and benzyl groups could be utilized as electrophiles and afford 2-amino-imidazo[4,5-
b]pyridines.  This protocol grants access to these molecules for future applications. 
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4.0  TOTAL SYNTHESIS OF PENTOSIDINE 
4.1 BACKGROUND: 
Pentosidine (18) is an advanced glycation endproduct (AGE) containing an imidazo[4,5-
b]pyridine core that has attracted interest as a biochemical marker.
131
 It was discovered as an 
extracellular protein crosslink by Monnier in 1989, and is one of only a handful of characterized 
AGEs.
132
 Pentosidine is a naturally occuring biological fluorophore, and as such has found use in 
non-invasive diagnostics.  It has been reported as a chemical marker of diabetic complications, 
kidney dysfunction, oxidative stress, aging and age-related diseases.
133-140
 Recently, Veralight 
Inc. has begun marketing a device that utilizes the spectroscopic properties of AGEs to carry out 
a non-invasive method of detecting type II diabetes.
141-144
 Biosynthetically, pentosidine is 
believed to be a protein cross-link derived from a post-translational Maillard reaction of arginine 
and lysine residues with a pentose (ribose shown).
145
 (Schemes 15 & 16) 
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Scheme 15: Proposed Biosynthesis of Pentosidine I 
 
Scheme 16: Proposed Biosynthesis of Pentosidine II 
 
 There is also recent evidence that pentosidine is both a singlet oxygen sensitizer and an 
antioxidant.
146, 147
 Pentosidine is available commercially, however its low supply and 
corresponding high price make it difficult to study.
148
 Therefore, we sought to develop a 
straightforward route to pentosidine that would allow us to explore the properties of this 
molecule. 
From a synthetic point of view pentosidine (18) presents an interesting structural target. 
The imidazo[4,5-b]pyridine core has attracted casual interest in the literature, with few direct 
efforts at preparation.
41-43, 71, 74, 149-152
 The challenges inherent in this molecular architecture are 
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derived from the need to generate this moiety in a cost efficient and chemically straightforward 
manner. 
 
Figure 7: Pentosidine 
 
4.1.1 Previous Syntheses 
There have been three published syntheses of Pentosidine to date. The first was published 
in 1989 and is not a total-synthesis, but a one-step biomimetic synthesis.
132
 Sell and Monnier 
simply mixed the biological starting materials (arginine, lysine and ribose) while heating in an 
aqueous environment and purified the mixture via HPLC to give 0.02% yield of pentosidine. 
While this method of production has the advantage of utilizing very cheap starting materials, the 
yield and tedious purification, do not lend themselves to large scale production. Their synthesis 
does, however, help to support the proposed biological pathway to pentosidine.
145
 More recently 
Cravotto and co-workers have improved upon this method, increasing the yield to 8%.
153
 This 
was accomplished by using Nα-Boc protected amino acids in the presence of Ba(OH)2 in DMF; 
followed by TFA deprotection. However this route also required HPLC purification and the use 
of microwave technology makes this route impractical for large scale production.  
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The first total-synthesis of pentosidine was published by Shioiri and co-workers in 
1991
48, 154
 with 9 steps in the longest linear sequence giving a 15% yield, and 15 total steps. 
Utilizing a pinene derived chiral auxiliary 61 to create side-chain iodide 63 over 7 steps. 
(Scheme 17)  
 
Scheme 17: Preparation of Iodide 63 
The imidiazo[4,5-b]core core of the molecule was derived from 2,3-diaminopyridine (67) 
which is quite expensive (> $10/g). The first step of their synthesis was a selective trityl-
protection which proceeds in moderate yield, and was further elaborated onto the imidazo[4,5-
b]pyridine core using a guanylation with thioisocyanate 66 and cyclized using stoichiometric 
mercury (II) chloride giving imidazo[4,5-b]pyridine 70 in moderate yield. The synthesis was 
completed by regioselective alkylation of the nucleophillic pyridine nitrogen with iodide 63, and 
subsequent global deprotection to give pentosidine as its TFA salt. 
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Scheme 18: Shioiri’s Endgame 
 
More recently Sayre’s group published their approach and total-synthesis of 
pentosidine.
155, 156
 Their approach also starts from 2,3-diaminopyridine (67) to provide 
heterocycle 72 over 2 steps in excellent yield. (Scheme 19) 
 
 
Scheme 19: Preparation of Imidazo[4,5-b]pyridine 72 
 
Sayre derived the two chiral centers present in the natural product from their parent 
amino acids. Iodide 77 was synthesized from Nα-Cbz-Lysine by diazotization of the unprotected 
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amine, substitution with water and acidic hydrolysis of the Cbz group to give 74. The amino acid 
was protected using the Urech hydantoin synthesis
157
 and the terminal alcohol was subsequently 
converted into iodide 77 in two steps. Ornithine 79 was prepared by Nδ-Cbz-ornithine 78 in a 
similar fashion. (Scheme 20) 
 
 
Scheme 20: Sayre’s Side-Chain Synthesis 
 
The total synthesis was completed by alkylation of the pyridine nitrogen with iodide 77, 
chlorination of the sulfide, SNAr of the resulting choride with amine 79, and deprotection of the 
hydantoins under thermal acidic conditions in the presence of glycine. This produces the 
hydrochloride salt of pentosidine which was exchanged for the acetate during purification. This 
synthesis is a short seven linear steps with a yield of 5.7%. However, the low yield is misleading 
because only three steps are outside the longest linear sequence, all of which are high yielding; 
as opposed to Shioiri’s synthesis where multiple low yielding steps are not part of the longest 
linear sequence. 
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Scheme 21: Sayre’s Endgame 
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4.2 RETROSYNTHESIS: 
Retrosynthetically we envisioned disconnections at C2 and N4, leaving an imidazo[4,5-
b]pyridine core with an electron-donating protecting group at N1. This protection scheme is 
required so that N4 will be activated for selective alkylation. Without N1 or N3 blocked, a 
mixture of N1, N3 and N4 alkylation products is obtained.
41
 Additionally, Shioiri demonstrated 
that electron-withdrawing groups deactivated the imidazo[4,5-b]pyridine for alkylation at any 
position.
48
 These disconnections would allow the introduction of protected ornithine and lysine 
residues, thus avoiding asymmetric reactions and chiral auxiliaries by generating the 
stereocenters from the chiral pool. Utilizing a cross-coupling / cyclization strategy for the 
preparation of imidazo[4,5-b]pyridines allows use of 3-amino-2-chloropyridine as our starting 
material.
74
 (vida supra) Using this route, we would avoid using 2,3-diaminopyridine which is 
problematic to functionalize in a regioselective manner.
48, 154, 158
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Scheme 22: Retrosynthetic Analysis 
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4.3 FORWARD SYNTHESIS 
4.3.1 Core Synthesis 
Our synthesis commenced with commercially available amino-2-chloropyridine 84,
159
 
which was protected as its 2,4-dimethoxybenzyl (DMB) amine (24c) via a reductive amination.
50, 
158
 This protecting group was chosen carefully with three important requirements: 1) be electron-
donating, 2) easily removable, ideally under acidic conditions for a global deprotection, 3) 
installed in one-step from 3-amino-2-chloropyridine. The 2,4-dimethoxybenzyl group fulfils all 
of these requirements. As a benzyl group it was electron-donating, it can be deprotected by acid, 
and it can be installed using the previously demonstrated reductive amination methodology. 
(vida supra) We then applied our palladium-catalyzed amide coupling/cyclization methodology 
to generate the core imidazo[4,5-b]pyridine in a single operation.
74
 High yields have consistently 
been obtained for this reaction on 2.5 - 5 gram scale. Compound 25c was chlorinated at the 2-
position using hexachloroethane & LDA, giving chloro-azole 49a in 81% yield.
126
 This three-
step sequence rapidly assembles the activated imidazo[4,5-b]pyridine core in high yield on gram 
scale. (Scheme 23) 
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Scheme 23: Pentosidine Core Synthesis 
 
4.3.2 Side Chains 
Ornithine residue 83 was prepared in excellent yield from commercially available Boc-
Orn(Z)-OH, by esterification with an isourea followed by Cbz cleavage with Pd/C and H2. 
(Scheme 24) The lysine fragment can be prepared from Boc-Lys(H)-OH via alcohol 86 using the 
method of Adamczyk.
160
  Alcohol 86 was then transformed to the desired iodide under Appel 
conditions in 91% yield. This short, two step route avoids the seven step sequence pursued by 
Shioiri.  In addition the stereocenter was installed from commercially available lysine 85.
48, 154
 
 
 
Scheme 24: Side Chains 
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4.3.3 Functionalization of C2 
Functionalization of C2 with the ornithine side-chain 83 proved unexpectedly 
complicated. (Table 10) We first explored palladium catalyzed methods developed by 
Senanayake for the synthesis of the 2-aminobenzimidazole, Norastemizole.
110, 112
 Unfortunately, 
only low yields of the desired product 83 were obtained (entries 1-5). Having previously reported 
C2 functionalization using an SNAr reaction with an iodide analogous to 87, we returned to this 
for installation of the ornithine residue.
74
 Initial attempts proved unsatisfactory due to the 
propensity of ornithine 83 to cyclize and form δ-lactam 88 (entry 6).161 Switching to DMF as the 
solvent resulted in the dimethylamine adduct as the only isolable addition product (entry 7). The 
halide was modified from iodine to the more electronegative chlorine 49a to increase the 
reactivity of the azole for nucleophilic attack. Use of 49a combined with excess ornithine 83 led 
to formation of desired product 82 in 87% yield (entries 8 and 9).  Efforts to lower the 
equivalents of ornithine 83 using either fluoride
107
 or DABCO
162-164
 as nucleophilic catalysts did 
not improve the yield or selectivity (entries 10 and 11). Using this optimized procedure, we were 
able to synthesize >1g of 82 in a single campaign. 
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entry X conditionsc solvent yield (%) 82:88 
1 I A toluene 10 1:0 
2 I B t-
AmOH 
0 - 
3 Cl A toluene 13 1:0 
4 Cl B t-
AmOH 
39 1:1 
5 Cl B toluene 44 2:1 
6 I C EtOH 0 - 
7 I C DMF 0d - 
8a Cl D EtOH 31 2:1 
9a Cl D n-
BuOH 
87 1:0b 
10 Cl E TGME 0 - 
11 I F DMA 0 - 
Table 10: Orn Installation 
a2.0 Equivalents Orn. bAfter purification, 1:1 ratio prior to purification. cConditions A: 1.5 mol % Pd2(dba)3, 4.5 mol % 
BINAP, NaOt-Bu, reflux. Conditions B: 1.5 mol % Pd2(dba)3, 4.5 mol % BippyPhos, K3PO4, reflux. Conditions C: Na2CO3, 
reflux. Conditions D: EtN(iPr)2, reflux. Conditions E: KF, 2,6-lutidine, 120 °C. Conditions F: cat. DABCO, Na2CO3. 
dDimethylamine addition observed 
 
4.3.4 Endgame 
As aforementioned, electron-donating substituents installed at C2 and N1 activate N4 for 
alkylation. Iodide 63 and imidazo[4,5-b]pyridine 82 were refluxed in THF to provide iodide salt 
89, the fully protected pentosidine. Purification of pyridinium salts are known to be 
problematic;
165
 however, to our delight, 89 was purified using standard silica gel 
chromatography.
166
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Scheme 25: Installation of Lysine Side Chain 
 
With protected pentosidine in hand, all that remained was the deprotection of various 
protecting groups, including: N-Boc, tert-butyl ester, and the dimethoxybenzyl group. By design 
these groups were removed under acidic conditions, although the DMB group required a cation 
scavenger such as triethylsilane or H2O to intercept the resulting benzyl cation and prevent 
reversion to the protected starting material. Heating the reaction in 10:1 TFA / H2O for 48h 
proved to be the most effective protocol, allowing for a simple reverse-phase silica gel plug as 
purification to give the trifluoroaceate salt of the natural product in 91% yield. Following this 
protocol, pentosidine (18) was obtained as the TFA salt without the need for tedious HPLC 
purification.
167
  In our hands, we were able to prepare 112 mg of pentosidine in a single-
campaign over the six step sequence. 
 
 
Scheme 26: Global Deprotection 
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In summary, we accomplished a short, rapid total synthesis of pentosidine that utilizes a 
highly efficient synthesis of imidazo[4,5-b]pyridine 25c. Use of economical SNAr and alkylation 
chemistry allows for a scalable and reproducible synthetic route. This approach provides 
pentosidine with only six steps in the longest linear sequence (ten total steps) in 30.1% yield. The 
high efficiency of the synthesis, low-cost of the starting materials, and absence of toxic reagents 
makes this a practical method for research scale synthesis of pentosidine, thereby allowing 
further studies of this interesting natural product. 
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5.0  SYNTHESIS OF IMIDAZO[4,5-C]PYRIDINES 
The imidazo[4,5-c]pyridine scaffold is an important pharmacophore which has proven to 
be useful for a number of biologically relevant targets.
29, 168-176
 Previously these compounds have 
been prepared from the relevant diaminopyridines; however these compounds are difficult to 
obtain due to problematic regioselective functionalization.  
We recently published a new route for the preparation of imidazo[4,5-b]pyridines (IMPs), 
utilizing an amide cross-coupling strategy and starting from inexpensive and readily available 3-
amino-2-chloropyridine.
74
 This strategy also allows for the regioselective synthesis of the N1 
substituted IMPs with either alkyl or aryl substitution at the two position. Based upon the success 
of this approach, we explored the cooresponding 3-amino-4-chloropyridines for the formation of 
desirable imidazo[4,5-c]pyridines; this approach would provide access to these heterocycles that 
are difficult to access by other means.  
Unfortunately, although the 3-amino-2-chloropyridines, are easily functionalized by 
reductive amination
50
 and Chan-Lam techniques 
59, 60
, the corresponding 3-amino-4-
chloropyridine failed to provide the desired products under identical reaction conditions. Due to 
these unforseen difficulties, as well as the cost and availability of 3-amino-4-chloropyridine, we 
elected to investigate 3-aminopyridine as an entry to these systems. Of note, commercial 3-
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amino-4-chloropyridine rapidly decomposed under ambient storage conditions, yielding an 
unknown insoluble byproduct, even after purification. 
Functionalization of 3-aminopyridines at the 4 position is well known using directed 
metallation chemistry.
177-182
 (Scheme 27) While the majority of this work has been carried out 
using the pivaloyl amide, we elected to utilize the tert-butoxycarbamate (Boc) due to the ease of 
removal after the desired transformation. 
 
 
Scheme 27: Pivaloyl Directed Functionalizations 
 
Protection of 3-aminopyridine has traditionally been carried out under basic conditions, 
however, this leads to a mixture of the mono and bis Boc protected aminopyridine.
183
 To avoid 
this issue we elected to employ an alternative procedure utilizing only Boc anhydride in aqueous 
isopropanol, which gave 91 in 87% yield.
184
 The chloro substituent was installed using Kelly’s 
metallation protocol and utilizing hexachloroethane as the electophillic chlorine source.
126
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Scheme 28: Synthesis of 3-Bocaminio-4-chloropyridine 
With the desired 4-chloropyridine in hand, we focused on installing the desired 
functionality on the N3 nitrogen. Alkyl & benzyl moieities were installed from 92 with sodium 
hydride and the relevent alkyl or benzyl electrophile followed by removal of the Boc group with 
TFA to give compounds 94a – 94c. (Scheme 29) 
 
 
Scheme 29: Alkylations 
 
However, installation of aryl and heteroaryl functionality by this strategy would not be 
practical, and an alternative approach was explored. One possibility was to use a palladium 
catalyzed reaction, however, due to the aryl chloride present in our substrate we dismissed this 
strategy due to competitive coupling events. Copper-catalyzed couplings were examined to avoid 
these problems. Basic pyridines are known to interfere with these reactions, and pyridine itself is 
occasionally used as a ligand.
185
 However, despite these potential difficulties, we surmised 
copper-catalyzed conditions could be developed which would afford the desired products. 
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Entry Ligand Solvent 
Conversionb 
(%) 
Yieldb 
(%) 
1 DMEDA DMF 100 0 
2 DMEDA Tol 100 0 
3 DMEDA Dioxane 79 43 
4 EDA Dioxane 71 59 
5 L1 Tol 70 65 
6 L1 Dioxane 100 96c 
7 L2 Dioxane 72 trace 
8d L1 Dioxane 100 65 
9e L1 Dioxane 77 74 
10f L1 Dioxane 19 19 
Table 11: Copper Catalyzed Amidation Optimization 
a Reaction Conditions: 10 mol% CuI, 20 mol% Ligand, 2 Eq. Base, 0.5 M. b Using mesitylene as an internal standard  c 
Isolated yield d 20 mol% CuI, 40 mol% Ligand e Cs2CO3 used as the base 
f K2CO3 used as the base. DMEDA = N,N’-
Dimethylethylenediamine. EDA = Ethylenediamine. L1= (+/-) trans-1,2-Diaminocyclohexane. L2 = (+/-) N,N’-Dimethyl-1,2-
diaminocyclohexane.  
 
Figure 8: Diamine Ligands 
 
Exploration of this reaction commensed with copper (I) iodide and diamine ligands 
commonly used for copper-catalyzed amidation.
186-189
 (Table 11) No activity was observed using 
N,N’-Dimethylethylenediamine (DMEDA) in either DMF or toluene; 79% conversion and  43% 
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yield was obtained in 1,4-dioxane. (Entries 1-3) Ethylenediamine (EDA), a more unencumbered 
ligand, gave 71% conversion and an increased 59% yield. (Entry 4) The more rigid trans-1,2-
diaminocyclohexane gave similar moderate results when the reaction was carried out in toluene, 
when 1,4-dioxane was utilized complete conversion and 96%  isolated yield was obtained. 
(Entries 5 & 6) The more electron-rich N,N’-dimethyl analog L2 gave moderate conversion 
(72%) but only trace product. This result supports Buchwald’s hypothesis that the coupling of 
sterically bulky secondary amides are aided by unencumbered diamine ligands.
187, 188
 (Entry 7) 
Attempts to further improve the coupling to shorten the reaction time, and further improve the 
yield by changing the base or increasing the catalyst loading were unsuccessful. (Entries 8-10) 
 
 
Entry ArX 
Yield of 
Amidationb 
(%) 
Yield of 
Deprotectionb 
(%) 
 
 
 
 
1 
2 
 
 R = H 
 R = Me 
 
 
 
 
96 
76 
 
 
 
 
97 
92 
 
 
 
 
 
3 d 
4 d 
5 d 
6 d 
 
  
 R = OMe 
 R = C(O)Me 
 R = CN 
 R = CF3 
 
 
 
 
 
30 
90 
84 
79 
 
 
 
 
 
83 
89 
71 
89 
7 
 
97 96 
8 
 
- 54c 
9 
 
- 58c 
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Table 12: Copper-Catalyzed Amidation Scope
a 
a Reaction Conditions: 1) 10 mol% CuI, 20 mol% L1, 2 Eq. K3PO4, 1,4-Dioxane (0.5 M); 2) 25% TFA in CH2Cl2 . 
b Isolated 
Yield c Over two steps. d Reaction Performed by Robert Wilson 
 
 
Figure 9: Diamine Ligands 
 
With amidation conditions in hand, we explored the substrate scope of this reaction. 
(Table 12) As shown previously, iodobenzene performed in excellent 96% yield, intermiediate 
95h was deprotected under acidic conditions to provide 94h in 97% yield. (Entry 1) 4-
Iodotoluene gave 76% and 92% respectively for the amidation and deprotection sequence. (Entry 
2) Aryl bromides were also effective under the reaction conditions. Electron-rich 4-
bromoanisole, gave only 30% yield for the amidation. (Entry 3) Electron-poor aryl bromides 
bromoacetophenone, benzonitrile and benzotrifluoride all gave good to excellent yields. (Entries 
4-6) Both five and six-membered heterocycles undergo amidation under the optimized 
conditions, with 2-bromopyridine giving an excellent 97% yield. (Entry 7) 2-Bromothiophene 
and 3-bromothiophene coupled effectively, although full conversion was not observed, thus the 
mixture was subjected to deprotection conditions and the yield was obtained over the two step 
sequence. (Entries 8 & 9) 
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Entry Ligand Conversion (%)b Yield(%)b 
1 Me3(OMe)t-BuXPhos 100 90
c 
2 cBRIDP 100 81 
3 BippyPhos 100 87 
4
d
 TrippyPhos 10 trace 
5
d
 RuPhos 15 0 
6
e
 (t-Bu3PH)BF4 17 0 
7
e
 (Cy3PH)BF4 18 0 
8
e
 XantPhos 17 0 
Table 13: Pd-Catalyzed Cyclization Optimization
a 
a Reaction Conditions: 94h, Pd (1 mol %), ligand ( 5 mol %), 1.5 eq. Formamide, 0.2 M t-BuOH, 110 °C, 4 h. b Using mesitylene 
as an internal standard. c Isolated yield. d Reaction carried out by Robert Wilson. e Reaction carried out by Lauren Kaminsky. 
 
With ample amounts of the desired 3-amino-4-chloropyridine substrates, we moved onto 
the dehydrative cyclization chemistry. (Table 13) Utilizing 3-phenylamino-4-chloropyridine 
(94h) as a test substrate under conditions analogous to those used for the 3-amino-2-
chloropyridines.
74
 The newly developed Me3(OMe)t-BuXPhos
78
 ligand was utilized in place of 
previously employed Me4t-BuXPhos or t-BuBrettPhos ligands, due to availability. This ligand 
performed well in the amidation / cyclization sequence, giving the desired imidazo[4,5-
c]pyridine in 90% yield.  The cBRIDP
190
 ligand developed by Takasago and Singer’s 
BippyPhos
54
 also gave complete conversion to the desired imidazo[4,5-c]pyridine 96h, with 
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slightly reduced yields. TrippyPhos
89
 gave only trace product, while RuPhos, tri-tert-
butylphosphine, tricyclohexylphosphine, and XantPhos all displayed no reactivity. 
 
 
Entry R 
Yield 
(%)b 
Product 
1 
CH2(C6H5) 94a 84 96a 
2 
CH2(2,5-OMe-C6H3) 94b 85 96b 
3d 
CH2(3,5-OMe-C6H3) 94c 52 96c 
4 c 
CH2(4-F-C6H4) 94d 75 96d 
5c 
CH2(4-Ph-C6H4) 94e 75 96e 
6c 
Me 94f 58 
96f 
7 
n-Pr 94g 85 
96g 
8 
Ph 94h 
90 96h 
9c 
4-OMePh 94i 
80 96i 
10c 
4-MePh  94j 
89 96j 
11c 
4-CF3Ph 94k 91 96k 
12c 
4-C(O)Me 94l 
87 96l 
Table 14: Imidazo[4,5-c]pyridine Reaction Scope 
a Reaction Conditions: 94 , Pd (1 mol %), ligand ( 5 mol %), 1.5 eq. Formamide, 0.2 M t-BuOH, 110 °C, 4 h. b Isolated yield. 
cReaction carried out by Robert Wilson. d Reaction carried out by Lauren Kaminsky. 
 
With the reaction optimization complete, attention was turned to examining the reaction 
scope. As shown in table 14, the reaction provided the desired imidazo[4,5-c]pyridines in 
moderate to excellent yields. Benzyl derivitives performed well; with electron-donating, 
electron-withdrawing, arly and fluorine substitution tolerated under the reaction conditions. 
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(Entries 1-5) Methyl and n-propyl substitution performed well giving 58% and 85% yields 
respectively. (Entries 6 & 7) The aryl substituted derivatives provided the cyclized products in 
excellent 80 – 91% yields, with both electron-poor and electron-rich aryl systems performing 
admirably. (Entries 8 -12)  
 In summary, we have developed copper-catalyzed conditions for the amidation of 3-
NBoc-4-chloropyridine with aryl and heteroaryl halides to provide monoarylated 3-amino-4-
chloropyridines after subsequent deprotection. This methodology, does not react with chloro 
functionality on the pyridine leaving it available for subsequent reactions, such as our palladium 
catalyzed amidation / cyclization methodology to produce imidazo[4,5-c]pyridines. 
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6.0  REGIOSELECTIVE AMIDATION OF POLYCHLORINATED 
AMINOPYRIDINES 
Polysubstituted pyridines and pyridine derivatives are found in many natural products, 
pharmaceutical motifs as well as other useful systems.
191-194
 Palladium catalyzed cross-coupling 
using polyhalogenated pyridines would provide a straightforward entry into these valuable 
systems, provided it could be done regioselectively. Previously, we have successfully carried out 
a Suzuki coupling at the six position 3-Boc(methyl)amino-6-bromo-2-chloropyridine, and there 
have been many reported examples of chemoselective reactions.
58, 195, 196
  Some progress on this 
front has been reported recently in the literature, with Yang and co-workers using an amide as a 
directing group for a palladium catalyzed Suzuki coupling.
197
 (Scheme 30, eq. 1) Yang obtained 
poor to moderate yields with regioselectivities ranging from 4:1 to 15:1. More recently, Langer 
and co-workers have published the regioselective Suzuki coupling of 2,6-dichloro-3-
trifluoromethylpyridine with a sub-stoichiometric amount of boronic acid; obtaining complete 
regioselectivity and good to excellent yields.
198
 (Scheme 30, eq. 2) 
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Scheme 30: Directed Suzuki Couplings 
 
Another attempt at a regioselective palladium catalyzed Suzuki coupling of a 2,6-
dichloro-3-nitropyridine utilized a ligand based approach.
199
 However, although preference for 
the two-position was observed, the major product observed was the bis-arylated product when 
two equivalents of the boronic acid was used. When only one equivalent of the boronic acid was 
utilized, the preference for the C2 coupled product was pronounced, with up to a 73% yield of 
98, although C6 and bis-coupled products were also observed. 
 
 
Scheme 31: Suzuki Coupling of 2,6-Dichloro-3-nitropyridine 
 
Previously, we had observed regioselective Buchwald-Hartwig amidation under our 
newly developed XantPhos conditions with 2-chloro-N-(4-chlorobenzyl)pyridin-3-amine (24s). 
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(vida supra). One of our objectivies in our reexamination of imidazopyridines synthesis was to 
utilize polychlorinated pyridines, providing the desired imidazopyridines with additional 
functional handles. To our delight when 101 & 102 were subjected to the reaction conditions we 
observed a regioselective coupling event. As illustrated in scheme 32, the 3-amino-2,5-
dichloropyridine 101 was selectively coupled to give 103 in excellent yield. The corresponding 
2,6-dichloro species also was selectively coupled, giving 104 in 72% yield. 
 
 
Scheme 32: Regioselective Amidation 
 
The selectivity in the 2,5-dichloropyridine, easily rationalized by examining bond-
dissociation energies (BDEs).
200
 The two-position has a 2.8 kcal/mol lower BDE than the five-
position. Other methods of determining which halogen will react first have been developed, but 
all reinforce the reactivity of the two-position over the five-position.
201, 202
 Choice of ligand and 
solvent have also been shown to effect which site reacts first in other systems.
195, 196, 203
 
While the 2,5-dichloro system performs well, the corresponding 2,6-dichloropyridine 
fails to react completely under the conditions. We observed no products arising from a coupling 
event at the six-position, however the reaction only proceeded to 75% conversion. Calculations 
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indicate that the BDE difference between the two and six positions is minimal, with the six 
position favored by 0.2 kcal / mol. This suggests that the regioselective coupling could be 
directed by the amino functionality, transforming a functional group that normally interferes with 
reactivity to a directing group.
204
 
 
 
Figure 10 : BDE Calculations 
(Calculations conducted by Tom Juliano, Korter Group, Syracuse University) 
 
We then proceded to perturb the conditions in an effort to improve the efficiency of the 
reaction, while maintaining the high degree of regioselectivity. (Table 15) Increasing the catalyst 
and ligand loading proved detrimental to the reaction. (Entry 3) Increased reaction time did not 
substantially improve the yield. (Entry 4) In an effort to improve the solubility of the base, and 
before we discovered that the byproduct was reduction of the chloropyridine, we added water to 
the reaction; although this produced what we believe is 5-amino-2-chloropyridine. (Entries 5-7) 
Altering the ligand proved to be quite detrimental to the reaction, giving reduced conversion and 
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an increased amount of the reduced product. (Entries 8 – 14). However, the closely related 
DPEPhos gave complete conversion, prompting a further exploration with both XantPhos and 
DPEPhos. (Entry 15) Altering the solvent mixture ratio allowed for complete conversion with 
both XantPhos and DPEPhos, although the result was an increase in the reduced product’s yield. 
(Entries 16 -20) Changing the base also proved ineffectual. (Entries 21 – 23)  
 
 
Entry Ligand Base Rxn. Time Conversion (%)
h
 Yield (Reduced) (%)
h
 
1 XantPhos K3PO4 6.5 h 75 72
i
 
2 XantPhos K3PO4 8 h 80 74
i
 
3
a
 XantPhos K3PO4 7 h 57 49 
4 XantPhos K3PO4 22 h 83 76 
5
b
 XantPhos K3PO4 6 h 100 52 (43) 
6
c
 XantPhos K3PO4 18 h 100 45 (47) 
7
d
 XantPhos K3PO4 18 h 100 34 (36) 
8 dppf K3PO4 18 h 67 34 (24) 
9 dppb K3PO4 18 h 44 Trace (44) 
10 (t-Bu)3PHBF4 K3PO4 18 h 7 0 (Trace) 
11 Cy3PHBF4 K3PO4 18 h 13 0 (13) 
12 dppm K3PO4 18 h 25 0 (25) 
13 dppe K3PO4 18 h 40 0 (40) 
14 Rac-BINAP K3PO4 18 h 25 12 (Trace) 
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15 DPEPhos K3PO4 18 h 100 58 (24) 
16
e
 DPEPhos K3PO4 7 h 100 73 (22) 
17
f
 DPEPhos K3PO4 7 h 100 78 (21) 
18
g
 DPEPhos K3PO4 7 h 100 63 (25) 
19
f
 XantPhos K3PO4 7 h 80 52 (34) 
20
g
 XantPhos K3PO4 7 h 53 40 (12) 
21 XantPhos NaOt-Bu 18 h 100 29 (24) 
22 XantPhos Cs2CO3 7 h 100 72 (23) 
Table 15: Dichloropyridine Reaction Optimization 
a 
2% Pd2(dba)3·CHCl3, 10% ligand. 
b
 5 Eq. H2O. 
c
 1 Eq. H2O. 
d
 0.5 Eq. H2O. 
e
 Run in 4:1 (Dioxane:t-
AmOH). 
f
 2:1 
g
 1:1. 
h
 Using mesitylene as an internal standard.  
i
Isolated Yield, Unknown Yield of Reduced Product 
 
In summary, we have discovered reaction conditions for the regioselective amidation of 
polychlorinated aminopyridines to provide the chlorinated imidazo[4,5-b]pyridines. Further 
exploration of the reaction conditions and substrate will be carried out to improve this reaction 
by minimizing the formation of the reduced byproducts and increasing the yield. Additional 
explorations will also determine the substrate scope of this reaction. 
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7.0  APPENDEX I: EXPERIMENTALS 
7.1 GENERAL EXPERIMENTAL 
GENERAL PROCEDURES: Unless otherwise indicated, all reactions were conducted in oven-
(140°C) or flame-dried glassware using distilled and degassed solvents under positive pressure 
of dry argon with standard Schlenk techniques.  All air-sensitive reagents were stored in an 
MBraun labmaster glovebox containing dry argon gas.  Dry tetrahydrofuran (THF), toluene, 
acetonitrile (CH3CN), and methylene chloride (DCM) were obtained by passing commercially 
available pre-dried, oxygen-free formulations through two activated alumina columns using an 
MBraun MB-SPS solvent purification system.  Stainless steel syringes or cannulae that had been 
oven-dried (140°C) and cooled under an argon atmosphere or in a desiccator were used to 
transfer air- and moisture-sensitive liquids.  Yields refer to chromatographically and 
spectroscopically (
1
H NMR) homogeneous materials, unless otherwise stated.  Reactions were 
monitored by thin-layer chromatography (TLC) carried out on precoated glass plates of silica gel 
(0.25 mm) 60 F254 from EMD Chemicals Inc. using the indicated solvent system. Visualization 
was accomplished with ultraviolet light (UV 254 nm), or by shaking the plate in a sealed jar 
containing silica gel and Iodine.  Alternatively, plates were treated with one of the following 
solutions (this was accomplished by holding the edge of the TLC plate with forceps or tweezers 
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and immersing the plate into a wide-mouth jar containing the desired staining solution) and 
carefully heating with a hot-air gun (450°C) for approximately 1-2 min (NOTE: excess stain was 
removed by resting the TLC on a paper towel prior to heating): 10% phosphomolybdic acid in 
ethanol, 1% potassium permanganate/7% potassium carbonate/0.5% sodium hydroxide aqueous 
solution, and/or anisaldehyde in ethanol with 10% sulfuric acid.  Flash column chromatography 
was performed using Silia Flash® P60 silica gel (40-63 μm) from Silicycle.  All work-up and 
purification procedures were carried out with reagent grades solvents (purchased from VWR) in 
air.   
  
INSTRUMENTATION: Infrared (IR) spectra were recorded on a Thermo Nicolet IR-100 
spectrometer, νmax in cm
-1
, and were obtained from samples prepared as thin films between NaCl 
plates.   
1
H NMR spectra were recorded on a Bruker Avance DPX-300 (300 MHz) spectrometer.  
Chemical shifts are reported in parts per million (ppm) and are calibrated using residual 
undeuterated solvent as an internal reference (CDCl3: δ 7.26 ppm).  Data are reported as follows: 
chemical shift, multiplicity, coupling constants (Hz), and integration.  The following 
abbreviations or combinations thereof were used to explain the multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, pent = pentet, sext = sextet, sept = septet, m = multiplet, at = 
apparent triplet, aq = apparent quartet, br = broad.  
13
C NMR spectra were recorded on a Bruker 
Avance DPX-300 (75 MHz) spectrometer with complete proton decoupling.  Chemical shifts are 
reported in ppm and are calibrated using residual undeuterated solvent as an internal reference 
(CDCl3: δ 77.16 ppm). 
19
F NMR spectra were recorded on a Bruker Avance DPX-300 (282.4 
MHz) spectrometer.  Chemical shifts are reported in ppm and are calibrated using solvent as an 
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external reference (CFCl3: δ 0.00 ppm). High resolution mass spectra (HRMS) were performed 
at the mass spectrometry facility of CUNY Hunter College (New York, New York), or SUNY 
Buffalo (Buffalo, New York) or Old Dominion University (Norfolk, VA).  Enantiomeric ratios 
were determined by chiral high performance liquid chromatography (HPLC) analysis on a 
Varian Prostar instrument using chiral analytical columns as stated, in comparison with authentic 
racemic samples. Optical rotations were measured at a sodium D line (589 nm) on a Rudolph 
Research Analytical Autopol III polarimeter and reported as follows: [α]D
T
 λ (c in g/100 mL), in 
the designated reagent grade solvent. Melting points (m.p.) are uncorrected and were recorded 
using an Electrothermal Mel-Temp® melting point apparatus. Elemental Analyses were 
performed on a Costech ECS 4010 elemental analyzer with a thermal conductivity detector and 2 
meter GC column maintained at 50°C. 
  
72 
 
 
7.2 1ST GENERATION 
Reductive Amination General Procedure
50
: 
2-Chloro-N-(4-methoxybenzyl)pyridin-3-amine (24a)
50
 
To a flame-dried 250 mL RBF was added 3-amino-2-chloropyridine (5.0 
g, 38.89 mmol), 60 mL EtOAc and p-Methoxybenzaldehyde (5.18 mL, 
42.78 mmol). The mixture was allowed to stir until complete dissolution 
(about 5 min) at which time trifluoroacetic acid (5.77 mL, 77.78 mmol) was added as a single 
portion via syringe and the reaction mixture immediately turned yellow.  After stirring at rt for 2 
min sodium triacetoxyborohydride was added in two equal portions 1 minute apart. After 30 min 
the reaction was judged complete by TLC and quenched by the addition of 20% NaOH(aq) (30 
mL); the pH was adjusted to 8 by addition of  NaOH(s) (50 pellets). The layers were then 
separated and the organic layer was washed with brine (30 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give a blue tinged solid which was recrystallized with 40 mL of 3:1 
EtOAc : Hexanes to give 9.64 g (99%) of colorless cubes. 
 
1
H NMR (300 MHz, CDCl3) δ = 7.71 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 7.03 
(dd, J = 8.1 Hz, 4.5 Hz, 1H), 6.89 (d, J = 8.7 Hz, 2H), 6.84 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.75 (br 
s, 1H), 4.31 (d,  J = 5.4 Hz, 2H), 3.81 (s, 3H) 
 
MP: 90 – 91 °C 
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Rf (20% EtOAc / Hexanes): 0.24 
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N-Benzyl-2-chloropyridin-3-amine (24b)
50
 
Following the general procedure, 3-amino-2-chloropyridine (2.0 g, 15.56 
mmol), 120 mL EtOAc, benzaldehyde (1.74 mL, 17.11 mmol), trifluoroacetic 
acid (2.31 mL, 31.11 mmol) and sodium triacetoxyborohydride (3.95 g, 18.67 
mmol) were combined and stirred for 15 minutes.  The reaction was quenched with 20% 
NaOH(aq) and the pH was adjusted with NaOH(s) (20 pellets). The layers were separated, the 
organic layer was washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo to give crude 24b which was recrystallized from 14 mL of 1:1 Hexanes:EtOAc to give 
24b as a colorless cubes (2.5 g, 74%) 
 
1
H NMR (300 MHz, CDCl3) δ = 7.72 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.41 – 7.27 (m, 5H), 7.03 
(dd, J = 7.8 Hz, 4.5 Hz, 1H), 6.83 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.84 (br s, 1H), 4.41 (s, 2H) 
 
MP: 76 – 77 °C  
 
Rf (20% EtOAc / Hexanes): 0.23
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2-Chloro-N-(2,4-dimethoxybenzyl)pyridin-3-amine (24c) 
Following the general procedure, 3-amino-2-chloropyridine (10.0 g, 
77.8 mmol), 120 mL EtOAc, 2,4-dimethoxybenzaldehyde (14.2 g, 85.6 
mmol), trifluoroacetic acid (11.6 mL, 17.7 mmol) and sodium 
triacetoxyborohydride (19.8 g, 93.3 mmol) were combined and stirred for 60 minutes.  The 
reaction was quenched with 20% NaOH(aq) and the pH was adjusted with NaOH(s) (70 pellets). 
The layers were separated, the organic layer was washed with brine (30 mL), dried over MgSO4, 
filtered and concentrated in vacuo to give 18.7 g of crude 24c which was recrystallized from 80 
mL of 2:1 Hexanes:EtOAc to give 24c as a pale green crystalline solid (15.15 g, 70%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.69 (d, J= 3 Hz, 1H), 7.14 (d, J= 8.1 Hz, 1H), 7.04 (ddd, J= 
8.1, 4.8, 0.6 Hz, 1H), 6.90 (dd, J= 8.1, 1.5 Hz, 1H), 6.48 (d, J= 2.4 Hz, 1H), 6.43 (dd, J= 8.1, 2.4 
Hz, 1H), 4.82 (at, J= 5.1 Hz, 1H), 4.30 (d, J= 5.7 Hz, 2H), 3.85 (s, 3H), 3.80 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 160.6, 158.5, 141.0, 137.3, 136.3, 129.4, 123.4, 118.1, 118.0, 
104.0, 98.8, 55.5, 55.4, 42.5 
 
FT-IR: (NaCl, thin film) ν = 3423, 2937, 2836, 1614, 15841505, 1463, 1289, 1207, 1156, 1035 
cm
-1
. 
 
HRMS (ESI) Calc (C14H15ClN2O): 278.0825, Found: 278.0822 
 
MP: 56-58 °C 
 
Rf (20% EtOAc / Hexanes): 0.23 
  
76 
 
 
2-Chloro-N-(3-fluorobenzyl)pyridin-3-amine (24d) 
Following the general procedure, 3-amino-2-chloropyridine (2.0 g, 15.56 
mmol), 24 mL EtOAc, 3-fluorobenzaldehyde (1.81 mL, 17.12 mmol), 
trifluoroacetic acid (2.31 mL, 31.12 mmol) and sodium triacetoxyborohydride (3.96 g, 18.67 
mmol) were combined and stirred for 30 minutes. The reaction was quenched with 20% 
NaOH(aq) and the pH was adjusted with NaOH(s) (20 pellets). The layers were separated, the 
organic layer was washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo to give 3.24 g of crude 24d which was recrystallized from 10 mL of 1:1 Hexanes:EtOAc 
to give 24d as a white crystalline solid (2.41 g, 66%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.74 (dd, J=1.8 Hz, 4.8 Hz, 1H), 7.36-7.29 (m, 1H), 7.12 (d, 
J=7.8 Hz, 1H), 7.06-6.95 (m, 3H), 7.78 (dd, J=1.2 Hz, 7.8 Hz, 1H), 4.89 (s, 1H), 4.42 (d, J = 5.7 
Hz, 2H) 
13
C NMR (75.4 MHz, CDCl3) δ= 164.7, 161.4, 140.5 (d, JC-F = 25.4 Hz), 140.2, 137.0, 136.7, 
130.3 (d, JC-F = 30.5 Hz), 123.3, 122.4 (d, JC-F = 10.7 Hz), 117.9, 114.0 (dd, JC-F = 169 Hz, 78.8 
Hz), 46.6 (d, JC-F = 6.2 Hz), 
19
F NMR (282.4 MHz, CDCl3) δ= -112.81 (dt, J= 9.0 Hz, 6.0 Hz) 
FT-IR: (NaCl, thin film) ν = 3430, 3064, 2916, 2850, 1586, 1490, 1325, 1251, 1102, 1056, 784 
cm
-1
. 
HRMS (ESI) Calc (C12H11ClFN2O): 237.0589, Found: 237.0588 
MP: 93-95 °C 
Rf (20% EtOAc / Hexanes):  0.25 
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2-Chloro-N-(2-chlorobenzyl)pyridin-3-amine (24e) 
Following the general procedure 3-amino-2-chloropyridine (2.0 g, 15.56 
mmol), 24mL EtOAc, 2-chlorobenzaldehyde (1.92 mL, 17.11 mmol), 
trifluoroacetic acid (2.31 mL, 31.11 mmol) and sodium triacetoxyborohydride (3.95 g, 18.67 
mmol) were combined and stirred for 30 minutes. The reaction was quenched with 20% 
NaOH(aq) and the pH was adjusted with NaOH(s) (20 pellets). The layers were separated, the 
organic layer was washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo to give a white solid which was recrystallized from 45 mL of 2:1 Hexanes:EtOAc to give 
24e as colorless cubes (3.73 g, 87%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.73 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.45 – 7.38 (m, 1H), 7.34 – 
7.30 (m, 1H), 7.29 – 7.19 (m, 2H), 7.04 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.78 (dd, J = 8.1 Hz, 1.5 
Hz, 1H), 4.94 (br s, 1H), 4.51 (d, J = 6 Hz, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 140.3, 137.2, 137.0, 135.0, 133.3, 129.9, 128.9, 128.5, 127.2, 
123.5, 118.0, 45.1 
 
FT-IR (NaCl, thin film) ν = 3428, 3063, 2929, 1585, 1564, 1492, 1443, 1386, 1325, 1055 cm-1. 
 
HRMS (ESI) Calc (C12H11N2Cl2): 253.0294, Found: 253.0291 
 
MP: 85 – 86 °C 
 
Rf (20% EtOAc / Hexanes): 0.38 
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2-Chloro-N-(pyridin-2-ylmethyl)pyridin-3-amine (24f) 
Following the general procedure 3-amino-2-chloropyridine (1.0g, 7.78 mmol), 
12mL EtOAc, 2-pyridine carboxaldehyde (0.81 mL, 8.56 mmol), 
trifluoroacetic acid (1.2 mL, 15.6 mmol) and sodium triacetoxyborohydride 
(1.98 g, 9.34 mmol) were combined and stirred for 30 minutes. The reaction was quenched with 
20% NaOH(aq) and the pH was adjusted with NaOH(s) (20 pellets). The layers were separated, the 
organic layer was washed with brine (10 mL), dried over MgSO4, filtered and concentrated in 
vacuo to give of 24f as brown viscous oil, which was used without further purification (1.63 g, 
95%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.61 (ddd, J = 4.8 Hz, 1.5 Hz, 0.9 Hz, 1H), 7.73 (dd, J = 4.8 Hz, 
1.8 Hz, 1H), 7.67 (td, J = 7.8 Hz, 1.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.33 - 7.19 (m,  1H), 
7.05 (ddd, J = 12.6 Hz, 4.5 Hz, 0.6 Hz, 1H), 6.85 (dd, J = 7.8 Hz, 1.5 Hz, 1H), 5.52 (br s, 1H), 
4.50 (d, J= 5.4 Hz) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 157.1, 149.5, 140.6, 137.6, 137.3, 137.0, 123.6, 122.8, 121.6, 
118.1, 48.6 
 
FT-IR (NaCl, thin film) ν = 3371, 3063, 1587, 1491, 1435, 1389, 1326, 1055, 996, 789, 757, 729 
cm
-1
. 
 
HRMS (ESI) Calc (C11H11Cl1N3): 220.0636, Found: 220.0632 
 
Rf (20% EtOAc / Hexanes): 0.20 
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2-Chloro-N-cyclohexylpyridin-3-amine (24g)
50
 
Following the general procedure 3-amino-2-chloropyridine (1.0 g, 7.78 mmol), 12 
mL EtOAc, cyclohexanone (0.89 mL, 8.56 mmol), trifluoroacetic acid (1.2 mL, 
15.6 mmol) and sodium triacetoxyborohydride (1.98 g, 9.34 mmol) were combined 
and stirred for 30 minutes. The reaction was quenched with 20% NaOH(aq) and the pH was 
adjusted with NaOH(s) (20 pellets). The layers were separated, the organic layer was washed with 
brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo to give of 24g as a yellow 
oil, which was used without further purification (1.73 g, 99%). 
 
1
H NMR (300 MHz, CDCl3) δ= 7.65 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.05 (dd, J = 8.1 Hz, 4.5 Hz, 
1H), 6.87 (dd, J = 8.1 Hz, 1.8 Hz, 1H), 4.25 (br s, 1H), 3.25 (br s, 1H), 2.04-2.00 (m, 2H), 1.82-
1.64 (m, 4H), 1.41-1.23 (m, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 140.0, 137.0, 135.8, 123.4, 117.8, 51.3, 32.9, 25.8, 24.8 
 
Rf (20% EtOAc / Hexanes): 0.48 
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2-Chloro-N-neopentylpyridin-3-amine (24i)
58
 
Following the general procedure 3-amino-2-chloropyridine (1.0 g, 7.78 mmol), 
12mL EtOAc, pivaldehyde (0.93 mL, 8.56 mmol), trifluoroacetic acid (1.2 mL, 
15.6 mmol) and sodium triacetoxyborohydride (1.98 g, 9.34 mmol) were combined and stirred 
for 30 minutes. The reaction was quenched with 20% NaOH(aq) and the pH was adjusted with 
NaOH(s) (20 pellets). The layers were separated, the organic layer was washed with brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to give of 24i as a dark blue oil, 
which was used without further purification (1.48 g, 95%) 
 
1
H NMR (300 MHz, CDCl3) δ = 7.66 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.07 (dd, J = 8.1 Hz, 4.5 Hz, 
1H), 6.89 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.40 (br s, 1H), 2.92 (d, J = 5.1 Hz, 2H), 1.02 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 141.5, 136.9, 135.8, 123.5, 117.3, 55.0, 32.2, 27.6 
  
Rf (20% EtOAc / Hexanes): 0.45 
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2-Chloro-N-cyclopentylpyridin-3-amine (24j)
50
 
Following the general procedure 3-amino-2-chloropyridine (1.29 g, 10.0 mmol), 
15mL EtOAc, cyclopentanone( 0.97 mL, 11.0 mmol), trifluoroacetic acid (1.54 mL, 
20.0 mmol) and sodium triacetoxyborohydride (2.54 g, 12.0 mmol) were combined and stirred 
for 30 minutes. The reaction was quenched with 20% NaOH(aq) and the pH was adjusted with 
NaOH(s) (20 pellets). The layers were separated, the organic layer was washed with brine (10 
mL), dried over MgSO4, filtered and concentrated in vacuo to give 24j as a yellow oil, which 
was used without further purification (1.61 g, 82%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.67 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 7.07 (ddd, J = 8.1 Hz, 4.5 Hz, 
0.6 Hz, 1H), 6.90 (dd, J = 8.1 Hz, 1.8 Hz, 1H), 4.32 (br s, 1H), 3.76 (sext, 6.3 Hz, 1H),  2.12 – 
1.98 (m, 2H), 1.85 – 1.45 (m, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 140.6, 137.0, 135.9, 123.4, 118.1, 54.2, 33.4, 24.1 
 
Rf (20% EtOAc / Hexanes): 0.48 
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2-Chloro-N-(cyclohexylmethyl)pyridin-3-amine (24k)
50
 
Following the general procedure 3-amino-2-chloropyridine (1.29 g, 10.0 
mmol), 15mL EtOAc, cyclohexane carboxaldehyde (1.32 mL, 11.0 mmol), 
trifluoroacetic acid (1.54 mL, 20.0 mmol) and sodium triacetoxyborohydride (2.54 g, 12.0 mmol) 
were combined and stirred for 30 minutes. The reaction was quenched with 20% NaOH(aq) and 
the pH was adjusted with NaOH(s) (20 pellets). The layers were separated, the organic layer was 
washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo to give of 24k 
as a yellow oil, which was used without further purification (1.95 g, 87%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.66 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 7.06 (dd, J = 7.8 Hz, 4.5 Hz, 
1H), 6.85 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.41 (br s, 1H), 2.98 (t, J = 6.3 Hz, 2H) 1.87 – 1.52 (m, 
6H), 1.36 – 0.90 (m, 5H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 141.1, 136.9, 135.8, 123.5, 117.3, 49.8, 37.3, 21.2, 26.5, 25.9 
 
Rf (20% EtOAc / Hexanes): 0.49 
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2-Chloro-N-(4-methoxybenzyl)-4-methylpyridin-3-amine (26) 
Following the general procedure 3-amino-2-chloro-4-methylpyridine 
(2.0 g, 14.03 mmol), 21.6mL EtOAc, 4-methoxybenzaldehyde(1.88 mL, 
15.43 mmol), trifluoroacetic acid (2.08 mL, 28.06 mmol) and sodium 
triacetoxyborohydride (3.57 g, 16.83 mmol) were combined and stirred for 30 minutes. The 
reaction was quenched with 20% NaOH(aq) and the pH was adjusted with NaOH(s) (20 pellets). 
The layers were separated, the organic layer was washed with brine (10 mL), dried over MgSO4, 
filtered and concentrated in vacuo to an oil which was purified on a 5% EtOAc/Hexanes silica 
gel column to give 26 as a colorless oil (2.98 g, 81%) 
 
1
H NMR (300 MHz, CDCl3) δ= 7.81 (d, J = 4.8 Hz, 1H), 7.23 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 
4.8 Hz, 1H), 6.84 (d, J = 8.7 Hz, 2H), 4.17 (s, 2H), 3.92 (br s, 1H), 3.76 (s, 3H), 2.33 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.0, 143.7, 131.3, 140.8, 139.9, 131.3, 129.0, 125.9, 114.0, 
55.2, 51.4, 19.1 
 
FT-IR (NaCl, thin film) ν = 2956, 2917, 2849, 1611, 1586, 1512, 1248, 1174, 1100, 1033, 823 
cm
-1
. 
 
Anal. Calc C14H15ClN2O: C, 64.00; H, 5.75; N, 10.66; found C, 63.61; H, 5.45; N, 10.37 
 
Rf (20% EtOAc / Hexanes): 0.25 
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2-Chloro-N-isopropylpyridin-3-amine (24h)
205
 
To a flame-dried 5 mL RBF equipped with a stirbar was added 2,2-
dimethoxypropane (1.91 mL, 15.6 mmol) followed by 3-amino-2-chloropyridine 
(1.0 g, 7.78 mmol). The flask was equipped with a reflux condenser and heated to reflux for 6h 
in a 90°C pre-heated oil bath. The reaction was then concentrated in vacuo, dissolved in 25 mL 
MeOH and sodium borohydride (1.74 g, 45.9 mmol) was added portionwise over 20 minutes. 
Upon completion of the addition, TLC incidcated consumption of the starting material and the 
reaction was quenched with 15 mL of water, and extracted with CH2Cl2 (4 x 15 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated to give 1.1 g of crude 
product which was purified on a silica gel column (4.5 cm x 12 cm), eluting with 10% MTBE / 
Hexanes to give 800 mg (61%) of 24h as a colorless oil. 
 
1
H NMR (300 MHz, CDCl3) δ= 7.67 (dd, J = 4.6 Hz, 1.6 Hz, 1H), 7.07 (dd, J = 8.1 Hz, 4.6 Hz, 
1H), 6.87 (dd, J = 8.0 Hz, 1.6 Hz, 1H), 4.19 (brs, 1H), 3.61 (sept, J = 6.2 Hz, 1H),  1.26 (d, J = 
6.3 Hz, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 140.1, 137.0, 135.9, 123.5, 117.8, 44.0, 22.7 
 
Rf (20% EtOAc / Hexanes): 0.44 
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2-Chloro-N-methylpyridin-3-amine (24l)
206
 
To a flame-dried 25 mL RBF equipped with a stirbar was added tert-butyl 
2-chloropyridin-3-ylcarbamate
207
 (500 mg, 2.19 mmol) and DMF (10 mL). The reaction was 
cooled to 0°C (ice-water bath) and sodium hydride (60% wt in mineral oil) (66 mg, 2.74 mmol) 
was added carefully. The reaction mixture was stirred for 10 min, at which time methyl iodide 
(0.17 mL, 2.74 mmol) was added. The reaction was allowed to warm to RT and stirred for 2 h at 
which time TLC indicated consumption of the pyridine. The reaction was quenched by the 
addition of H2O (5 mL), and diluted with EtOAc (10 mL). The layers were separated and the 
aqueous layer was extracted with EtOAc (2 x 10mL). The combined organic layers were washed 
with H2O (3 x 10 mL), brine (10 mL), dried over Na2SO4 and concentrated in vacuo to give 525 
mg of a yellow oil, which was taken on without further purification. 
 The oil prepared above was dissolved in 7.2 mL CH2Cl2 and added to a 25 mL 
flame-dried RBF equipped with a stirbar. Trifluoroacetic acid (0.35 mL, 4.54 mmol) was added 
dropwise and the reaction stirred for 3h, at which time TLC indicated consumption of the starting 
material. The reaction was quenched with 2M NaOH(aq) (10 mL), and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (2 x 6 mL), the combined organic layers were 
washed with brine (5 mL), dried over Na2SO4 and concentrated in vacuo to give 300 mg of a 
brown oil, which was used without further purification. 
 
1
H NMR (300 MHz, CDCl3) δ= 7.62 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.04 (dd, J = 8.1 Hz, 4.5 Hz, 
1H), 6.78 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 2.81 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 141.8, 137.0, 136.2, 123.6, 116.9, 30.0 
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(R)-2-Chloro-N-(1-phenylethyl)pyridin-3-amine (24m) 
To an oven-dried 100 mL Schlenk-tube equipped with a stirbar was added 3-
iodo-2-chloro-pyridine (1.0 g, 4.2 mmol) and toluene (10.5 mL). To this slurry 
was added palladium (II) acetate (47 mg, 0.21 mmol), rac-BINAP (431 mg, 
0.21 mmol), cesium carbonate (2.04 g, 6.3 mmol), (R)-1-phenylethylamine (0.51 mL, 4.0 mmol), 
triethylamine (0.06 mL, 0.42 mmol). The reaction mixture was degassed by 2 x vacuum / Ar(g) 
purge cycles, equipped with a cold-finger, and heated to reflux in a 110 °C pre-heated oil-bath 
for 36 h. The reaction mixture was then cooled to RT, diluted with H2O (10 mL), EtOAc (15 
mL), and filtered through a Celite plug. The layers were separated, the organic layer dried over 
MgSO4 and concentrated in vacuo to give a grey solid. The crude product was purified on a silica 
gel column (4.5 cm x 12 cm) eluting with 10% EtOAc / Hexanes to give 650 mg of 24m as an 
off-white solid (67%). 
 
1
H NMR (300 MHz, CDCl3) δ= 7.65 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 7.38 – 7.21 (m, 5H), 6.90 (dd, 
J = 8.1 Hz, 4.8 Hz, 1H), 6.60 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.75 (br s, 1H), 4.48 (pent, J = 6.3 Hz, 
1H), 1.60 (d, 6.9 Hz, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ= 143.6, 139.8, 137.0, 136.5, 129.0, 127.4, 125.7, 123.3, 118.9, 
53.3, 25.2 
FT-IR (NaCl, thin film) ν = 3420, 3061, 3028, 2979, 1583, 1561, 1488, 1451, 1383, 1328, 1311, 
1055, 788, 701 cm
-1
. 
HRMS (ESI) Calc (C13H13ClN2)H
+
: 233.0840, Found: 233.0845 
MP: 68 - 70 °C 
[α]D = -102° (c = 1.0, MeOH) 
Rf (20% EtOAc / Hexanes): 0.40 
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(S)-2-Chloro-N-(1-phenylethyl)pyridin-3-amine (24n) 
To an oven-dried 100 mL Schlenk-tube equipped with a stirbar was added 3-
iodo-2-chloro-pyridine
58
 (1.0 g, 4.2 mmol) and toluene (10.5 mL). To this 
slurry was added sequentially palladium (II) acetate (47 mg, 0.21 mmol), rac-BINAP (431 mg, 
0.21 mmol), cesium carbonate (2.04 g, 6.3 mmol), and (S)-1-phenylethylamine (0.51 mL, 4.0 
mmol), triethylamine (0.06 mL, 0.42 mmol). The reaction mixture was degassed by 2x vacuum / 
Ar(g) purge cycles. The Schlenk flask was equipped with a cold-finger condenser under a positive 
pressure of argon gas and  heated to reflux in a 110 °C pre-heated oil-bath for 36 h, cooled to RT, 
diluted with H2O  (10 mL) and EtOAc (15 mL), the mixture was then filtered through a Celite 
plug. The layers were separated, the organic layer dried over MgSO4 and concentrated in vacuo 
to give a grey solid. The crude product was purified on a silica gel column (4.5 cm x 12 cm) 
eluting with 10% EtOAc / Hexanes to give 620 mg of 24n as a white solid (64%). 
 
1
H NMR (300 MHz, CDCl3) δ= 7.65 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 7.38 – 7.21 (m, 5H), 6.90 (dd, 
J = 8.1 Hz, 4.8 Hz, 1H), 6.61 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 4.76 (br s, 1H), 4.48 (br q, J = 6.3 Hz, 
1H), 1.60 (d, 6.9 Hz, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ= 143.9, 140.2, 137.2, 136.8, 129.3, 127.8, 126.0, 123.7, 119.3, 
53.7, 25.5 
FT-IR (NaCl, thin film) ν = 3420, 3061, 3028, 2979, 1583, 1561, 1488, 1451, 1383, 1328, 1311, 
1055, 788, 701 cm
-1
. 
HRMS (ESI) Calc (C13H12N2Cl)H
+
: 233.0840, Found: 233.0846 
MP: 69 - 70 °C 
[α]D = +102° (c = 1.0, MeOH) 
Rf (20% EtOAc / Hexanes): 0.40 
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2-Chloro-N-phenylpyridin-3-amine (24o)
58
 
To a flame-dried 100 mL RBF equipped with a stirbar was added activated 4Å 
mol. Sieves (2 g), phenylboronic acid (1.9 g, 15.56 mmol), 3-amino-2-chloropyridine (1.0 g, 7.78 
mmol), Cu(OAc)2 (2.12 g, 11.67 mmol), pyridine (1.23 mL, 15.5 mmol) and CH2Cl2 (39 mL). 
The flask was equipped with a balloon of O2(g) and stirred for 4d at which time TLC showed 
consumption of the pyridine. The reaction was quenched with NH4OH(aq) (15 mL) causing a 
color change to dark blue from brown. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 ml). The combined organic layers were washed with brine (20 
mL), dried over MgSO4, filtered and concentrated to give a brown oil. The oil was purified on a 
silica gel column (4.5 cm x 12 cm), eluting with 10% EtOAc / hexanes to give 1.34 g of a white 
crystalline solid (84%).  
 
1
H NMR (300 MHz, CDCl3) δ= 7.87 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 7.49 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.40 – 7.33 (m, 2H), 7.20 – 7.13 (m, 2H), 7.13 – 7.05 (m, 2H), 6.14 (br s, 1H) 
 
MP: 72 – 76 °C 
 
Rf (20% EtOAc / Hexanes): 0.36 
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2-Chloro-N-(4-methoxyphenyl)pyridin-3-amine (24p)
28
 
To a flame-dried 100 mL RBF equipped with a stirbar was added 5g of activated 
4Å mol. sieves, p-methoxyphenylboronic acid (2.36 g, 15.56 mmol) followed by 
3-amino-2-chloropyridine (1.0 g, 7.78 mmol), Cu(OAc)2 (2.12 g, 11.67 mmol), 
pyridine (1.23 mL, 15.56 mmol) and CH2Cl2 (39 mL). The reaction was stirred for 6 d at RT 
under a balloon of O2(g). The reaction was quenched with NH4OH(aq)(15 mL); the layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic 
layers were washed with brine (20 mL), dried over MgSO4, filtered and concentrated to give a 
purple oil which was purified on a silica gel column (4.5 cm x 12 cm), eluting with 20% EtOAc / 
hexanes to give 650 mg of a white crystalline solid (36%).  
 
1
H NMR (300 MHz, CDCl3) δ= 7.77 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.16 (dd J = 8.1 Hz, 1.8 Hz, 
1H), 7.11 (d, J = 8.7 Hz, 2H), 7.00 (dd, J = 8.1 Hz, 4.5 Hz, 1H), 6.89 (d, J = 9 Hz), 5.99 (br s, 
1H), 3.81 (s, 3H) 
 
MP = 62 – 63 °C 
 
Rf (20% EtOAc / Hexanes): 0.28 
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tert-Butyl 2-chloro-6-phenylpyridin-3-yl(methyl)carbamate (SI2) 
To an oven-dried 100 mL RBF equipped with a stirbar was added KHMDS 
(5.29 g, 26.5 mmol) and 26.5 mL THF. The reaction was stirred until 
dissolution (0.5 h), cooled to 0°C (ice-water bath). 6-Bromo-2-chloropyridin-3-amine
205
 (2.5 g, 
12.05 mmol) was added as a 1M solution in THF (12 mL), the reaction mixture was stirred for 
10 min at which time di-tert-butyl dicarbonate (2.76 g, 12.65 mmol) was added as a solid. The 
reaction mixture was stirred for 0.5 h at which time iodomethane (0.83 mL, 13.26 mmol) was 
added via syringe. The reaction was warmed to RT, stirred for 10 h, quenched with 20 mL water, 
and diluted with 20 mL EtOAc. The layers were separated, and the aqueous layer was extracted 
with EtOAc (3 x 15 mL). The combined organic layers were washed with brine, dried over 
MgSO4, and concentrated in vacuo to give 2.1 g of tert-butyl 6-bromo-2-chloropyridin-3-
yl(methyl)carbamate (SI1) a white solid (54%). 
To a flame-dried 50 mL RBF equipped with a stirbar was added pyridine SI1 (1.0 g, 3.1 
mmol), 1,4-dioxane (15.5 mL), phenylboronic acid (397 mg, 3.3 mmol) and potassium carbonate 
(1.33 g, 9.61 mmol). The reaction mixture was degassed by 3x vacuum / Ar(g) purge cycles, 
tetrakis(triphenylphosphine)palladium (179 mg, 0.16 mmol) added, and the reaction mixture 
placed in an 80°C pre-heated oil-bath. The reaction mixture was then stirred for 48 h, cooled to 
RT, diluted with EtOAc (15 ml), washed with water (10 mL), brine (5 mL), dried over MgSO4, 
concentrated in vacuo to give a dark brown solid which was purified on a silica gel column, 
eluting with 10% EtOAc / Hexanes to give 460 mg of a pale yellow solid (47%). 
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1
H NMR (300 MHz, CDCl3) δ=8.10 – 7.90 (m, 2H), 7.75 – 7.60 (m 2H), 7.55 – 7.30 (m, 3H), 
3.19 (s, 2.7 H, rotomer), 3.14 (s, 0.3H, rotomer), 1.60 – 1.20 (2 x brs, rotomers, 9H) 
13
C NMR (75.4 MHz, CDCl3) δ= 156.0, 154.4, 149.8, 138.4, 137.2, 136.3, 129.8, 129.0, 127.1, 
119.4, 81.1, 36.3, 28.3 
 
FT-IR (NaCl, thin film) ν = 2917, 1708, 1533, 1458, 1438, 1366, 1318, 1153, 1064, 748 cm-1. 
 
Anal. Calc C17H19ClN2O2: C, 64.05; H, 6.01; N, 8.79; found C, 64.04; H, 5.63; N, 8.48 
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2-Chloro-N-methyl-6-phenylpyridin-3-amine (27) 
To a flame-dried 25 mL RBF equipped with a stirbar was added SI2 (450 mg, 
1.41 mmol) followed by 4.7 mL CH2Cl2. Trifluoroacetic acid (0.23 mL, 2.96 mmol) was added 
dropwise and the reaction mixture stirred at RT for 24h. The reaction mixture was quenched with 
1N NaOH(aq)(10 mL). The layers were separated,  and the aqueous layer was extracted with 
CH2Cl2 (2 x 5 mL), combined organic layers dried over MgSO4, filtered, concentrated in vacuo 
and purified on a silica gel column, eluting with 20% EtOAc / Hexanes to give 290 mg of a pale 
brown crystalline solid (94%). 
 
1
H NMR (300 MHz, CDCl3) δ= 7.93 – 7.80 (m, 2H), 7.59 (d, J = 8.4 Hz, 1H), 7.45 – 7.38 (m, 
2H), 7.35 – 7.28 (m, 1H), 6.97 (d, J = 8.1 Hz, 1H), 2.96 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 144.8, 140.6, 138.3, 136.7, 128.7, 127.9, 125.9, 120.1, 117.7, 
30.1 
 
FT-IR (NaCl, thin film) ν = 2915, 2886, 1592, 1491, 1055 cm-1. 
 
Anal. Calc C12H11ClN2: C, 65.91; H, 5.07; N, 12.81; found C, 65.83; H, 5.24; N, 12.93 
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N-Butyl-3-chloropyrazin-2-amine (28) 
To a flame-dried 25 mL RBF equipped with a stirbar was added 2,3-
dichloropyrazine (5.0 g, 33.6 mmol), 1,4-dioxane (8 mL), n-butylamine (4.0 mL, 
40.3 mmol) and triethylamine (7.02 mL, 50.3 mmol). The reaction vessel was equipped with a 
condenser, and heated to 100°C in a pre-heated oil-bath for 8 h. The reaction was cooled to RT, 
concentrated, diltuted with H2O (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
organic layers were washed with brine (10 mL), dried over Na2SO4, decanted, and concentrated 
in vacuo to give 28 as a yellow oil, which was used without further purification (6.1 g, 98%).  
 
1
H NMR (300 MHz, CDCl3) δ= 7.93 (d, J = 2.7 Hz, 1H), 7.54 (d, J = 2.7 Hz, 1H), 5.18 (br s, 
1H), 3.45 (td, J = 6.9 Hz, 5.7 Hz, 2H), 1.64 (pent, J = 6.9 Hz, 2H), 1.43 (sex, J = 7.5 Hz, 2H), 
0.97 (t, J = 7.2 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 151.2, 140.7, 134.7, 130.3, 41.2, 31.5, 20.2, 13.9 
 
FT-IR (NaCl, thin film) ν = 3439, 3351, 2958, 2872, 1582, 1520, 1465, 1436, 1350, 1238, 1169, 
1046, 827 cm
-1
. 
 
HRMS (ESI+) Calc (C18H12ClN3)H
+
: 186.0793, Found: 186.0801 
 
Rf (20% EtOAc / Hexanes): 0.51 
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N-Benzyl-3-chloropyrazin-2-amine (29) 
To a flame-dried 25 mL RBF equipped with a stirbar was added 2,3-
dichloropyrazine (5.0 g, 33.6 mmol), 8 mL 1,4-dioxane, benzyl amine (4.4 
mL, 40.3 mmol) and triethylamine (7.02 mL, 50.3 mmol). The reaction vessel was equipped with 
a condenser, and heated to 100°C in a pre-heated oil-bath for 8h. The reaction mixture was 
cooled to RT, concentrated, diltuted with H2O (15 mL) and extracted with CH2Cl2 (3 x 20 mL). 
The combined organic layers were washed with brine (20 mL), dried over Na2SO4 and 
concentrated in vacuo to give 29 as a yellow crystalline sold, which was used without further 
purification (5.3 g, 72%).  
 
1
H NMR (300 MHz, CDCl3) δ= 7.97 (d, 3 Hz, 1H), 7.61 (d, J = 2.7 Hz, 1H), 7.40 – 7.27 (m, 
5H), 5.50 (br s, 1H), 4.67 (d, J = 5.7 Hz, 2H) 
 
MP: 53 – 55 °C 
 
Rf (20% EtOAc / Hexanes): 0.40 
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Palladium-Catalyzed Amidation/Cyclization Representative Procedure: 
1-(4-Methoxybenzyl)-1H-imidazo[4,5-b]pyridine (25a) 
To an oven-dried 25 mL Schlenk-tube equipped with a stirbar was added 
Pd2(dba)3 · CHCl3 (20.8 mg, 0.02 mmol), 2-di-t-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-tri-i-
propylbiphenyl (L1) (48 mg, 0.1 mmol), K3PO4 (639 mg, 3.01 mmol) and 2-chloro-N-(4-
methoxybenzyl)pyridin-3-amine (24a) (500 mg, 2.01 mmol) (if solid). The tube was evacuated 
and refilled with Ar(g).  Formamide (0.12 mL, 3.01 mmol) was added via syringe as a single 
portion, followed by the chloropyridine (if liquid) in 4 mL of tert-butanol. The reaction mixture 
was degassed with 3 x vacuum / Ar(g) purge cycles.  The reaction vessel was then equipped with 
a cold-finger condensor under a positive pressure of argon gas and immersed in a 110°C pre-
heated oil-bath for 4h at which time TLC indicated consumption of the chloro-pyridine. The 
reaction was cooled to room temperature, diluted with MeOH (4 mL) filtered through a Celite 
plug and concentrated in vacuo to give a dark brown oil. The crude product was purified on a 
silica gel column (4.5 cm x 12 cm), eluting with 4% MeOH in CH2Cl2 to give 408 mg of a brown 
crystalline solid (85%).  
1
H NMR (300 MHz, CDCl3) δ= 8.56 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.16 (s, 1H), 7.58 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.20 – 7.15 (m, 3H), 6.88 (d, 8.7 Hz, 2H), 5.30 (s, 2H), 3.80 (s, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ= 159.5, 156.3, 145.1, 144.7, 128.6, 126.5, 126.0, 118.4, 117.9, 
114.3, 55.2, 48.9 
FT-IR (NaCl, thin film) ν = 3361, 3071, 2932, 2835, 1610, 1513, 1493, 1288, 1253, 1033 cm-1. 
HRMS (ESI+) Calc (C14H14N3O) (M + H): 240.1131, Found: 240.1132 
MP: 120 - 122 °C 
Rf (4% MeOH / CH2Cl2): 0.23 
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1-Benzyl-1H-imidazo[4,5-b]pyridine (25b)
41
 
Following the general experimental; N-benzyl-2-chloropyridin-3-amine 
(24b) (87.5 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettPhos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.024 mL, 0.6 
mmol) were combined with 2 mL tert-butanol in a 25 mL Schlenk flask. After 4h TLC analysis 
indicated the reaction was complete.  The reaction was cooled to RT, filtered through Celite, 
concentrated and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / 
CH2Cl2 to give 25b as 75 mg of a yellow solid (90%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.14 (s, 1H), 7.53 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.34 – 7.24 (m, 3H), 7.18 – 7.08 (m, 3H), 5.34 (s, 2H) 
 
MP: 118 – 120 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-(2,4-Dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine (25c) 
Following the general experimental; 2-chloro-N-(2,4-
dimethoxybenzyl)pyridin-3-amine (24c) (2.5 g, 8.97 mmol), 
Pd2(dba)3·CHCl3 (93 mg, 0.09 mmol), L1 (215 mg, 0.45 mmol), K3PO4 (2.86 g, 13.45 mmol), 
formamide (0.53 mL, 13.45 mmol) were combined with 45 mL tert-butanol in a 100 mL Schlenk 
flask. After 5h the reaction was complete as indicated by TLC analysis. The reaction mixture 
was cooled to RT, diluted with MeOH (20 mL), filtered through Celite, concentrated in vacuo 
and purified on a silica gel column(4.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 
25c as 1.96 g of a dark yellow solid (82%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.47 (dd, J= 4.8 Hz, 1.5 Hz, 1H), 8.13 (s, 1H), 7.68 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.11 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.06 (d, J = 8.7 Hz, 1H), 6.42 – 6.37 (m, 2H), 
5.21 (s, 2H), 3.75 (s, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 161.5, 158.5, 156.4, 145.8, 144.6, 130.5, 126.3, 118.3, 117.9, 
115.4, 104.4, 98.9, 55.5, 55.4, 44.7 
 
FT-IR (NaCl, thin film) ν = 2917, 2848, 1613, 1589, 1509, 1414, 1289, 1209, 1158, 1033 cm-1. 
 
HRMS (ESI+) Calc (C15H16N3O2) (M + H): 270.1237, Found: 240.1136 
 
MP: 131 – 134 °C 
 
Rf (4% MeOH / CH2Cl2): 0.22 
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1-(3-Fluorobenzyl)-1H-imidazo[4,5-b]pyridine (25d) 
Following the general experimental; 2-chloro-N-(3-fluorobenzyl)pyridin-3-amine 
(24d) (95 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettphos 
(9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 mmol) 
were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the reaction was 
complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and purified 
on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25d as 82 mg 
of a green solid (90%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.52 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.17 (s, 1H), 7.53 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.28 (td, J = 7.8 Hz, 6 Hz, 1H), 7.13 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.01 – 6.95 
(m, 1H), 6.93 – 6.90 (m, 1H), 6.85 – 6.81 (m, 1H), 5.36 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 163.1 (d, JC-F = 247 Hz), 156.4, 145.4, 145.2, 137.3 (d, JC-F = 
7 Hz), 130.9 (d, JC-F = 8 Hz), 126.1, 122.7 (d, JC-F = 3 Hz), 118.4, 118.4, 115.6 (d, JC-F = 20 Hz), 
114.2 (d, JC-F = 20 Hz), 48.9 (d, JC-F = 1.7 Hz) 
 
19
F NMR (282.4 MHz, CDCl3) δ= -111.79 (td, J = 8.5 Hz, 5.6 Hz) 
 
FT-IR (NaCl, thin film) ν = 1612, 1592, 1492, 1452, 1415, 1377, 1261, 1293, 1252, 780 cm-1. 
 
HRMS (ESI) Calc (C13H11N3F1): 228.0932, Found: 228.0929 
 
MP: 117 - 121°C 
 
Rf (4% MeOH / CH2Cl2): 0.23 
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1-(2-Chlorobenzyl)-1H-imidazo[4,5-b]pyridine (25e) 
Following the general experimental; 2-chloro-N-(2-chlorobenzyl)pyridin-3-amine 
(24e) (101 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettphos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 
mL, 0.6 mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the 
reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo 
and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 
25e as 50 mg of a green solid (51%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.61 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.26 (s, 1H), 7.70 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.49 (dd, J = 7.8 Hz, 1.2 Hz, 1H), 7.34 (td, J = 7.5 Hz, 1.5 Hz, 1H), 7.29 – 7.21 
(m, 2H), 7.01 (dd, J = 7.5 Hz, 1.5 Hz, 1H), 5.53 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.3, 145.7, 145.3, 133.4, 132.4, 130.3, 130.2, 129.0, 127.6, 
126.2, 118.4, 118.4, 47.1 
 
FT-IR (NaCl, thin film) ν = 3391, 2963, 2923, 1642, 1611, 1494, 1444, 1416, 1378, 1262, 1295, 
1212, 780 cm
-1
. 
 
HRMS (ESI) Calc (C13H11N3Cl1): 244.0636, Found: 244.0643 
 
MP: 135 – 137 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-(Pyridin-2-ylmethyl)-1H-imidazo[4,5-b]pyridine (25f) 
Following the general experimental; 2-chloro-N-(pyridin-2-
ylmethyl)pyridin-3-amine (24f) (93 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 
mg, 0.004 mmol), L1 (9.6 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 
0.6 mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the 
reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo 
and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 
25f as 81 mg of a brown solid (95%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.60 (ddd, J = 4.8 Hz, 1.5 Hz, 0.9 Hz, 1H), 8.57 (dd, J  = 4.8 
Hz, 1.5 Hz, 1H), 8.31 (s, 1H), 7.70 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 7.65 (td, J = 7.8 Hz, 1.8 Hz, 
1H), 7.28 – 7.22 (m, 1H), 7.20 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 5.50 (s, 
2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.4, 154.8, 150.1, 145.7, 145.3, 145.2, 137.6, 123.5, 121.5, 
118.7, 118.5, 51.3 
 
FT-IR (NaCl, thin film) ν = 3391, 1647, 1614, 1495, 1419, 1439, 1379, 1363, 1292, 783 cm-1. 
 
HRMS (ESI) Calc (C12H10N4): 210.0905, Found: 210.0905 
 
MP: 165 – 169 °C 
 
Rf (4% MeOH / CH2Cl2): 0.20 
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1-Cyclohexyl-1H-imidazo[4,5-b]pyridine (25g) 
Following the general experimental; 2-chloro-N-cyclohexylpyridin-3-amine 
(24g) (84.3 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettPhos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.024 mL, 0.6 
mmol) were combined with 2 mL tert-butanol in a 25 mL Schlenk flask. After 4h the reaction 
was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25g as 
69 mg of a white solid (90%).  
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.18 (s, 1H), 7.75 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.18 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.18 (tt, J = 12 Hz, 3.9 Hz, 1H), 2.24 – 2.13 
(m, 2H), 2.02 – 1.92 (m, 2H), 1.88 – 1.72 (m, 3H), 1.49 (qt, J = 12.9 Hz, 3.3 Hz, 2H), 1.30 (qt, J 
= 12.6 Hz, 3.0 Hz, 1H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 145.0, 142.8, 125.6, 118.4, 117.8, 56.2, 33.3, 25.7, 25.4 
 
FT-IR (NaCl, thin film) ν = 2935, 2858, 1607, 1486, 1414, 1281, 1219, 786 cm-1. 
 
HRMS (ESI) Calc (C12H15N3): 201.1265, Found: 201.1266 
 
MP: 151 – 153 °C 
 
Rf (4% MeOH / CH2Cl2): 0.25 
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1-Isopropyl-1H-imidazo[4,5-b]pyridine (25h) 
Following the general experimental; 2-chloro-N-isopropylpyridin-3-amine (24h) 
(68 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettphos (9.7 
mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 mmol) were combined 
with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 3 h the reaction was complete, the 
reaction cooled to RT, filtered through Celite, concentrated in vacuo and purified on a silica gel 
column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25h as 59 mg of a white solid 
(91%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.53 (dd, J = 4.5 Hz, 1.2 Hz, 1H), 8.19 (s, 1H), 7.75 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.20 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.63 (sept, J = 6.6 Hz, 1H), 1.61 (d, J = 6.6 
Hz, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.4, 144.9, 142.6, 125.5, 118.5, 117.9, 48.6, 22.6 
 
FT-IR (NaCl, thin film) ν = 2980, 2936, 1607, 1488, 1397, 1306, 1282, 1225, 786 cm-1. 
 
HRMS (ESI) Calc (C9H11N3)H
+
: 162.1026, Found: 162.1033 
 
MP:  134 – 136 °C 
 
Rf (4% MeOH / CH2Cl2): 0.25 
  
104 
 
1-Neopentyl-1H-imidazo[4,5-b]pyridine (25i) 
Following the general experimental; 2-chloro-N-neopentylpyridin-3-amine 
(24i) (71.3 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettphos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 
mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 3 h the reaction 
was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25i as 
57 mg of a white solid (75%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.55 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.07 (s, 1H), 7.72 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.22 (dd, J = 8.1 Hz, 4.5 Hz, 1H), 3.94 (s, 2H), 1.02 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 155.9, 146.4, 144.8, 127.3, 118.6, 118.2, 57.2, 33.9, 27.9 
 
FT-IR (NaCl, thin film) ν = 3466, 2956, 2873, 1641, 1495, 1416, 1400, 1383, 1364, 1297 cm-1. 
 
HRMS (ESI) Calc (C11H15N3)H
+
: 190.1339, Found: 190.1347 
 
MP: 139 – 142 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-Cyclopentyl-1H-imidazo[4,5-b]pyridine (25j) 
Following the general experimental; 2-chloro-N-cyclopentylpyridin-3-amine (24j) 
(78.7 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettPhos (9.7 
mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.024 mL, 0.6 mmol) were combined 
with 2 mL tert-butanol in a 25 mL Schlenk flask. After 4h the reaction was complete, the 
reaction cooled to RT, filtered through Celite, concentrated in vacuo and purified on a silica gel 
column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25j as 64 mg of a white solid 
(85%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.16 (s, 1H), 7.75 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.19 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.73 (pent, J = 13.8 Hz, 1H), 2.36 – 2.22 (m, 
2H), 2.08 – 1.73 (m, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.8, 145.0, 143.2, 126.0, 118.6, 117.8, 57.6, 32.3, 24.0 
  
FT-IR (NaCl, thin film) ν = 2959, 2873, 1605, 1477, 1412, 1291, 1226, 782 cm-1. 
 
HRMS (ESI) Calc (C11H13N3): 187.1109, Found: 187.1109 
 
MP: 90 – 94 °C 
 
Rf (4% MeOH / CH2Cl2): 0.25 
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1-(Cyclohexylmethyl)-1H-imidazo[4,5-b]pyridine (25k) 
Following the general experimental; 2-chloro-N-(cyclohexylmethyl)pyridin-
3-amine (24k) (89.9 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 
mmol), t-BuBrettPhos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.024 mL, 
0.6 mmol) were combined with 2 mL tert-butanol in a 25 mL Schlenk flask. After 4h the 
reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo 
and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 
25k as 72.3 mg of a white solid (84%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 8.01 (s, 1H), 7.67 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.17 (dd J = 8.1 Hz, 4.8 Hz, 1H), 3.95 (d, J = 7.2 Hz, 2H), 1.86 – 1.51 (m, 6H), 
1.21 – 0.86 (m, 5H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.3, 145.6, 144.8, 126.5, 118.1, 118.0, 51.9, 38.5, 30.8, 26.0, 
25.5 
 
FT-IR (NaCl, thin film) ν = 3100, 3050, 2928, 2848, 1610, 1493, 1447, 1414, 1383, 1286, 1205, 
1145, 786 cm
-1
. 
 
HRMS (ESI) Calc (C13H17N3): 215.1421, Found: 215.1422 
 
MP: 105 – 108 °C 
 
Rf (4% MeOH / CH2Cl2): 0.26 
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1-Methyl-1H-imidazo[4,5-b]pyridine (25l)
208
 
Following the general experimental; 2-chloro-N-methylpyridin-3-amine (24l) (57 
mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), L1 (9.6 mg, 0.02 mmol), K3PO4 (128 
mg, 0.6 mmol), formamide (0.022 mL, 0.6 mmol) were combined with 2.0 mL tert-butanol in a 
25 mL Schlenk flask. After 4 h the reaction was complete, the reaction cooled to RT, filtered 
through Celite, concentrated in vacuo and purified on a silica gel column (2.5 cm x 12 cm), 
eluting with 4% MeOH / CH2Cl2 to give 25l as 47 mg of a brown solid (89%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.52 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.03 (s, 1H), 7.68 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.19 (dd, J = 7.8 Hz, 4.5 Hz, 1H), 3.83 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.2, 145.7, 144.9, 126.8, 118.1, 117.7, 31.5 
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(R)-1-(1-Phenylethyl)-1H-imidazo[4,5-b]pyridine (25m) 
Following the general experimental; (R)-2-chloro-N-(1-phenylethyl)pyridin-
3-amine (24m) (93 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 
mmol), t-BuBrettphos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 
0.6 mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the 
reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo 
and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 
25m as 70 mg of a pale yellow solid (77%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.52 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.32 (s, 1H), 7.44 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.35 – 7.28 (m, 3H), 7.19 – 7.14 (m, 2H), 7.09 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 
5.62 (q, J = 7.2 Hz, 1H), 2.01 (d, J = 6.9 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 145.2, 143.3, 140.0, 129.3, 128.6, 126.0, 125.9, 119.2, 
118.1, 56.0, 21.5 
 
FT-IR (NaCl, thin film) ν = 3402, 2959, 2982, 1606, 1486, 1455, 1414, 1390, 1280, 1230, 1025, 
783 cm
-1
. 
 
HRMS (ESI) Calc (C14H13N3)H
+
: 224.1182, Found: 224.1188 
 
MP: 119 - 121°C 
 
[α]D = + 25° (0.08, MeOH) 
 
Rf (4% MeOH / CH2Cl2): 0.23 
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(S)-1-(1-Phenylethyl)-1H-imidazo[4,5-b]pyridine (25n) 
Following the general experimental; (S)-2-chloro-N-(1-phenylethyl)pyridin-
3-amine (24n) (93 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), 
t-BuBrettphos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 
mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the reaction 
was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25n as 
71 mg of a green solid (79%). 
1
H NMR (300 MHz, CDCl3) δ= 8.46 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.26 (s, 1H), 7.39 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.32 – 7.20 (m, 3H), 7.15 – 7.08 (m, 2H), 7.02 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 
5.57 (q, J = 6.9 Hz, 1H), 1.95 (d, J = 6.9 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 145.1, 143.2, 140.0, 129.2, 128.4, 126.0, 125.9, 119.1, 
118.0, 56.0, 21.4 
 
FT-IR (NaCl, thin film) ν = 3375, 3085, 2983, 1607, 1487, 1455, 1415, 1290, 1281, 1281, 1230, 
783 cm
-1
. 
 
HRMS (ESI) Calc (C14H13N3)H
+
: 224.1182, Found: 224.1188 
 
MP: 119 - 121°C 
 
[α]D = - 50° (0.24, MeOH) 
 
Rf (4% MeOH / CH2Cl2): 0.23 
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1-Phenyl-1H-imidazo[4,5-b]pyridine (25o) 
Following the general experimental; 2-chloro-N-(phenyl)pyridin-3-amine 
(24o) (82 mg, 0.36 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), L1 (9.6 
mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 
mmol) were combined with 2 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the reaction 
was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 25o as 
76.5 mg of a white solid (98%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.65 (d, J = 4.5 Hz, 1H), 8.37 (s, 1H), 7.89 (dd, J = 8.1 Hz, 1.2 
Hz, 1H), 7.65 – 7.57 (m, 2H), 7.55 – 7.47 (m, 3H), 7.30 (dd, J = 8.4 Hz, 4.8 Hz, 1H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 145.6, 145.6, 144.5, 135.8, 130.5, 128.8, 126.3, 124.0, 119.1, 
119.0 
 
FT-IR (NaCl, thin film) ν = 3124, 1597, 1502, 1477, 1412, 1301, 1194, 785  cm-1. 
 
HRMS (ESI) Calc (C12H9N3): 195.0796, Found: 195.0794 
 
MP:  120 – 124 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-(4-Methoxyphenyl)-1H-imidazo[4,5-b]pyridine (25p) 
Following the general experimental; 2-chloro-N-(4-methoxyphenyl)pyridin-3-
amine (24p) (85 mg, 0.36 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettPhos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide 
(0.022 mL, 0.6 mmol) were combined with 1.8 mL tert-butanol in a 25 mL Schlenk flask. After 
3 h the reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in 
vacuo and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to 
give 25p as 74 mg of a white solid (91%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.8 Hz, 1.8 Hz, 1H), 8.23 (s, 1H), 7.73 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.35 (dd, J = 9 Hz, 2.4 Hz, 2H), 7.20 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.05 (dd, J = 
9 Hz, 2.1 Hz, 2H), 3.85 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.7, 156.3, 145.4, 144.5, 129.4, 126.6, 125.5, 118.7, 118.6, 
115.4, 55.7 
 
FT-IR (NaCl, thin film) ν = 3401, 3080, 2963, 2839, 1609, 1517, 1489, 1415, 1252, 1030, 975, 
836 cm
-1
. 
 
HRMS (ESI) Calc (C13H12O1N3): 226.0975, Found: 226.0971 
 
MP: 125 – 129 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-(2,4-Dimethoxybenzyl)-2-phenyl-1H-imidazo[4,5-b]pyridine (30) 
Following the general experimental; 2-chloro-N-(2,4-
dimethoxybenzyl)pyridin-3-amine (24c) (111.5 mg, 0.4 mmol), 
Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettphos (9.7 mg, 0.02 
mmol), K3PO4 (128 mg, 0.6 mmol), benzamide (73 mg, 0.6 mmol) were combined with 2.0 mL 
tert-butanol in a 25 mL Schlenk flask. After 24 h no further progress was observed by TLC, the 
reaction was cooled to RT, filtered through Celite, concentrated in vacuo and purified on a silica 
gel column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to give 30 as 89 mg of a green 
semi-solid (65%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.86-7.74 (m, 2H), 7.53-7.36 
(m, 4H), 7.11 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 
6.32 (dd, J = 8.4 Hz, 2.4 Hz), 5.38 (s, 2H), 3.76 (s, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 160.9, 157.6, 156.5, 155.9, 145.2, 131.9, 130.3, 129.8, 129.5, 
128.8, 128.6, 127.8, 127.6, 118.9, 118.0, 116.2, 104.2, 98.8, 53.5, 44.2 
 
FT-IR (NaCl, thin film) ν = 3000, 2937, 2838, 1674, 1612, 1589, 1508, 1468, 1412, 1386, 1209, 
1032  cm
-1
. 
 
HRMS (ESI) Calc (C21H20N3O2): 346.1550, Found: 346.1545 
 
Rf (4% MeOH / CH2Cl2): 0.29 
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1-(4-Methoxybenzyl)-2-methyl-1H-imidazo[4,5-b]pyridine (31) 
Following the general experimental; 2-chloro-N-(4-
methoxybenzyl)pyridin-3-amine (24a) (111.5 mg, 0.4 mmol), 
Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettphos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 
0.6 mmol), acetamide (35 mg, 0.6 mmol) were combined with 2.0 mL tert-butanol in a 25 mL 
Schlenk flask. After 24 h no further progress was observed by TLC. The reaction was cooled to 
RT, filtered through Celite, concentrated in vacuo and purified on a silica gel column (2.5 cm x 
12 cm), eluting with 3% MeOH / CH2Cl2 to give 31 as 61 mg of a green solid (60%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.45 (dd, J = 4.8 Hz, 1.2 Hz, 1H), 7.46 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.07 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.96 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 5.23 (s, 
2H), 3.75 (s, 3H), 2.60 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.5, 155.6, 154.7, 144.4, 127.7, 127.7, 127.2, 117.5, 117.3, 
114.5, 55.4, 47.0, 14.4 
 
FT-IR (NaCl, thin film) ν = 3249, 2936, 2839, 1612, 1513, 1415, 1252, 1178, 782 cm-1. 
 
HRMS (ESI) Calc (C15H15N3O)Na+: 276.1107, Found: 276.1103 
 
MP: 110 – 112 °C 
 
Rf (4% MeOH / CH2Cl2): 0.26 
  
114 
 
1-(4-Methoxybenzyl)-7-methyl-1H-imidazo[4,5-b]pyridine (32) 
Following the general experimental; 2-chloro-N-(4-methoxybenzyl)-
4-methylpyridin-3-amine (26) (93 mg, 0.4 mmol), Pd2(dba)3·CHCl3 
(4.14 mg, 0.004 mmol), L1 (9.6 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 
mL, 0.6 mmol) were combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 4 h the 
reaction was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo 
and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 32 
as 92 mg of a green solid (91%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.34 (d, J = 4.8 Hz, 1H), 8.01 (s, 1H), 6.93 – 6.77 (m, 5H), 5.44 
(s, 2H), 3.74 (s, 3H), 2.43 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.5, 156.5, 146.2, 145.1, 131.4, 128.3, 127.3, 125.6, 120.8, 
114.6, 55.4, 50.3, 17.9 
 
FT-IR (NaCl, thin film) ν = 3053, 2959, 2933, 2837, 1696, 1608, 1586, 1513, 1493, 1357, 1249, 
1178, 1031, 821 cm
-1
. 
 
Anal. Calc C15H15N3O: C, 71.13; H, 5.97; N, 16.59; found C, 71.43; H, 5.81; N, 16.61 
 
MP: 105 – 108 °C 
 
Rf (4% MeOH / CH2Cl2): 0.20 
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1-Methyl-5-phenyl-1H-imidazo[4,5-b]pyridine (33)  
Following the general experimental; 2-chloro-N-methyl-6-phenylpyridin-3-
amine (27) (87.5 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), L1 (9.6 mg, 0.02 
mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 mmol) were combined with 2.0 
mL tert-butanol in a 25 mL Schlenk flask. After 3 h the reaction was complete, the reaction 
cooled to RT, filtered through Celite, concentrated in vacuo and purified on a silica gel column 
(2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 33 as 81 mg of a pale brown solid 
(89%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.13 – 8.08 (m, 2H), 7.99 (s, 1H), 7.67 (1/2 AB d, J = 8.4 Hz, 
1H), 7.64 (1/2 AB d, J = 8.4 Hz, 1H), 7.49 – 7.41 (m, 2H), 7.40 – 7.33 (m, 1H), 3.78 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.4, 152.9, 146.1, 139.8, 128.7, 128.5, 127.2, 125.8, 118.2, 
115.6, 31.5 
 
FT-IR (NaCl, thin film) ν = 2920, 2852, 1613, 1574, 1495, 1461, 1436, 1407, 1345, 1293, 1199, 
1051, 762 cm
-1
. 
 
Anal. Calc C13H11N3: C, 74.62; H, 5.30; N, 20.08; found C, 74.95; H, 5.49; N, 20.37 
 
MP: 157 – 160 °C 
 
Rf (4% MeOH / CH2Cl2): 0.23 
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1-Butyl-1H-imidazo[4,5-b]pyrazine (34) 
Following the general experimental; N-butyl-3-chloropyrazin-2-amine (28) 
(74 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-BuBrettphos 
(9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.022 mL, 0.6 mmol) were 
combined with 2.0 mL tert-butanol in a 25 mL Schlenk flask. After 2 h the reaction was 
complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and purified 
on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 34 as 70 mg of 
a yellow solid (99%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (d, J = 2.7 Hz, 1H), 8.32 – 8.30 (m, 2H), 4.29 (t, J = 7.2 
Hz, 2H), 1.90 (pent, J = 7.5 Hz, 2H), 1.35 (hex, J = 7.5 Hz, 2H), 0.93 (t, J = 7.5 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 146.1, 147.0, 140.1, 140.0, 138.6, 44.2, 31.9, 20.0, 13.6 
 
FT-IR (NaCl, thin film) ν = 3412, 3096, 2057, 2960, 2874, 1655, 1570, 1486, 1464, 1402, 1351, 
1196, 850, 757, 638 cm
-1
. 
 
HRMS (ESI) Calc (C9H12N4)H
+
: 177.1135, Found: 177.1142 
 
MP: 84 - 86°C 
 
Rf (4% MeOH / CH2Cl2): 0.23  
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1-Benzyl-1H-imidazo[4,5-b]pyrazine (35) 
Following the general experimental; N-benzyl-3-chloropyrazin-2-amine (29) 
(87.9 mg, 0.4 mmol), Pd2(dba)3·CHCl3 (4.14 mg, 0.004 mmol), t-
BuBrettPhos (9.7 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 mmol), formamide (0.024 mL, 0.6 
mmol) were combined with 2 mL tert-butanol in a 25 mL Schlenk flask. After 0.5 h the reaction 
was complete, the reaction cooled to RT, filtered through Celite, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 35 as 
74 mg of a white solid (88%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (d, J = 2.7 Hz, 1H), 8.35 (d, J = 2.4 Hz, 1H), 7.40 – 7.28 
(m, 5H), 5.46 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 149.0, 146.9, 140.3, 139.9, 138.9, 135.0, 129.2, 128.7, 180.0, 
47.8 
 
FT-IR (NaCl, thin film) ν = 2020, 2100, 1643, 1483, 1454, 1400, 1353 cm-1. 
 
HRMS (ESI) Calc (C12H10N4): 210.0904, Found: 210.0905 
 
MP: 128-130 °C 
 
Rf (4% MeOH / CH2Cl2): 0.27 
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2-Iodo-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine (36) 
To a flame-dried 25 mL RBF equipped with a stirbar was added 
diisopropylamine (0.60 mL, 4.28 mmol) and THF (6.4 mL). The reaction was cooled to -78 °C 
(CO2/acetone) and n-BuLi (2.1 mL, 2.0M in hexanes, 4.2 mmol) was added slowly. After 0.5 h 
1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine (25a) (500 mg, 2.09 mmol) was added as a 
solution in THF (2.5 mL) and the reaction was stirred for 0.5 h.  Next, iodine (1.06 g, 4.2 mmol) 
was added as a solution in THF (2.1 mL) and the reaction mixture was stirred for 1.5 h. The 
reaction mixture was removed from the cooling bath and allowed to warm to RT.  The reaction 
was quenched with saturated Na2S2O3 (aq) (5 mL), diluted with EtOAc (10 mL) and stirred for 0.5 
h before the layers were separated. The aqueous layer was extracted with EtOAc (3x 20 mL), the 
combined organic layers were washed with brine (20 mL), dried over Na2SO4, decanted, and 
concentrated in vacuo. The crude product was purified on a silica gel column (4.5 cm x 12 cm) 
eluting with 4% MeOH / CH2Cl2 to give 640 mg of a brown solid. (84%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.48 (dd, J= 4.8 Hz, 1.5 Hz, 1H), 7.54 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.12 – 7.05 (m, 3H), 8.85 (dt, J = 4.5 Hz, 2.1 Hz, 2H), 5.34 (s, 2H), 3.78 (s, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ= 159.8, 157.7, 145.3, 128.4, 126.7, 118.4, 118.1, 114.6, 108.3, 
55.5, 51.1 
FT-IR (NaCl, thin film) ν = 2927, 2835, 1611, 1513, 1404, 1251, 1177, 1030, 764 cm-1. 
HRMS (ESI) Calc (C14H12IN3O2): 365.0022, Found: 365.0025 
MP: 125 – 128 °C 
Rf (4% MeOH / CH2Cl2): 0.27 
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4-(1-(4-Methoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-yl)morpholine 
(37) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
iodide 36 (90 mg, 0.246 mmol) in EtOH (1.3 mL) followed by morpholine(26 μL, 0.296 mmol) 
and sodium carbonate (39 mg, 0.37 mmol). The reaction was equipped with a cold-finger and 
heated in a 80°C pre-heated oil-bath for 60 h. The reaction was then cooled to RT, diluted with 3 
mL MeOH, filtered through a Celite plug, washing with MeOH (1 mL) and concentrated in 
vacuo. The crude product was purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% 
MeOH / CH2Cl2 to give 80 mg of a yellow oil (99%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.32 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.21 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.03 (d, J = 8.7 Hz, 2H), 6.95 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.84 (d, J = 6.6 Hz, 2H), 3.81 – 
3.75 (m, 4H), 3.37 – 3.32 (m, 4H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.6, 159.4, 155.2, 143.7, 128.5, 127.3, 127.2, 116.6 (x2), 
114.6, 66.4, 55.4, 50.6, 47.6 
 
FT-IR (NaCl, thin film) ν = 3053, 2962, 2915, 2853, 1612, 1583, 1514, 1411, 1368, 1250, 1177, 
1117, 1031, 855, 778 cm
-1
. 
 
HRMS (ESI) Calc (C18H20N4O2): 324.1589, Found: 324.1586 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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N-Butyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-amine (38) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
iodide 36 (35 mg, .096 mmol) in EtOH (0.48 mL) followed by n-butyl amine (19 μL, 0.19 mmol) 
and sodium carbonate (25 mg, 0.24 mmol). The reaction was equipped with a cold-finger and 
heated in a 80°C pre-heated oil-bath for 72 h. The reaction was then cooled to RT, diluted with 
H2O (3 mL) and CH2Cl2 (3 mL), the layers separated and the aqueous layer was extracted by 
CH2Cl2 (2 x 3mL). The combined organic layers were washed with brine (5 mL), dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified on a silica gel 
column (2.5 cm x 12 cm), eluting with 4% MeOH / CH2Cl2 to give 24.5 mg of a yellow oil 
(83%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.20 (br d, J = 4.5 Hz, 1H), 7.21 (br d, J = 6.9 Hz, 1H), 7.07 (br 
d, J = 8.7 Hz, 2H), 7.00 – 6.80 (m, 3H), 5.02 (s, 2H), 4.43 (br s, 1H), 3.78 (s, 3H), 3.58 – 3.45 
(m, 2H), 1.54 (pent, J = 7.2 Hz, 2H), 1.25 (sext, J = 7.5 Hz), 0.86 (t, J = 7.2 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.7, 156.4, 142.2, 128.9, 128.0, 127.7, 126.7, 114.8, 114.7, 
113.6, 55.5, 45.4, 43.2, 31.8, 20.0, 13.9 
 
FT-IR (NaCl, thin film) ν = 3213, 2957, 2932, 2870, 1611, 1564, 1513, 1oi7ui420, 1247, 1177, 
1034, 772 cm
-1
. 
 
HRMS (ESI) Calc (C18H23N4O1): 311.1866, Found: 311.1855 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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1-Me-5-PhIP (38)
69
 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
sodamide (213 mg, 5.5 mmol) followed by 1-methyl-5-phenyl-1H-imidazo[4,5-b]pyridine (33) 
(52 mg, 0.25 mmol) and of anhydrous m-xylene (2.5 mL). The reaction was equipped with a 
cold-finger, placed in a 130°C pre-heated oil-bath and stirred for 4 h at which time TLC 
indicated consumption of the azole. The reaction cooled to RT, diluted with CH2Cl2 (3 mL) and 
carefully quenched with water (4 mL). The layers were separated, aqueous layer was extracted 
with CH2Cl2 (3 x 4 mL). The combined organic layers were dried over MgSO4 and concentrated 
in vacuo to give a red solid. The crude solid was purified on a silica gel column, eluting with 
10% MeOH in CH2Cl2 to give 53 mg of a yellow solid (95%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.05 – 7.99 (m, 2H), 7.53 – 7.38 (m, 4H), 7.34 – 7.28 (m, 1H), 
6.97 (br s, 2H), 3.53 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 157.8, 156.5, 148.1, 140.4, 128.4, 127.4, 127.1, 126.1, 114.1, 
110.5, 28.9 
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7.3 2ND GENERATION 
 
2-chloro-N-(2,5-dimethoxybenzyl)pyridin-3-amine (24q)  
Following the reductive amination general procedure, 3-amino-2-
chloropyridine (2.0 g, 7.78 mmol), 24 mL ethyl acetate, 2,5-
dimethoxybenzaldehyde (2.84 g, 17.11 mmol), trifluoroacetic acid (2.31 
mL, 31.11 mmol) and sodium triacetoxyborohydride (3.95 g, 18.67 mmol) were combined and 
stirred for 15 minutes. The reaction was quenched with 20% NaOH and the pH was adjusted 
with NaOH(s). The layers were separated, the organic layer washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was recrystallized from 40 mL of 
5:1 Hexanes:EtOAc to give 24q as a white crystalline solid (2.8 g, 65%) 
1
H NMR (300 MHz, CDCl3) δ = 7.69 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.03 (dd, J = 8.1 Hz, 4.5 Hz, 
1H), 6.88 (dd, J = 7.8 Hz, 1.5 Hz, 1H), 6.85-6.74 (m, 3H), 4.92 (br s, 1H), 3.83 (s, 3H), 3.73 (s, 
3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 153.7, 151.6, 140.9, 137.3, 136.6, 127.0, 123.5, 118.1, 115.1, 
112.4, 111.4, 55.9, 55.8, 42.8 
 
FT-IR: (NaCl, thin film) ν = 2999, 2943, 2834, 1584, 1495, 1217, 1052, 791 cm-1. 
 
Anal. Calc.  C14H15ClN2O2  C, 60.33; H, 5.42; N, 10.05; found C, 60.14; H, 5.68; N, 9.93 
 
MP: 51-53 °C 
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2-chloro-N-(4-(dimethylamino)benzylpyridine-3-amine (24r)  
Following the reductive amination general procedure, 3-amino-2-
chloropyridine (2.0 g, 7.78 mmol), 24 mL ethyl acetate, 4-
dimethylaminobenzaldehyde (2.55 g, 17.11 mmol), trifluoroacetic acid 
(2.31 mL, 31.11 mmol) and sodium triacetoxyborohydride (3.95 g, 18.67 mmol) were combined 
and stirred for 15 minutes. The reaction was quenched with 20% NaOH and the pH was adjusted 
with NaOH(s). The layers were separated, the organic layer washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was recrystallized from 30 mL of 
2:1 Hexanes:EtOAc to give 24r as an off-white crystalline solid (2.35 g, 58%) 
1
H NMR (300 MHz, CDCl3) δ = 7.69 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H), 7.05 
(dd, J = 7.8 Hz, 4.5 Hz, 1H), 6.89 (dd, J = 8.1 Hz, 1.8 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 4.69 (br 
s, 1H), 4.26 (d, J = 5.4 Hz, 2H), 2.96 (s, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 150.3, 140.9, 137.1, 136.4, 128.5, 125.2, 123.5, 117.8, 112.8, 
47.2, 40.7 
 
FT-IR: (NaCl, thin film) ν = 2845, 2798, 1614, 1584, 1524, 1483, 1327, 1205, 1093, 1059, 804 
cm
-1
. 
 
Anal. Calc.  C14H16ClN3  C, 64.24; H, 6.16; N, 16.05; found C, 64.58; H, 6.01; N, 15.70 
 
MP: 91-93 °C 
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2-chloro-N-(4-chlorobenzyl)pyridin-3-amine (24s) 
Following the reductive amination general procedure, 3-amino-2-
chloropyridine (2.0 g, 7.78 mmol), 24 mL ethyl acetate, p-
chlorobenzaldehyde (2.4 g, 17.11 mmol), trifluoroacetic acid (2.31 mL, 
31.11 mmol) and sodium triacetoxyborohydride (3.95 g, 18.67 mmol) were combined and stirred 
for 10 minutes. The reaction was quenched with 20% NaOH and the pH was adjusted with 
NaOH(s). The layers were separated, the organic layer washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was recrystallized from 80 mL of 15% 
Hexanes/EtOAc to give 24s as a white crystalline solid (3.70 g, 99%) 
1
H NMR (300 MHz, CDCl3) δ = 7.73 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.33 (d, J = 8.7 Hz, 2H), 7.27 
(d, J = 8.7 Hz, 2H), 7.03 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.77 (dd, J = 7.8 Hz, 1.5 Hz, 1H), 4.85 (br 
s, 1H), 4.39 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 140.4, 137.2, 137.0, 136.3, 133.4, 129.1, 128.5, 123.5, 118.0, 
46.8 
 
FT-IR: (NaCl, thin film) ν = 3066, 2850, 1584, 1561, 1491, 1381, 1321, 1086, 1054, 796 cm-1. 
 
Anal. Calc.  C12H10Cl2N2  C, 56.94; H, 3.98; N, 11.07; found C,56.72; H, 4.26; N, 11.09 
 
MP: 109-109.5 °C 
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2-chloro-N-(4-(trifluoromethyl)benzyl)pyridin-3-amine (24t) 
Following the reductive amination general procedure, 3-amino-2-
chloropyridine (1.0 g, 7.78 mmol), 24 mL ethyl acetate, p-
trifluoromethylbenzaldehyde (1.63 g, 9.3 mmol), trifluoroacetic acid 
(1.16 mL, 15.56 mmol) and sodium triacetoxyborohydride (2.14 g, 10.1 mmol) were combined 
and stirred for 10 minutes. The reaction was quenched with 20% NaOH and the pH was adjusted 
with NaOH(s). The layers were separated, the organic layer washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was purified on a silica gel 
column eluting with 20% EtOAc / Hexanes to give 2t as a colorless oil (2.01 g, 90%) 
 
1
H NMR (300 MHz, CDCl3) δ = 7.71 (dd, J = 1.8 Hz, 4.8 Hz, 1H), 7.59 (d, J = 8.1 Hz, 2H), 7.44 
(d, J = 7.8 Hz, 2H), 6.99 (dd, J = 4.8 Hz, 8.1 Hz, 1H), 6.73 (dd, J = 1.5 Hz, 7.8 Hz, 1H), 4.98 (br 
s, 1H), 4.47 (d, J = 5.7 Hz, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 142.1, 140.3, 137.2, 137.1, 130.0 (q, J = 32.2 Hz), 127.2, 
125.8 (q, J = 4.0 Hz), 124.1 (q, J = 270 Hz), 123.5, 118.0, 46.9 
 
FT-IR: (NaCl, thin film) ν = 3065, 2904, 2857, 1919, 1619, 1588, 1503, 1418, 1325, 1097, 
1017, 830, 730, 651 cm
-1
. 
 
Anal. Calc.  C13H10ClF3N2  C, 54.46; H, 3.52; N, 9.49; found C, 54.75; H, 3.36; N, 9.49  
  
126 
 
2-chloro-N-(3-nitrobenzyl)pyridin-3-amine (24u) 
Following the reductive amination general procedure, 3-amino-2-
chloropyridine (2.0 g, 15.6 mmol), 24 mL ethyl acetate, 3-
nitrobenzaldehyde (2.6 g, 17.1 mmol), trifluoroacetic acid (2.31 mL, 
31.11 mmol) and sodium triacetoxyborohydride (3.96 g, 18.67 mmol) were combined and stirred 
for 3 hours. The reaction was quenched with 20% NaOH and the pH was adjusted with NaOH(s). 
The layers were separated, the organic layer washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was recrystallized from Hexanes/EtOAc to give 24u as 
a yellow crystalline solid (3.9 g, 74%) 
1
H NMR (300MHz, CDCl3) = 8.22 (d, J=1.5 Hz, 1H), 8.12 (dd, J=8.1 Hz, 1.2 Hz, 1H), 7.77 
(dd, J=4.8 Hz, 1.8 Hz, 1H), 7.69 (dd, J=7.8 Hz, .6 Hz, 1H), 7.55 (t, J=15.9 Hz, 1H) 7.04 (dd, 
J=8.1 Hz, 4.8 Hz, 1H), 6.75 (dd, J=8.1 Hz, 1.5 Hz, 1H), 4.54 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 148.8, 140.3, 140.1, 137.6, 137.5, 132.9, 130.1, 123.5, 122.9, 
122.0, 118.0, 46.9 
 
FT-IR (NaCl, thin film) ν =3068, 2865, 1585, 1527, 1348, 1056 cm-1 
 
Anal. Calc.  C12H10ClN3O2  C, 54.66; H, 3.82; N, 15.94; found C, 54.77; H, 3.99; N, 15.61  
 
MP: 103-107 C 
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N-(4-methoxybenzyl)pyridin-3-amine (39) 
To an oven-dried 100 mL round-bottom flask was added 3-aminopyridine (2.5 
g, 26.6 mmol) and 41 mL of EtOAc. p-Anisaldehyde (3.56 mL, 29.3 mmol) and trifluoroacetic 
acid (4.07 mL, 53.2 mmol) were added, and the reaction was stirred 10 min. Sodium 
triacetoxyborohydride (6.8 g, 31.9 mmol) was added portionwise, and the reaction stirred 30 
min. Additional sodium triacetoxyborohydride (1g) was added, and the reaction stirred a further 
30 min. The reaction was quenched with 1M NaOH(aq) and basified to pH 11 with NaOH(s). The 
reaction mixture was diluted with EtOAC, and the layers separated. The aqueous layer was 
extracted with EtOAc (40 mL), and the combined organic layers were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo to give 5.2 g of a yellow solid. The crude solid 
was recrystallized from EtOAc / Hexanes to give 4.1 g of a white solid. (72%) 
 
1
H NMR (300MHz, CDCl3) = 8.05 (d, J = 2.7 Hz, 1H), 7.95 (dd, J = 1.2 Hz, 4.5 Hz, 1H), 7.27 
(d, J = 8.7 Hz, 2H), 7.05 (ddd, J = 0.6 Hz, 4.5 Hz, 8.4 Hz, 1H), 6.92 – 6.81 (m, 3H), 4.24 (d, J = 
5.1 Hz, 2H), 4.14 (br s, 1H), 3.79 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.1, 144.2, 139.0, 136.3, 130.6, 128.8, 123.8, 118.6, 114.2, 
55.4, 47.4 
 
FT-IR (NaCl, thin film) ν = 3229. 1578, 1511, 1414, 1246, 1176, 1031, 796, 707 cm-1 
 
Anal. Calc. C13H14N2O  C, 72.87; H, 6.59; N, 13.07; found C, 72.78; H, 6.36; N, 12.82 
 
MP: 149-151 C 
  
128 
 
 
General Procedure C: Cyclization of 2-Chloro-3-aminopyridines 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added Pd2(dba)3·CHCl3 (1 mol 
%), XantPhos (5 mol %), K3PO4 (1.5 Eq.) and the pyridine (1 Eq.). The reaction vessel was 
evacuated under vacuum and refilled with Ar(g). 1,4-Dioxane and t-AmOH (10:1, 0.2 M) were 
then added via syringe and the reaction mixture was degassed by three vacuum/Ar(g) purge 
cycles. The reaction vessel was then equipped with a cold-finger, and placed in a pre-heated 110 
°C oil-bath and stirred for the specified time. Upon consumption of the pyridine (as judged by 
TLC analysis) the reaction was allowed to cool to RT, diluted with methanol, and passed through 
a Celite plug, washing with additional methanol. The crude product was concentrated in vacuo, 
and applied to a silica gel column, eluting with the specified eluent. 
 
1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine (25a) 
2-Chloro-N-(4-methoxybenzyl)pyridin-3-amine (100mg, 0.4 mmol) was reacted 
following general procedure C for 6 h. The crude product was purified by flash column 
chromatography (3% MeOH in CH2Cl2) to yield the product as an off-white solid (89 mg, 93%).  
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.11 (s, 1H), 7.54 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.15 – 7.05 (m, 3H), 6.83 (d, 8.7 Hz, 2H), 5.26 (s, 2H), 3.75 (s, 3H)  
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1-(2,4-Dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine (25c) 
2-chloro-N-(2,4-dimethoxybenzyl)pyridin-3-amine (279 mg, 1.0 
mmol) was reacted following general procedure C for 7 h. The crude 
product was purified by flash column chromatography (3% MeOH in 
CH2Cl2) to yield the product as a beige solid (217 mg, 81%).  
1
H NMR (300 MHz, CDCl3) δ= 8.52 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.16 (s, 1H), 7.71 (dd, 
J = 8.1 Hz, 1.5 Hz, 1H), 7.16 (dd, J= 8.1 Hz, 4.8 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H), 6.46 – 6.40 
(m, 2H), 5.25 (s, 2H), 3.78 (s, 6H)  
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1-(2,5-Dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine (25q) 
2-chloro-N-(2,5-dimethoxybenzyl)pyridin-3-amine (112 mg, 0.4 mmol) 
was reacted following general procedure C for 6.5 h. The crude product 
was purified by flash column chromatography (3% MeOH in CH2Cl2) 
to yield the product as a beige solid (92 mg, 85%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.48 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.15 (s, 1H), 7.68 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.12 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.77 (d, J = 1.8 Hz, 2H), 6.65 (br s, 1H), 5.25 
(s, 2H), 3.74 (s, 3H), 3.66 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.3, 153.6, 151.4, 145.8, 144.7, 126.3, 123.9, 118.3, 118.0, 
116.0, 113.8, 111.6, 55.8, 55.8, 44.9 
 
FT-IR (NaCl, thin film) ν = 3051, 2951, 2835, 1610, 1504, 1412, 1286, 1227, 1047, 783, 592 
cm
-1
. 
 
EA: Calculated: C15H15N3O2, C; 66.75; H, 5.61; N, 15.60; found C, 66.75; H, 5.87; N, 15.93 
 
MP: 143 – 144 °C 
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4-((1H-imidazo[4,5-b]pyridin-1-yl)methyl)-N,N-dimethylaniline 
(25r) 
2-Chloro-N-(4-(dimethylamino)benzyl)pyridin-3-amine (105 mg, 0.4 
mmol) was reacted following general procedure C for 6.5 h. The crude product was purified by 
flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a beige solid (95 
mg, 94%).  
1
H NMR (300 MHz, CDCl3) δ= 8.48 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.08 (s, 1H), 7.57 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.09 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.05 (d, J = 9 Hz, 2H), 6.62 (d, J = 9 Hz, 2H), 
5.19 (s, 2H), 2.89 (s, 6H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 150.5, 145.2, 144.8, 128.7, 126.2, 121.5, 118.5, 118.0, 
112.5, 49.3, 40.4 
 
FT-IR (NaCl, thin film) ν = 3051, 3000, 2951, 2835, 1610, 1503, 1464, 1411, 1286, 1227, 1046, 
783 cm
-1
. 
 
EA: Calculated: C15H16N4, C; 71.40; H, 6.39; N, 22.21; found C, 71.56; H, 6.12; N, 22.35 
 
MP: 115 – 119 °C 
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1-(4-Fluorobenzyl)-1H-imidazo[4,5-b]pyridine (25v) 
2-chloro-N-(4-fluorobenzyl)pyridin-3-amine (95 mg, 0.4 mmol) was 
reacted following general procedure C for 6.5 h. The crude product was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a brown 
solid (87 mg, 96%).  
1
H NMR (300 MHz, CDCl3) δ= 8.48 (dd, J=4.8 Hz, 1.8 Hz, 1H) 8.14 (s, 1H), 7.53 (dd, J=8.1 
Hz, 1.5 Hz, 1H), 7.16-7.10 (m, 3H), 7.01-6.96 (m, 2H), 5.33 (s, 2H)  
 
1-(2-chlorobenzyl)-1H-imidazo[4,5-b]pyridine (25e) 
2-Chloro-N-(2-chlorobenzyl)pyridin-3-amine (101 mg, 0.4 mmol) 
was reacted following general procedure C for 6.5 h. The crude product was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a brown 
solid (77 mg, 79%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.51 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.16 (s, 1H), 7.60 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.39 (dd, J = 8.1 Hz, 1.2 Hz, 1H), 7.25 (td, J = 7.5 Hz, 1.5 Hz, 1H), 7.17 (dd, J 
= XX Hz, 1.2 Hz, 1H), 7.13 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 5.44 (s, 2H)  
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1-(4-chlorobenzyl)-1H-imidazo[4,5-b]pyridine (25s) 
2-Chloro-N-(4-chlorobenzyl)pyridin-3-amine (101mg, 0.4 mmol) was 
reacted following general procedure C for 6.5 h. The crude product was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a white 
solid (92 mg, 94%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.14 (s, 1H), 7.50 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.11 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 7.07 (d, J = 8.7 Hz, 
2H), 5.33 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.5, 145.3, 145.2, 134.5, 133.3, 129.4, 128.5, 126.0, 118.4, 
118.3, 48.8 
 
FT-IR (NaCl, thin film) ν = 3072, 2973, 1610, 1494, 1409, 1293, 1215, 1176, 1079, 1014, 782 
cm
-1
. 
 
EA: Calculated: C13H10ClN3, C; 64.07; H, 4.14; N, 17.24; found C, 64.20; H, 3.99; N, 17.05 
 
MP: 134 – 136 °C 
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1-benzyl-1H-imidazo[4,5-b]pyridine (25b) 
N-benzyl-2-chloropyridin-3-amine (85 mg, 0.4 mmol) was reacted following 
general procedure C for 6.5 h. The crude product was purified by flash 
column chromatography (4% MeOH in CH2Cl2) to yield the product as a brown solid (71 mg, 
85%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.14 (s, 1H), 7.53 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.34 – 7.24 (m, 3H), 7.18 – 7.08 (m, 3H), 5.34 (s, 2H) 
 
(R)-1-(1-Phenylethyl)-1H-imidazo[4,5-b]pyridine (25m) 
(R)-2-chloro-N-(1-phenylethyl)pyridin-3-amine (93 mg, 0.4 mmol) was 
reacted following general procedure C for 6.5 h. The crude product was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a brown 
solid (85 mg, 96%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.52 (dd, J = 4.5 Hz, 1.5 Hz, 1H), 8.30 (s, 1H), 7.43 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.37 – 7.28 (m, 3H), 7.19 – 7.14 (m, 2H), 7.08 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 
5.61 (q, J = 7.2 Hz, 1H), 2.00 (d, J = 6.9 Hz, 3H)  
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1-(4-(trifluoromethyl)benzyl)-1H-imidazo[4,5-b]pyridine (25t) 
2-chloro-N-(4-(trifluoromethyl)benzyl)pyridin-3-amine (115 mg, 0.4 
mmol) was reacted following general procedure C for 7 h. The crude 
product was purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the 
product as a beige solid (105 mg, 95%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.19 (s, 1H), 7.57 (d, J = 8.1 
Hz, 2H), 7.51 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 7.25 (d, J = 8.1 Hz, 2H), 7.15 (dd, J = 8.1 Hz, 4.8 Hz, 
1H), 5.46 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 145.4, 138.9, 131.0 (q, JC-F = 32.5 Hz), 127.4, 126.3 (q, 
JC-F = 3.8 Hz), 126.1, 123.8(q, JC-F = 270.8 Hz), 118.5, 118.3, 48.9 
 
19
F NMR (282.4 MHz, CDCl3) δ= - 63.2 
 
FT-IR (NaCl, thin film) ν = 3083, 2053, 3023, 2978, 1612, 1495, 1329, 1290, 1159, 1065, 1017, 
782 cm
-1
. 
 
EA: Calculated: C14H19N3F3, C; 60.65; H, 3.64; N, 15.16; found C, 60.20; H, 3.61; N, 15.20 
 
MP: 159 – 160 °C 
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1-(3-nitrobenzyl)-1H-imidazo[4,5-b]pyridine (25u) 
2-chloro-N-(3-nitrobenzyl)pyridin-3-amine (105 mg, 0.4 mmol) was 
reacted following general procedure C for 6.5 h. The crude product was 
purified by flash column chromatography (4 % MeOH in CH2Cl2) to yield the product as a 
brown solid (58 mg, 57%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.57 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.25 (s, 1H), 8.21 – 8.15 (m, 
1H), 8.12 (app t, J = 1.8 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.46 – 7.41 (m, 1H), 7.18 (dd, J = 8.1 Hz, 
4.5 Hz, 1H), 5.53 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 156.6, 148.8, 145.6, 145.3, 137.1, 132.9, 130.6, 125.9, 123.8, 
122.2, 118.7, 118.2, 48.7 
 
FT-IR (NaCl, thin film) ν = 3051, 2927, 2852, 1610, 1529, 1493, 1413, 1349, 1291, 1212, 728 
cm
-1
. 
 
EA: Calculated: C13H10N4O2, C; 61.41; H, 3.96; N, 22.04; found C, 61.13; H, 3.86; N, 22.41 
 
MP: 115 – 118 °C 
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1-Phenyl-1H-imidazo[4,5-b]pyridine (25o) 
2-Chloro-N-phenylpyridin-3-amine (82 mg, 0.4 mmol) was reacted following 
general procedure C for 6 h. The crude product was purified by flash column 
chromatography (3% MeOH in CH2Cl2) to yield the product as a white solid (73 
mg, 94%).  
1
H NMR (300 MHz, CDCl3) δ= 8.57 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.30 (s, 1H), 7.81 (dd, J = 8.4 
Hz, 1.8 Hz, 1H), 7.60 – 7.51 (m, 2H), 7.49 – 7.41 (m, 3H), 7.21 (dd, J = 8.1 Hz, 4.8 Hz, 1H) 
 
1-cyclopentyl-1H-imidazo[4,5-b]pyridine (25j) 
2-chloro-N-cyclopentylpyridin-3-amine (80 mg, 0.4 mmol) was reacted following 
general procedure C for 6.5 h. The crude product was purified by flash column 
chromatography (3% MeOH in CH2Cl2) to yield the product as an off-white solid (64 mg, 85%). 
1
H NMR (300 MHz, CDCl3) δ= 8.51 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.14 (s, 1H), 7.74 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.18 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.71 (pent, J = 6.9 Hz, 1H), 2.35 – 2.15 (m, 
2H), 2.05 – 1.70 (m, 6H) 
 
1-isopropyl-1H-imidazo[4,5-b]pyridine (25h) 
2-chloro-N-isopropylpyridin-3-amine (68 mg, 0.4 mmol) was reacted following 
general procedure C for 6.5 h. The crude product was purified by flash column 
chromatography (3% MeOH in CH2Cl2) to yield the product as an off-white solid (59 mg, 91%).  
1
H NMR (300 MHz, CDCl3) δ= 8.53 (dd, J = 4.5 Hz, 1.2 Hz, 1H), 8.19 (s, 1H), 7.75 (dd, J = 8.1 
Hz, 1.5 Hz, 1H), 7.20 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.63 (sept, J = 6.6 Hz, 1H), 1.61 (d, J = 6.6 
Hz, 6H) 
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1-(2,4-dimethoxybenzyl)-2-phenyl-1H-imidazo[4,5-b]pyridine (30) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was 
added Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 
mmol), K3PO4 (128 mg, 0.6 mmol) and the 2-chloro-N-(2,4-
dimethoxybenzyl)pyridin-3-amine (112 mg, 1.0 mmol). The reaction vessel was evacuated under 
vacuum and refilled with Ar(g). Benzamide (73 mg, 0.6 mmol) was added followed by 1,4-
Dioxane and t-AmOH (10:1, 0.2 M) and the reaction mixture was degassed by three 
vacuum/Ar(g) purge cycles. The reaction vessel was then equipped with a cold-finger, and placed 
in a pre-heated 110 °C oil-bath and stirred for 18h. The reaction was then allowed to cool to RT, 
diluted with methanol, and passed through a Celite plug, washing with additional methanol. The 
crude product was concentrated in vacuo, and purified on a silica gel column, eluting with 3.5 % 
MeOH / CH2Cl2 to give the product as a pale yellow solid (108 mg, 78%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.54 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.86-7.74 (m, 2H), 7.53-7.36 
(m, 4H), 7.11 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.63 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 
6.32 (dd, J = 8.4 Hz, 2.4 Hz), 5.39 (s, 2H), 3.77 (s, 6H) 
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1-(4-methoxybenzyl)-2-methyl-1H-imidazo[4,5-b]pyridine (31) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), K3PO4 
(128 mg, 0.6 mmol) and the 2-chloro-N-(4-methoxybenzyl)pyridin-3-amine (100 mg, 1.0 mmol). 
The reaction vessel was evacuated under vacuum and refilled with Ar(g). Acetamide (35 mg, 0.6 
mmol) was added followed by 1,4-Dioxane and t-AmOH (10:1, 0.2 M) and the reaction mixture 
was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then equipped with a 
cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 18h. The reaction was then 
allowed to cool to RT, diluted with methanol, and passed through a Celite plug, washing with 
additional methanol. The crude product was concentrated in vacuo, and applied to a silica gel 
column, eluting with 3.5 % MeOH / CH2Cl2 to give the product as a off-white solid (84 mg, 
83%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.47 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.48 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 7.08 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.97 (d, J = 9 Hz, 2H), 6.82 (d, J = 8.7 Hz, 2H), 5.25 (s, 
2H), 3.76 (s, 3H), 2.62 (s, 3H) 
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2-Cyclohexyl-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine (47) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), K3PO4 
(128 mg, 0.6 mmol) and the 2-chloro-N-(4-methoxybenzyl)pyridin-3-amine (100 mg, 1.0 mmol). 
The reaction vessel was evacuated under vacuum and refilled with Ar(g). 
Cyclohexanecarboxamide (76 mg, 0.6 mmol) was then added followed by 1,4-Dioxane and t-
AmOH (10:1, 0.2 M) and the reaction mixture was degassed by three vacuum/Ar(g) purge cycles. 
The reaction vessel was then equipped with a cold-finger, and placed in a pre-heated 110 °C oil-
bath and stirred for 24h. The reaction mixture was then allowed to cool to RT, diluted with 
methanol, and passed through a Celite plug washing with additional methanol. The crude product 
was concentrated in vacuo, and purified on a silica gel column, eluting with 3.5 % MeOH / 
CH2Cl2 to give the product as an off-white solid (57 mg, 44%). Which was a 3:1 mixure of the 
desired product and cyclohexanecarboxamide; all attempts at further purification were 
unsuccessful. 
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(E)-1-(4-methoxybenzyl)-2-styryl-1H-imidazo[4,5-b]pyridine (48) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), K3PO4 (128 mg, 0.6 
mmol) and the 2-chloro-N-(4-methoxybenzyl)pyridin-3-amine (100 mg, 1.0 mmol). The reaction 
vessel was evacuated under vacuum and refilled with Ar(g). Trans-Cinnamamide (88 mg, 0.6 
mmol) was then added followed by 1,4-Dioxane and t-AmOH (10:1, 0.2 M) and the reaction 
mixture was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then equipped 
with a cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 24h. The reaction 
mixture was then allowed to cool to RT, diluted with methanol, and passed through a Celite plug, 
washing with additional methanol. The crude product was concentrated in vacuo, and purified on 
a silica gel column, eluting with 3.5 % MeOH / CH2Cl2 to give the product as a fluffy pale-
yellow solid (130 mg, 96%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.48 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 8.11 (d, J = 15.9 Hz, 1H), 
7.53 – 7.42 (m, 3H), 7.47 – 7.28 (m, 3H), 7.05 – 6.95 (m, 4H), 6.69 (d, J = 6.6 Hz, 2H), 5.34 (s, 
2H), 3.71 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.4, 155.9, 153.2, 145.4, 139.2, 135.6, 129.5, 128.9, 128.0, 
127.7, 127.5, 127.5, 117.6, 117.4, 114.5, 112.3, 55.3, 46.5 
 
FT-IR (NaCl, thin film) ν = 2957, 2934, 2836, 1634, 1611, 1513, 1409, 1251, 1177, 1032m 909 
cm
-1
. 
 
EA: Calculated: C22H19N3O, C; 77.40; H, 5.61; N, 12.31; found C, 77.62; H, 5.89; N, 12.49 
 
  
142 
 
MP: 123 – 124 °C 
 2-(furan-2-yl)-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine (46) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), 
K3PO4 (128 mg, 0.6 mmol) and the 2-chloro-N-(4-methoxybenzyl)pyridin-3-amine (100 mg, 1.0 
mmol). The reaction vessel was evacuated under vacuum and refilled with Ar(g). 2-Furanamide 
(67 mg, 0.6 mmol) was then added followed by 1,4-Dioxane and t-AmOH (10:1, 0.2 M) and the 
reaction mixture was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then 
equipped with a cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 24h. The 
reaction was then allowed to cool to RT, diluted with methanol, and passed through a Celite 
plug, washing with additional methanol. The crude product was concentrated in vacuo, and 
purified on a silica gel column, eluting with 3.5 % MeOH / CH2Cl2 to give the product as a white 
solid (118 mg, 97%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.57 (dd, J = 1.8 Hz, 0.6 Hz, 
1H), 7.52 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 7.29 (dd, J = 3.6 Hz, 0.9 Hz, 1H), 7.08 (dd, J = 8.1 Hz, 
4.8 Hz, 7.03 (d, J = 6.6 Hz, 2H), 6.78 (d, J = 6.6 Hz, 2H), 6.56 (dd, J = 3.3 Hz, 1.8 Hz, 1H), 5.64 
(s, 2H), 3.72 (s, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ= 159.2, 155.5, 146.0, 145.4, 144.9, 144.6, 144.3, 128.0, 127.8, 
118.1, 118.0, 114.9, 114.3, 112.3, 55.2, 48.2 
FT-IR (NaCl, thin film) ν = 3124, 2933, 2836, 1676, 1610, 1512, 1410, 1382, 1251, 1029, 912 
cm
-1
. 
EA: Calculated: C18H15N3O2, C; 70.81; H, 4.95; N, 13.76; found C, 70.88; H, 5.08; N, 14.01 
MP: 121 – 124 °C 
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1-(4-methoxybenzyl)-7-methyl-1H-imidazo[4,5-b]pyridine (32) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), K3PO4 
(128 mg, 0.6 mmol) and the 2-chloro-N-(4-methoxybenzyl)-4-methylpyridin-3-amine (112 mg, 
1.0 mmol). The reaction vessel was evacuated under vacuum and refilled with Ar(g). Formamide 
(27 mg, 0.6 mmol) was then added followed by 1,4-Dioxane and t-AmOH (10:1, 0.2 M) and the 
reaction mixture was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then 
equipped with a cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 24h. The 
reaction mixture was then allowed to cool to RT, diluted with methanol, and passed through a 
Celite plug, washing with additional methanol. The crude product was concentrated in vacuo, 
and purified on a silica gel column, eluting with 3 % MeOH in CH2Cl2 to give the product as a 
yellow solid (71 mg, 70%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.39 (d, J = 4.8 Hz, 1H), 8.07 (s, 1H), 6.95 – 6.89 (m, 3H), 6.83 
(d, J = 6.3 Hz, 2H), 5.48 (s, 2H), 3.76 (s, 3H), 2.46 (s, 3H) 
 
 
 
  
144 
 
1-butyl-1H-imidazo[4,5-b]pyrazine (34) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), K3PO4 
(128 mg, 0.6 mmol) and the N-butyl-3-chloropyrazin-2-amine (74 mg, 1.0 mmol). The reaction 
vessel was evacuated under vacuum and refilled with Ar(g). Formamide (27 mg, 0.6 mmol) was 
then added followed by 1,4-Dioxane and t-AmOH (10:1, 0.2 M) and the reaction mixture was 
degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then equipped with a cold-
finger, and placed in a pre-heated 110 °C oil-bath and stirred for 2h. The reaction was then 
allowed to cool to RT, diluted with methanol, and passed through a Celite plug, washing with 
additional methanol. The crude product was concentrated in vacuo, and applied to a silica gel 
column, eluting with 4 % MeOH in CH2Cl2 to give the product as a yellow solid (58 mg, 83%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.51 (d, J = 2.7 Hz, 1H), 8.32 – 8.30 (m, 2H), 4.29 (t, J = 7.2 
Hz, 2H), 1.91 (pent, J = 7.5 Hz, 2H), 1.35 (hex, J = 7.5 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H) 
 
 
  
145 
 
1-benzyl-1H-imidazo[4,5-b]pyrazine (35)  
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (12 mg, 0.02 mmol), 
K3PO4 (128 mg, 0.6 mmol) and the N-benzyl-3-chloropyrazin-2-amine (88 mg, 1.0 mmol). The 
reaction vessel was evacuated under vacuum and refilled with Ar(g). Formamide (27 mg, 0.6 
mmol) was then added followed by 1,4-Dioxane & t-AmOH (10:1, 0.2 M) and the reaction 
mixture was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then equipped 
with a cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 1h. The reaction 
mixture was then allowed to cool to RT, diluted with methanol, and passed through a Celite plug, 
washing with additional methanol. The crude product was concentrated in vacuo, and purified on 
a silica gel column, eluting with 3 % MeOH in CH2Cl2 to give the product as a yellow solid (80 
mg, 95%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.52 (d, J = 2.7 Hz, 1H), 8.34 (d, J = 2.7 Hz, 1H), 8.31 (s, 1H), 
7.35 – 7.26 (m, 5H), 5.45 (s, 2H) 
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7.4 SNAR 
1-(4-Fluorobenzyl)-1H-imidazo[4,5-b]pyridine (SI3)  
To an oven-dried 25 mL Schlenk tube equipped with a magnetic stirbar 
was added 2-chloro-N-(4-fluorobenzyl)pyridin-3-amine
50
 (95 mg, 0.4 
mmol), Pd2(dba)3·CHCl3 (4.2 mg, 0.004 mmol), Me3(OMe)t-BuXPhos (9.9 mg, 0.02 mmol), and 
K3PO4 (128 mg, 0.6 mmol). The tube was evacuated and refilled with Ar(g) at which time 
formamide (24 μL, 6.3 mmol) and 2 mL tert-butanol were added. The reaction vessel was then 
subjected to three vacuum / Ar(g) purge cycles and placed into a preheated 120 C oil-bath. The 
reaction mixture was stirred for 3.5 h at which time TLC analysis indicated the chloropyridine 
was consumed. The reaction mixture was cooled to RT, filtered through a Celite plug, 
concentrated in vacuo and purified on a silica gel column (2.5 cm x 12 cm), eluting with 4% 
MeOH / CH2Cl2 to give 87 mg (96%) as a brown solid. 
1
H NMR (300 MHz, CDCl3) = 8.57 (dd, J=4.8 Hz, 1.8 Hz, 1H) 8.17 (s, 1H), 7.55 (dd, J=8.1 
Hz, 1.5 Hz, 1H), 7.19-7.14 (m, 3H), 7.08-7.01 (m, 2H), 5.35 (s, 2H) 
13
C NMR (75.4 MHz, CDCl3) δ= 162.8 (d, J=247.7 Hz), 156.6, 145.3, 145.2, 130.6 (d, J=3.3 
Hz), 129.1 (d, J= 8.4 Hz), 126.1, 118.4, 118.3, 116.3 (d, J = 21.8 Hz), 48.9 
19
F NMR (282.4 MHz, CDCl3) δ= -113.3 -113.4 (m) 
FT-IR: (NaCl, thin film) ν = 3054, 1609, 1510, 1492, 1414, 1361, 1292, 1223, 1158, 780 cm-1. 
EA: Calculated: C 68.71, H 4.44, N 18.49; Found: C 68.50, H 4.78, N 18.20 
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MP: 86-89 C 
 
 
General Procedure D: Chlorination 
2-chloro-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine 
(49a)
77
 
To a flame-dried 50 mL RBF equipped with a magnetic stirbar was 
added 14.9 mL of THF and diisopropylamine (1.07 mL, 7.64 mmol). The reaction mixture was 
cooled to -78 °C (CO2/acetone), n-BuLi (3.82 mL, 1.95M in hexanes, 7.46 mmol) was added 
slowly, and the reaction mixutre stirred for 1h at which time 1-(4-methoxybenzyl)-1H-
imidazo[4,5-b]pyridine
74
 (1.0 g, 3.73 mmol) was added as a solution in 7.5 mL of THF. The 
reaction mixutre was stirred for 1 h at which time hexachloroethane (1.77 g, 7.46 mmol) was 
added at -78°C as a solution in 4 mL of THF. The reaction mixutre was stirred for 2 h at -78 °C, 
warmed to RT and stirred for an additional 0.5 h. At this time the reaction was quenched with 2 
mL of NH4Cl(aq), diluted with 10 mL of H2O and poured into 20 mL of EtOAc. The layers were 
separated, and the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified on a silica gel column (4.5 cm x 12 cm) eluting with 3% MeOH / CH2Cl2 to 
give 920 mg of an oil that solidified to a brown solid when triturated with 5 mL of MeCN. (81%) 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.59 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.14 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.45 – 6.39 (m, 2H), 5.33 (s, 
2H), 3.79 (s, 3H), 3.78 (s, 3H) 
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13
C NMR (75.4 MHz, CDCl3) δ = 161.2, 158.1, 153.9, 144.9, 144.3, 129.9, 128.0, 118.5, 118.2, 
114.8, 104.2, 98.5, 55.4, 55.3, 43.8 
 
FT-IR: (NaCl, thin film) ν = 2939, 2837, 1612, 1589, 1509, 1463, 1410, 1371, 1278, 1210, 
1033, 834, 781 cm
-1
. 
 
HRMS (ESI) Calc (C15H14ClN3O2)Na+:, 326.0667 Found: 326.0671 
 
MP: 92 – 93 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24  
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1-Benzyl-2-chloro-1H-imidazo[4,5-b]pyridine (49b) 
Following general procedure D 6.64 mL of THF and diisopropylamine (0.47 
mL, 3.32 mmol) were combined and the reaction mixture was cooled to -
78°C. n-BuLi (1.3 mL, 2.5M, 3.24 mmol) was added, the reaction mixture was stirred for 1 h at 
which time 1-benzyl-1H-imidazo[4,5-b]pyridine
74
 (340 mg, 1.62 mmol) was added as a solution 
in 3.2 mL of THF. The reaction mixture was stirred for 1 h at which time hexachloroethane (767 
mg, 3.24 mmol) was added as a solution in 1.7 mL of THF. the reaction mixture stirred for 2 h at 
-78°C and then allowed to warm to rt over 0.5 h.  At this time the reaction was quenched with 2 
mL of NH4Cl(aq), diluted with 9 mL of H2O and poured into 20 mL of EtOAc. The layers were 
separated, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified on a silica gel column (4.5 cm x 12 cm) eluting with 4% MeOH / CH2Cl2 to 
give 244 mg of a red-brown solid. (62 %) 
1
H NMR: (300 MHz, CDCl3) δ= 8.46 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.49 (dd, J = 8.1 Hz, 1.2 Hz, 
1H), 7.30-7.27 (m, 3H) 7.14-7.09 (m, 3H), 5.37 (s, 2H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 154.1, 145.3, 144.0, 134.3, 129.2, 128.5, 127.8, 126.9, 118.6, 
118.0, 48.3 
 
FT-IR: (NaCl, thin film) ν = 2964, 1608, 1460, 1415, 1361, 1313, 1276, 1187, 781, 726, 696 
cm
-1
. 
 
HRMS Calc (C13H10ClN3)H
+
: 244.0636, Found: 244.0635 
 
  
150 
 
MP:  164-167º C 
  
151 
 
2-chloro-1-(4-Methoxybenzyl)-1H-imidazo[4,5-b]pyridine (49c) 
Following general procedure D, 5.14 mL of THF, diisopropylamine 
(0.36 mL, 2.57 mmol), n-BuLi (1.0 mL, 2.4M, 2.5 mmol), 1-(4-
Methoxybenzyl)-1H-imidazo[4,5-b]pyridine
74
 (300 mg, 1.25 mmol) as a solution in 2.5 mL of 
THF, and hexachloroethane (0.59 g, 2.5 mmol) as a solution in 1.3 mL of THF was added to a 
flame dried 50 mL RBF. The reaction mixture stirred for 1.5 h at -78 °C and warmed to RT. The 
reaction mixture was quenched with 2 mL of sat. NH4Cl(aq), diluted with 10 mL of H2O, and 
poured into 20 mL of EtOAc. The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over 
MgSO4, and concentrated in vacuo. The crude product was purified on a silica column (2.5 cm x 
12 cm) eluting with 3% MeOH / CH2Cl2 to give 0.168 g (49%) as a gold crystalline solid. 
 
1
H NMR (300 MHz, CDCl3) =8.53 (dd, J=4.8 Hz, 1.5 Hz, 1H), 7.54 (dd, J=8.1 Hz, 1.5 Hz, 
1H), 7.20-7.12 (m, 3H), 6.86 (d, J=9 Hz, 2H), 5.35 (s, 2H), 3.78 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) = 159.7, 154.1, 145.3, 144.0, 128.5, 127.7, 126.3, 118.6, 118.1, 
114.5, 55.3, 47.9 
 
FT-IR (NaCl, thin film) ν = 2355, 1611, 1513, 1463, 1370, 1250 cm-1. 
 
Anal: Calculated: C 61.43, H 4.42, N 15.35; Found: C 61.63, H 4.67, N, 15.26 
 
MP: 138-141 °C 
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2-Chloro-1-(4-fluorobenzyl)-1H-imidazo[4,5-b]pyridine (49d) 
Following general procedure D, 35.3 mL of THF, diisopropylamine 
(0.37 mL, 2.67 mmol), n-BuLi (1.5 mL, 1.75M, 2.6 mmol), 1-(4-
Fluorobenzyl)-1H-imidazo[4,5-b]pyridine (SI3) (300 mg, 1.3 mmol) as a solution in 1.75 mL of 
THF, hexachloroethane (0.61 g, 2.6 mmol) as a solution in 1.4 mL of THF was added to an oven 
dried 50 mL RBF. The reaction mixture stirred for 1 h at -78 °C, warmed to RT and stirred for 
0.5 h. The reaction mixture was quenched with 2 mL of sat. NH4Cl(aq), diluted with 8 mL of H2O, 
and poured into 20 mL of EtOAc. The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over 
MgSO4, and concentrated in vacuo. The crude product was purified on a silica column (2.5 cm x 
12 cm) eluting with 3% MeOH / CH2Cl2 to give 0.211 g (61%) as a light brown solid. 
 
1
H NMR ( 300MHz, CDCl3) = 8.46 (dd, J =4.8 Hz, 0.9 Hz, 1H), 7.51, (dd, J =8.1 Hz, 0.9 Hz, 
1H), 7.15-7.11 (m, 3H), 6.97 (t, J=15.3, 2H), 5.35 (s, 2H) 
 
13
C NMR (75.4 MHz, CDCl3) = 162.7 (d, J = 247.6 Hz), 154.2, 145.5, 143.9, 130.2 (d,  J= 3.2 
Hz), 128.9 (d, J = 8.3 Hz), 127.7, 118.8, 117.9, 116.3 (d, J = 21.8 Hz), 47.7 
 
19
F NMR (282.4 MHz, CDCl3) δ= -113.27  -113.37 (m) 
 
FT-IR (NaCl, thin film) ν = 1643, 1511, 1464, 1371, 1277, 1224 cm-1. 
 
Anal: Calculated: C 59.67, H 3.47, N 16.06; Found: C 59.43, H 3.57, N 16.04 
 
MP: 130-132°C 
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2-Chloro-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyridine (49c) 
Following general procedure D, 1.88 mL of THF, diisopropylamine 
(0.13 mL, 0.94 mmol), n-BuLi (0.43 mL, 2.15M, 0.92 mmol), 1-
(cyclohexylmethyl)-1H-imidazo[4,5-b]pyridine
74
 (100 mg, 0.46 mmol) as a solution in 0.92 mL 
of THF, hexachloroethane (0.23 g, 0.92 mmol) as a solution in 0.49 mL of THF was added to an 
flame dried 25 mL RBF. The reaction mixture stirred for 2 h at -78 °C, warmed to RT and stirred 
for 15 min. The reaction mixture was quenched with 2 mL of sat. NH4Cl(aq), diluted with 7 mL of 
H2O, and poured into 15 mL of EtOAc. The layers were separated and the aqueous layer was 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried 
over MgSO4, and concentrated in vacuo. The crude product was purified on a silica column (2.5 
cm x 12 cm) eluting with 3% MeOH / CH2Cl2 to give 78.2 mg (69%) as a green solid. 
 
1
H NMR (300 MHz, CDCl3) = 8.48 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.60 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.18 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 3.99 (d, J = 7.2 Hz, 2H), 1.88-1.57 (m, 6H), 1.18-1.00 
(m, 5H) 
 
13
C NMR (75.4 MHz, CDCl3) = 153.9, 145.1, 144.2, 128.3, 118.4, 117.9, 50.9, 38.3, 30.8, 26.0, 
25.6 
 
FT-IR (NaCl, thin film) ν = 2926, 2852, 1466, 1414, 1378 cm-1. 
 
EA: Calculated: C 62.52, H 6.46, N 16.83; Found: C 62.72, H 6.41, N 16.66 
 
MP: 130-133 C 
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2-chloro-1-isopropyl-1H-imidazo[4,5-b]pyridine (49f)  
Following general procedure D, 2.5 mL of THF, diisopropylamine (0.179 mL, 
1.27 mmol) were added, then cooled to -78 °C (CO2/acetone), n-BuLi (0.58 mL, 
2.15M, 1.24 mmol) was added slowly, the reaction mixture stirred for 1 h and 1-isopropyl-1H-
imidazo[4,5-b]pyridine
74
 (100 mg, 0.62 mmol) was added as a solution in 2.4 mL of THF. The 
reaction mixture was stirred for 50 min at which time hexachloroethane (294 mg, 1.24 mmol) 
was added at -78°C as a solution in 0.65 mL of THF. The reaction mixture was stirred 1.5 h at -
78 °C, warmed to RT over 0.5 h.  At this time the reaction was quenched with 2 mL of NH4Cl(aq), 
diluted with 5 mL of H2O and poured into 15 mL of EtOAc. The layers were separated, and the 
aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were washed 
with H2O, brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified on a silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH / CH2Cl to give 83 mg 
of a red/brown solid. (69%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.46 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.79 (dd, J = 7.5 Hz, 1.5 Hz, 
1H), 7.15 (dd, J = 8.4 Hz, 4.8 Hz, 1H), 4.96-4.86 (m, 1H), 1.61, (d, J = 4.5 Hz, 6H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 154.3, 144.9, 143.2, 126.2, 119.0, 118.0, 49.7, 21.3 
 
FT-IR: (NaCl, thin film) ν = 2984, 1647, 1454, 1409, 1354, 1298, 783 cm-1. 
 
HRMS Calc (C9H10ClN3)H
+
: 196.0636, Found: 196.0636 
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MP: 67-70 ºC 
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2-Chloro-1-neopentyl-1H-imidazo[4,5-b]pyridine (49g)  
Following general procedure D, 4.76 mL of THF, diisopropylamine (0.335 mL, 
2.38 mmol) were added then cooled to -78 °C (CO2/acetone) and, n-BuLi (1.19 
mL, 2.15M, 2.32 mmol) was added slowly, the reaction mixture stirred for 1 h and 1-neopentyl-
1H-imidazo[4,5-b]pyridine
74
 (220 mg, 1.16  mmol) was added as a solution in 2.4 mL of THF. 
The reaction mixture was stirred for 50 min at which time hexachloroethane (550 mg, 2.32 
mmol) was added at -78°C as a solution in 1.3 mL of THF. The reaction mixture was stirred 1 h 
at -78 °C, warmed to RT over 0.5 h.  At this time the reaction was quenched with 2 mL of sat. 
NH4Cl(aq), diluted with 15 mL of H2O and poured into 20 mL of EtOAc. The layers were 
separated, and the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic 
layers were washed with H2O, brine, dried over MgSO4, filtered, and concentrated in vacuo. The 
crude product was purified on a silica gel column (4.5 cm x 12 cm) eluting with 4% MeOH / 
CH2Cl2 to give 136 mg of a brown solid. (52%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.49 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.64 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 7.18 (dd, J = 8.1 Hz, 4.5 Hz, 1H), 4.00 (s, 2H), 1.03 (s, 9H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 154.0, 145.2, 145.1, 129.0, 118.9, 118.4, 56.0, 35.1, 28.5 
 
FT-IR: (NaCl, thin film) ν = 3053, 2966, 2874, 1605, 1463, 1412, 1400, 1374, 1285, 1175, 797, 
784 cm
-1
. 
 
Anal. Calc.  C11H14ClN3  C, 59.06; H, 6.31; N, 18.78; found C, 58.88; H, 6.11; N, 18.70 
 
MP: 121-125 ºC 
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2-Chloro-1-phenyl-1H-imidazo[4,5-b]pyridine (49h)  
 Following general procedure D, 6.3 mL of THF, diisopropylamine (0.44 mL, 
3.16 mmol) were added, then cooled to -78 °C (CO2/acetone) and, n-BuLi (1.43 
mL, 2.15M, 3.08 mmol) was added slowly, the reaction mixture stirred for 1h and 1-phenyl-1H-
imidazo[4,5-b]pyridine
74
 (300 mg, 1.54  mmol) was added as a solution in 3.1 mL of THF. The 
reaction mixture was stirred for 50 min at which time hexachloroethane (729 mg, 3.08 mmol) 
was added at -78°C as a solution in 1.7 mL of THF. The reaction mixture was stirred 1 h at -78 
°C, warmed to RT over 0.5 h.  At this time the reaction was quenched with 2 mL of NH4Cl(aq), 
diluted with 10 mL of H2O and poured into 12 mL of EtOAc. The layers were separated, and the 
aqueous layer was extracted with EtOAc (3 x 8 mL). The combined organic layers were washed 
with brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified on a silica gel column (4.5 cm x 12 cm) eluting with 4% MeOH / CH2Cl to give 219 mg 
of a brown solid. (63%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.59 (dd, J = 3.9 Hz, 1.8 Hz, 1H), 7.63-7.59 (m, 3H), 7.50 (dd, 
J = 8.1 Hz, 1.5 Hz, 1H), 7.45-7.42 (m, 2H), 7.23 (dd, J = 8.1 Hz, 4.8 Hz, 1H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 154.1, 145.8, 143.8, 133.9, 130.2, 129.9, 129.3, 127.2, 119.2, 
118.3 
 
FT-IR: (NaCl, thin film) ν = 1610, 1502, 1462, 1415, 1369, 1308, 1109, 777, 700 cm-1. 
 
Anal. Calc. C12H8ClN3 C, 62.76; H, 3.51; 18.30; found C, 62.49; H, 3.60; N, 18.08 
 
MP: 192-194 º C 
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General Procedure E: SNAr 
4-(1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-
yl)morpholine (50a)  
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added 
2-chloro-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine (49a)
77
 
(100 mg, 0.33 mmol), followed by 0.66 mL of n-BuOH, morpholine (35 μL, 0.40 mmol) and 
Na2CO3(s) (53 mg, 0.50 mmol). The reaction tube was equipped with a cold-finger condensor and 
placed in a pre-heated 120 °C oil-bath. After 18h TLC indicated consumption of the chloroazole 
the reaction mixture was cooled to RT, diluted with 2 mL MeOH, filtered through a Celite plug 
and concentrated in vacuo. The crude material was applied to a silica gel column (2.5 cm x 12 
cm), eluting with 3% MeOH / CH2Cl2 to give 113 mg of a brown solid. (97%) 
1
H NMR: (300 MHz, CDCl3) δ= 8.31 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.20 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 6.92 (dd, J = 7.8 Hz, 5.1 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 2.1 Hz, 1H), 6.34 
(dd, J = 8.4 Hz, 2.4 Hz, 1H), 5.07 (s, 2H), 3.82-3.75 (m, 10H), 3.34 (t, J = 4.8, 4H) 
 
13
C NMR: (105.9 MHz, CDCl3) δ= 160.8, 159.7, 157.6, 155.3, 143.5, 128.6, 127.3, 116.4, 
116.3, 115.9, 104.3, 98.7, 66.4, 55.5, 55.4, 50.4, 43.4 
FT-IR: (NaCl, thin film) ν = 2963, 2852, 1615, 1589, 1510, 1453, 1414, 1370, 1306, 1263, 
1157, 1118, 1032, 781 cm
-1
. 
 
HRMS Calc (C19H22N4O3)Na
+
: 377.1584, Found: 377.1580 
 
MP: 125-128 ºC 
1-(2,4-dimethoxybenzyl)-2-(piperidin-1-yl)-1H-imidazo[4,5-b]pyridine (50b)  
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Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-
1H-imidazo[4,5-b]pyridine (49a) (100mg, 0.33 mmol) was added to 
an oven-dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, 
piperidine (33 μL, 0.40 mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was equipped 
with a cold-finger condenser and placed in a pre-heated 120 °C oil-bath. After 18h TLC showed 
consumption of the chloroazole, the reaction mixture was cooled to RT, diluted with 2 mL of 
MeOH, filtered through a Celite plug and concentrated in vacuo. The crude material was applied 
to a silica gel column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to give 109 mg of a 
brown oil. (94%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.25 (dd, J = 5.0 Hz, 1.5 Hz, 1H), 7.13 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 6.86 (dd, J = 7.8 Hz, 5.0 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 2.3 Hz, 1H), 6.33 
(dd, J = 8.4 Hz, 2.3 Hz, 1H), 5.03 (s, 2H), 3.81 (s, 3H), 3.75 (s, 3H), 3.28 (app t, J = 5.5 Hz, 4H), 
1.72 – 1.52 (m, 6H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ=160.9, 160.6, 157.6, 155.6, 143.0, 128.7, 127.3, 116.2, 116.2, 
115.9, 104.1, 98.6, 55.4, 55.4, 51.2, 43.6, 25.6, 24.3 
 
FT-IR: (NaCl, thin film) ν = 2938, 2850, 1614, 1588, 1528, 1299, 1270, 1208, 1157, 1033, 776, 
732 cm
-1
. 
 
HRMS Calc (C20H24N4O2)Na
+
: 375.1791, Found: 375.1784 
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1-(2,4-dimethoxybenzyl)-N,N-diethyl-1H-imidazo[4,5-b]pyridin-2-
amine (50c) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-
1H-imidazo[4,5-b]pyridine (49a) (100 mg, 0.33 mmol) was added to 
an oven-dried 25 mL sealed tube, followed by 0.66 mL of n-BuOH, diethylamine (41 μL, 0.40 
mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was sealed and placed in a pre-heated 
120 °C oil-bath. After 36h TLC showed consumption of the chloroazole, the reaction mixture 
was cooled to RT, diluted with 2 mL of MeOH, filtered through a Celite plug and concentrated 
in vacuo. The crude material was applied to a silica gel column (2.5 cm x 12 cm), eluting with 
3% MeOH / CH2Cl2 to give 115 mg of a brown solid. (85%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.26 (dd, J = 5.0 Hz, 1.5 Hz, 1H), 7.15 (dd, J = 7.8 Hz, 1. Hz, 
1H), 6.86 (dd, J = 7.8 Hz, 5.0 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 2.3 Hz, 1H), 6.34 
(dd, J = 8.4 Hz, 2.3 Hz, 1H), 5.05 (s, 2H), 3.38 (s, 3H), 3.76 (s, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 160.6, 160.1, 157.6, 155.8, 143.0, 128.9, 127.2, 116.4, 115.8, 
115.6, 104.1, 98.6, 55.5, 55.5, 45.6, 43.7, 13.2 
 
FT-IR: (NaCl, thin film) ν = 2970, 2936, 1615, 1589, 1509, 1412, 1209, 1157, 1121, 1029, 776 
cm
-1
. 
 
Anal. Calc. C19H24N4O2 C, 67.04; H, 7.11; N, 16.08; found C, 67.42; H, 7.00; N, 16.08 
 
MP: 115-117 º C 
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N-benzyl-1-(2,4-dimethoxybenzyl)-N-methyl-1H-imidazo[4,5-
b]pyridin-2-amine (50d) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-
1H-imidazo[4,5-b]pyridine (49a) (100 mg, 0.33 mmol) was added to 
an oven-dried 25 mL Schlenk tube, followed by 0.66 mL of n-
butanol, N-benzylmethylamine (52  μL, 0.40 mmol) and Na2CO3 (53 mg, 0.50 mmol). The 
reaction tube was equipped with a cold-finger condenser and placed in a pre-heated 120 °C oil-
bath. After 18h TLC showed consumption of the chloroazole, the reaction mixture was cooled to 
RT, diluted with 2 mL of MeOH, filtered through a Celite plug and concentrated in vacuo. The 
crude material was applied to a silica gel column (2.5 cm x 12 cm), eluting with 3% MeOH / 
CH2Cl2 to give 115 mg of a brown oil. (90%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.26 (dd, J = 5.0 Hz, 1.1 Hz, 1H), 7.32 – 7.18 (m, 5H), 7.16 
(dd, J = 7.8 Hz, 1.3 Hz, 1H), 6.88 (dd, J = 7.8 Hz, 5.0 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.41 (d, 
J = 2.2 Hz, 1H), 6.32 (dd, J = 8.4 Hz, 2.3 Hz, 1H), 5.08 (s, 2H), 4.48 (s, 2H), 3.73 (s, 3H), 3.66 
(s, 3H), 2.94 (s, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 160.8, 160.5, 157.4, 155.4, 143.0, 137.2, 129.1, 128.5, 127.6, 
127.4, 127.1, 116.1, 115.9, 115.7, 104.1, 98.5, 57.4, 55.4, 55.2, 43.7, 39.1 
 
FT-IR: (NaCl, thin film) ν = 2950, 2850, 1614, 1590, 1540, 1453, 1413, 1303, 1269, 1209, 
1157, 1033, 777, 734 cm
-1
. 
 
HRMS Calc (C23H24N4O2)Na
+
: 411.1791, Found: 411.1782 
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N-benzyl-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine-2-
amine (50e) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-
1H-imidazo[4,5-b]pyridine (49a)
 
(100 mg, 0.33 mmol) in a solution 
of 0.66 mL of n-butanol, benzylamine (44 μL, 0.40 mmol), and sodium carbonate (53 mg, 0.50 
mmol) were added, immersed in a 120°C pre-heated oil-bath for 16h, allowed to cool to rt over 
0.5 h, diluted with 2 mL of MeOH, filtered through a Celite plug,  and concentrated in vacuo. 
The crude product was purified on a silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH / 
CH2Cl to give 105 mg of an off white solid. (85%) 
 
1
H NMR: (300 MHz, CDCl3) δ=8.22 (dd, J = 5.1 Hz, 1.2 Hz, 1H), 7.45 (dd, J = 7.8 Hz, 1.2 Hz, 
1H), 7.36-7.32 (m, 5H), 7.14 (d, J = 8.4 Hz, 1H), 6.95 (dd, J =7 .8 Hz, 5.4 Hz, 1H), 9.66 (dd, J = 
8.1 Hz, 2.4 Hz, 1H), 6.38 (d, J = 2.4, 1H), 5.66 (br s, 1H), 4.96 (s, 2H), 4.75 (d, J= 5.4, 2H), 3.78 
(s, 3H), 3.46 (s, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.3, 157.5, 156.4, 156.1, 142.1, 138.7, 130.9, 128.8, 128.4, 
127.8, 127.7, 115.7, 114.6, 113.7, 105.1, 98.9, 55.8, 55.2, 47.6, 40.6 
 
FT-IR: (NaCl, thin film) ν = 3250, 2937, 1617, 1565, 1509, 1454, 1419, 1356, 1266, 1209, 
1157, 1031 
 
Anal. Calc. C22H22N4O2 C, 70.57; H, 5.92; N, 14.96; found C, 70.25; H, 6.21; N, 15.07  
 
MP: 85-88 ºC 
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N-butyl-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-amine 
(50f) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100 mg, 0.33 mmol) was added to an 
oven-dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, n-butyl amine (39 μL, 0.40 
mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was equipped with a cold-finger 
condenser and placed in a pre-heated 120 °C oil-bath. After 18h TLC showed consumption of the 
chloroazole, the reaction mixture was cooled to RT, diluted with 2 mL of MeOH, filtered 
through a Celite plug and concentrated in vacuo. The crude material was applied to a silica gel 
column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to give 107 mg of a light brown 
solid. (96%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.08 (dd, J = 5.1 Hz, 1.4 Hz, 1H), 7.28 (dd, J = 7.7 Hz, 1.4 Hz, 
1H), 6.99 (d, J = 8.3 Hz, 1H), 6.82 (dd, J = 7.7 Hz, 5.1 Hz, 1H), 6.43 (d, J = 2.3 Hz, 1H), 6.38 
(dd, J = 8.3 Hz, 2.3 Hz, 1H), 5.33 (t, J = 5.0 Hz, 1H), 4.90 (s, 2H), 3.80 (s, 3H), 3.73 (s, 3H), 
3.49 (app q, J = 7.0 Hz, 2H), 1.58 (pent, J = 7.2 Hz, 2H), 1.32 (sex, J = 7.4 Hz, 2H), 0.88 (t, J = 
7.3 Hz, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.1, 157.6, 156.3, 141.5, 130.2, 127.6, 115.6, 114.3, 113.5, 
104.9, 98.8, 55.5, 55.4, 43.0, 40.5, 31.8, 20.0, 13.8 
 
FT-IR: (NaCl, thin film) ν = 2958, 1612, 1562, 1509, 1458, 1419, 1266, 1209, 1157, 1123, 
1036, 771 cm
-1
. 
 
Anal. Calc. C19H24N4O2 C, 67.04; H, 7.11; N, 16.46; found C, 66.89; H, 7.55; N, 16.18 
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MP: 91 – 93 ºC 
1-(2,4-dimethoxybenzyl)-N-isopropyl-1H-imidazo[4,5-b]pyridin-2-
amine (50g)  
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100 mg, 0.33 mmol) was added to an oven-
dried 25 mL sealed tube, followed by 0.66 mL of n-BuOH, isopropylamine (34 μL, 0.40 mmol) 
and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was equipped with a cold-finger condenser 
and placed in a pre-heated 120 °C oil-bath. After 36h TLC showed consumption of the 
chloroazole, the reaction mixture was cooled to RT, diluted with 2 mL of MeOH, filtered 
through a Celite plug and concentrated in vacuo. The crude material was applied to a silica gel 
column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to give 98 mg  of a brown solid. 
(92%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.11 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.32 (dd, J = 7.1 Hz, 1.5 Hz, 
1H), 7.06 (d, J = 8.3 Hz, 1H), 6.84 (dd, J = 7.7 Hz, 5.1 Hz, 1H), 6.45 (d, J = 2.3 Hz, 1H), 6.41 
(dd, J = 8.3 Hz, 2.4 Hz, 1H), 5.14 (br d, J = 7.3 Hz, 1H), 4.90 (s, 2H), 4.24 (oct, J = 6.5 Hz, 1H), 
3.85 (s, 3H), 3.75 (s, 3H), 1.25 (d, J = 6.5 Hz, 6H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.4, 157.7, 156.5, 155.7, 141.6, 130.7, 127.7, 115.8, 114.3, 
113.6, 105.1, 99.0, 55.6, 55.6, 45.0, 40.7, 23.4 
 
FT-IR: (NaCl, thin film) ν = 2968, 1600, 1559, 1508, 1419, 1265, 1208, 1157, 1130, 1034, 913, 
769, 732 cm
-1
. 
 
Anal. Calc. C18H22N4O2 C, 66.24; H, 6.79; N, 17.17; found C, 66.35; H, 6.94; N, 16.91 
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MP: 85 – 87 ºC 
  
166 
 
(R)-2-(1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]166yridine-2-
ylamino)-3-phenylpropan-1-ol (50i) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100mg, 0.33 mmol) was added to an 
oven-dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, D-
phenylalaninol (61 mg , 0.40 mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was 
equipped with a cold-finger condenser and placed in a pre-heated 120 °C oil-bath. After 18h 
TLC showed consumption of the chloroazole, the reaction mixture was cooled to RT, diluted 
with 2 mL of MeOH, filtered through a Celite plug and concentrated in vacuo. The crude 
material was applied to a silica gel column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to 
give 70 mg of a brown oil. (51%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.07 (dd, J = 5.1 Hz, 1.4 Hz, 1H), 7.28 – 7.22 (m, 1H), 7.20 – 
7.10 (m, 5H), 6.89 (d, J = 9.0 Hz, 1H), 6.83 (dd, J = 7.7 Hz, 5.2 Hz, 1H), 6.37 – 6.30 (m, 2H), 
4.78 (AB d, 16.2 Hz, 2H), 4.36 (br t, J = 4.8 Hz, 1H), 3.90 (dd, J = 11.4 Hz, 3.7 Hz, 1H), 3.79 – 
3.70 (m, 4H), 3.64 (s, 3H), 3.03 (d, J = 6.9 Hz, 2H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.2, 157.8, 156.3, 155.1, 140.6, 138.2, 130.4, 129.5, 128.5, 
128.0, 126.4, 115.3, 114.6, 114.6, 104.8, 98.9, 64.3, 56.8, 55.5, 55.5, 41.1, 37.4 
 
FT-IR: (NaCl, thin film) ν = 2669 (br), 1609, 1561, 1509, 1458, 1421, 1290, 1266, 1209, 1157, 
1037, 912, 742 cm
-1
. 
 
HRMS Calc (C24H26N4O3)Na
+
: 441.1897, Found: 441.1893 
 
[α]D = 26.5° (0.33, MeOH) 
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N-allyl-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-amine 
(50j) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100mg, 0.33 mmol) was added to an oven-
dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, allyl amine (30 μL, 0.40 mmol) and 
Na2CO3 (53 mg, 0.50 mmol). The reaction tube was equipped with a cold-finger condenser and 
placed in a pre-heated 120 °C oil-bath. After 18 h TLC showed consumption of the chloroazole, 
the reaction mixture was cooled to RT, diluted with 2 mL of MeOH, filtered through a Celite 
plug and concentrated in vacuo. The crude material was applied to a silica gel column (2.5 cm x 
12 cm), eluting with 3% MeOH / CH2Cl2 to give 70 mg of a pale-brown solid. (72%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.17 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.34 (dd, J = 7.5 Hz, 1.2 Hz, 
1H), 7.09 (d, J = 8.1 Hz, 1H), 6.86 (dd, J = 7.5 Hz, 5.1 Hz, 1H), 6.47-6.38 (m, 2H), 6.08-5.93 
(m, 1H), 5.38 (br t, J = 5.4 Hz, 1H), 5.26-5.10 (m, 2H), 4.96 (s, 2H), 4.19 (t, J = 5.4 Hz, 2H), 
3.81 (s, 3H), 3.77 (s, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.3, 157.6, 156.5, 156.1, 142.0, 135.0, 130.6, 127.7, 116.6, 
115.8, 114.5, 113.7, 105.0, 99.0, 55.6, 45.9, 40.8 
 
FT-IR: (NaCl, thin film) ν = 2917, 2849, 1610, 1561, 1509, 1459, 1420, 1289, 1266, 1130, 
1035, 772 cm
-1
. 
 
Anal. Calc. C18H20N4O2 C, 66.65; H, 6.21; N, 17.27; found C, 66.26; H, 6.58; N, 17.03 
 
MP: 86 – 88 ºC 
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(S)-1-(2,4-dimethoxybenzyl)-N-(1-phenylethyl)-1H-imidazo[4,5-
b]pyridin-2-amine (50k) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100mg, 0.33 mmol) was added to an oven-
dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, (S)-1-
phenylethylamine (49 μL, 0.40 mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was 
equipped with a cold-finger condenser and placed in a pre-heated 120 °C oil-bath. After 24 h 
TLC showed consumption of the chloroazole, the reaction mixture was cooled to RT, diluted 
with 2 mL of MeOH, filtered through a Celite plug and concentrated in vacuo. The crude 
material was applied to a silica gel column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to 
give 80 mg of a while solid. (62%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.14 (dd, J = 5.1 Hz, 1.4 Hz, 1H), 7.40 – 7.19 (m, 6H), 7.10 (d, 
J = 8.1 Hz, 1H), 6.86 (dd, J = 7.7 Hz, 5.1 Hz, 1H), 6.45 – 6.35 (m, 2H), 5.62 (d, J = 6.9, Hz, 1H), 
5.34 (pent, J = 6.7 Hz, 1H), 4.93 (AB d, J = 16.0 Hz, 2H), 3.76 (s, 3H), 3.54 (s, 3H), 1.61 (d, J = 
6.8 Hz, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.2, 157.5, 156.5, 155.4, 143.8, 141.9, 130.9, 128.6, 127.5, 
127.4, 126.5, 115.7, 114.4, 113.6, 105.0, 98.8, 55.5, 55.2, 52.3, 40.6, 22.2 
 
FT-IR: (NaCl, thin film) ν = 2971, 2935, 1597, 1558, 1509, 1418, 1209, 1127, 1033, 701 cm-1. 
 
HRMS Calc (C23H24N4O2)Na
+
: 411.1791, Found: 411.1787 
 
MP: 121-122 ºC 
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[α]D = 41.0° (0.55, MeOH) 
(R)-1-(2,4-dimethoxybenzyl)-N-(1-phenylethyl)-1H-imidazo[4,5-
b]pyridin-2-amine (50l) 
Following general procedure E, 2-chloro-1-(2,4-dimethoxybenzyl)-1H-
imidazo[4,5-b]pyridine (49a) (100 mg, 0.33 mmol) was added to an 
oven-dried 25 mL Schlenk tube, followed by 0.66 mL of n-BuOH, (R)-1-
phenylethylamine (49 μL, 0.40 mmol) and Na2CO3 (53 mg, 0.50 mmol). The reaction tube was 
equipped with a cold-finger condenser and placed in a pre-heated 120 °C oil-bath. After 24 h 
TLC showed consumption of the chloroazole, the reaction mixture was cooled to RT, diluted 
with 2 mL of MeOH, filtered through a Celite plug and concentrated in vacuo. The crude 
material was applied to a silica gel column (2.5 cm x 12 cm), eluting with 3% MeOH / CH2Cl2 to 
give 83 mg of a brown oil. (65%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.11 (dd, J = 5.1 Hz, 1.3 Hz, 1H), 7.40 – 7.19 (m, 6H), 7.08 (d, 
J = 8.1 Hz, 1H), 6.84 (dd, J = 7.7 Hz, 5.1 Hz, 1H), 6.43 – 6.36 (m, 2H), 5.72 (d, J = 7.0, Hz, 1H), 
5.30 (pent, J = 6.8 Hz, 1H), 4.91 (AB d, J = 16.1 Hz, 2H), 3.74 (s, 3H), 3.53 (s, 3H), 1.59 (d, J = 
6.8 Hz, 3H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 161.2, 157.4, 156.4, 155.4, 143.8, 141.8, 130.9, 128.6, 127.5, 
127.4, 126.5, 115.7, 114.3, 113.5, 105.0, 98.9, 55.5, 55.2, 52.3, 40.5, 22.2 
 
FT-IR: (NaCl, thin film) ν = 2970, 2934, 1599, 1508, 1419, 1266, 1208, 1033, 700 cm-1. 
 
HRMS Calc (C23H24N4O2)Na
+
: 411.1791, Found: 411.1787 
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MP: 122-123 ºC 
 
[α]D = -39.2° (0.71, MeOH) 
4-(1-benzyl-1H-imidazo[4,5-b]pyridine-2-yl)morpholine (51)  
Following general procedure E, 1-benzyl-2-chloro-1H-imidazo[4,5-
b]pyridine (49b) (81 mg, 0.33 mmol), 0.66 mL of n-BuOH, morpholine 
(34 μL, 0.40 mmol) and sodium carbonate (53 mg, 0.50 mmol) were 
added, immersed in a 120°C pre-heated oil-bath for 16h, allowed to cool to rt over 0.5 h, diluted 
with 2 mL of MeOH, filtered through a Celite plug,  and concentrated in vacuo. The crude 
product was purified on a silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH in CH2Cl 
to give 84 mg of a yellow-white solid. (88%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.34 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.34- 7.30 (m, 3H) 7.13-7.10 
(m, 2H), 6.94 (dd, J = 7.8 Hz, 5.1 Hz, 1H), 5.21 (s, 2H), 3.78 (t, J = 4.5 Hz, 4H), 3.34 (t, 4.8, 4H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ=159.6, 155.1, 143.7, 135.3, 129.3, 128.5, 128.1, 125.9, 116.6, 
116.6, 66.3, 50.6, 48.1 
 
FT-IR: (NaCl, thin film) ν =2964, 2917, 2855, 1624, 1584, 1527, 1451, 1414, 1368, 1274, 1116, 
1007, 855, 779, 734, 698 
 
HRMS Calc (C17H18N4O)Na
+
: 317.1372, Found: 317.1372 
 
MP:  123- 125.5 º C  
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4-(1-(4-Methoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-
yl)morpholine52)
74
  
Following general procedure E, 0.66 mL of n-BuOH, 2-chloro-1-(4-
methoxybenzyl)-1H-imidazo[4,5-b]pyridine (49c) (90 mg, 0.33 mmol), sodium carbonate (52 
mg, 0.495 mmol), and morpholine (0.034 mL, 0.396 mmol) were added to a 25 mL Schlenk 
tube. The reaction mixture was stirred overnight at which time TLC showed consumption of the 
starting material. The reaction mixture was warmed to room temperature, diluted with 2 mL of 
MeOH, filtered through Celite and concentrated in vacuo. The crude product was purified on a 
silica column (2.5 cm x 12 cm) eluting with 4% MeOH/ CH2Cl2 to give 79 mg as a gold solid. 
(74%) 
 
1
H NMR (300MHz, CDCl3) = 8.32 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.19 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 7.03 (d, J =  9 Hz, 2H), 6.93 (dd, J = 7.8 Hz, 4.8 Hz, 1H), 6.83 (d, J = 8.7 Hz, 2H), 5.26 (s, 
2H), 3.78 (t, J = 9.3 Hz, 4H), 3.75 (s, 3H), 3.34 (t, J = 9.3 Hz, 4H) 
 
13
C NMR (75.4 MHz, CDCl3) =159.6, 159.33, 155.2, 143.7, 128.4, 127.3, 127.2, 116.5, 114.6, 
66.4, 55.36, 50.6, 47.6 
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4-(1-(4-Fluorobenzyl)-1H-imidazo[4,5-b]pyridin-2-yl)morpholine(53)  
Following general procedure E, 0.66 mL of n-BuOH (0.5M), 2-chloro-1-
(4-fluorobenzyl)-1H-imidazo[4,5-b]pyridine (49d) (88 mg, 0.33 mmol), 
sodium carbonate (52 mg, 0.50 mmol), and morpholine (34 μL, 0.40 
mmol) were added to a 25 mL Schlenk tube. The reaction mixture was stirred overnight and TLC 
showed consumption of the starting material. The reaction mixture was warmed to room 
temperature, diluted with 2 mL MeOH, filtered through Celite and concentrated in vacuo. The 
crude product was purified on a silica column (2.5 cm x 12 cm) eluting with 4% MeOH/ CH2Cl2 
to give 54 mg as a gold solid. (52%) 
 
1
H NMR (300 MHz, CDCl3) = 8.35 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.19 (dd, J = 7.8 Hz, 1.2 Hz, 
1H), 7.13-6.94 (m, 5H), 5.18 (s, 2H), 3.79 (t, J = 9.3 Hz, 4H), 3.34 (t, J = 9.6 Hz, 4H) 
 
13
C NMR (75.4 MHz, CDCl3) = 162.4 (d, J = 247.1 Hz), 159.6, 155.3, 143.9, 131.1 (d, J = 3.3 
Hz), 128.3, 127.8 (d, J = 8.1 Hz), 116.7, 116.3 (d, J = 21.7 Hz), 66.4, 50.7, 47.5 
 
19
F NMR (282.4 MHz, CDCl3) δ= -114.1  -114.2 (m) 
 
FT-IR (NaCl, thin film) ν = 3004, 2855, 2344, 1718, 1608, 1508, 1411, 1274 cm-1. 
 
Anal. Calc. C17H17FN4O C, 65.37; H, 5.49; N, 17.94; found C, 65.13; H, 5.83; N, 18.04 
 
MP: 157-159 C 
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4-(1-(Cyclohexylmethyl)-1H-imidazo[4,5-b]pyridin-2-yl)morpholine 
(54)  
Following general procedure E, 0.66 mL of n-BuOH, 2-chloro-1-
(cyclohexylmethyl)-1H-imidazo[4,5-b]pyridine (49e) (82 mg, 0.33 mmol), 
sodium carbonate (52 mg, 0.50 mmol), and morpholine (0.034 mL, 0.40 mmol) were added to a 
25 mL Schlenk tube. The reaction mixture was stirred overnight and TLC showed consumption 
of the starting material. The reaction mixture was warmed to room temperature, diluted with 2 
mL MeOH, filtered through Celite and concentrated in vacuo. The crude product was purified on 
a silica column (2.5 cm x 12 cm) eluting with 4% MeOH/ CH2Cl2 to give 87 mg as a brown 
solid. (88%) 
1
H NMR (300 MHz, CDCl3) = 8.29 (dd, J = 4.8 Hz, 1.2 Hz, 1H), 7.42 (dd, J = 7.8 Hz, 1.5 Hz, 
1H), 6.99 (dd, J = 8.1 Hz, 5.1 Hz, 1H), 3.82 (t, J = 9 Hz, 4H), 3.78 (s, 2H), 3.32 (t, J = 9.3 Hz, 
4H), 1.89-1.82 (m, 1H), 1.65-1.58 (m, 3H), 1.44-1.40 (m, 2H), 1.11- 1.01 (m, 3H), 0.97-0.85 (m, 
2H) 
 
13
C NMR (75.4 MHz, CDCl3) = 159.8, 154.9, 143.4, 127.8, 116.8, 116.4, 66.5, 50.7, 50.6, 37.3, 
30.8, 26.1, 25.5 
 
FT-IR (NaCl, thin film) ν = 2928, 2366, 2344, 1773, 1637, 1419, 1116 cm-1 
 
HRMS Calc (C17H24N4O)Na
+
: 323.1842, Found: 323.1840 
 
MP: 112-117 C 
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4-(1-isopropyl-1H-imidazo[4,5-b]pyridine-2-yl)morpholine (55) 
Following general procedure E, 2-chloro-1-isopropyl-1H-imidazo[4,5-
b]pyridine (49f) (65.2 mg, 0.33 mmol), 0.66 mL of n-butanol, morpholine 
(34 μL, 0.40 mmol)and sodium carbonate (53 mg, 0.50 mmol) were added, immersed in a 120°C 
pre-heated oil-bath for 16 h, allowed to cool to RT over 0.5 h, diluted with 2 mL of MeOH, 
filtered through a Celite plug,  and concentrated in vacuo. The crude product was purified on a 
silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH / CH2Cl to give 65 mg of an off white 
solid. (79%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.32 (dd, J = 8.1 Hz, 1.5 Hz, 1H), 7.61 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 6.99 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 4.63-4.54 (m, 1H), 3.86 (t, J = 4.6 Hz, 4H), 3.30 (t, 4.6 
Hz, 4H), 1.54 (d, J = 6.9 Hz, 6H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 159.2, 155.5, 143.3, 125.6, 118.5, 116.2, 66.4, 51.4, 48.0, 
21.3 
 
FT-IR: (NaCl, thin film) ν= 3250, 2961, 2855, 1520, 1453, 1413, 1372, 1281, 1112, 963, 853, 
806, 791 cm
-1 
 
HRMS Calc (C13H18N4O)Na
+
: 269.1373, Found: 269.1371 
 
MP: 138-141 ºC 
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4-(1-neopentyl-1H-imidazo[4,5-b]pyridine-2-yl)morpholine (56)  
Following general procedure E, 2-chloro-1-neopentyl-1H-imidazo[4,5-
b]pyridine (49g) (74.5 mg, 0.33 mmol), 0.66 mL of n-BuOH, morpholine 
(34 μL, 0.40 mmol) and sodium carbonate (53 mg, 0.50 mmol) were added, immersed in a 
120°C pre-heated oil-bath for 16 h, allowed to cool to RT over 0.5 h, diluted with 2 mL of 
MeOH, filtered through a Celite plug,  and concentrated in vacuo. The crude product was 
purified on a silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH / CH2Cl to give 57 mg 
of a yellow/white solid. (63%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.35 (dd, J = 4.8 Hz, 1.2 Hz, 1H), 7.51 (dd, J = 8.1 Hz, 4.5 Hz, 
1H), 7.05 (dd, J = 7.8 Hz, 1.8 Hz, 1H) 3.86-3.82 (m, 6H), 3.27 (t, J = 4.5 Hz, 4H), 0.92 (s, 9H)  
 
13
C NMR: (75.4 MHz, CDCl3) δ=159.9, 154.3, 143.5, 128.1, 118.1, 116.7, 66.5, 54.8, 51.0, 
35.4, 28.8 
 
FT-IR: (NaCl, thin film) ν = 2963, 2856, 1520, 1452, 1413,  1368, 1280, 1116, 977, 784 cm-1 
 
HRMS Calc (C15H22N4O)Na
+
: 297.1686, Found: 297.1681 
 
MP: 121-126 °C 
  
176 
 
4-(1-phenyl-1H-imidazo[4,5-b]pyridine-2-yl)morpholine (57)  
Following general procedure E, 2-chloro-1-phenyl-1H-imidazo[4,5-
b]pyridine (49h) (65 mg, 0.33 mmol), 0.66 mL of n-butanol, morpholine 
(34 μL, 0.40 mmol)and sodium carbonate (53 mg, 0.50 mmol) were added, immersed in a 120 
°C pre-heated oil-bath for 16 h, allowed to cool to RT over 0.5 h, diluted with 2 mL of MeOH, 
filtered through a Celite plug,  and concentrated in vacuo. The crude product was purified on a 
silica gel column (2.5 cm x 12 cm) eluting with 4% MeOH in CH2Cl to give 76 mg of an off 
white solid. (82%) 
 
1
H NMR: (300 MHz, CDCl3) δ= 8.31 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.59-7.54 (m, 2H), 7.48-7.43 
(m, 3H), 7.27-7.24 (m, 1H), 6.93 (dd, J = 8.1 Hz, 5.1 Hz, 1H), 3.65 (t, J = 4.5 Hz, 4H), 3.32 (t, J 
= 4.5 Hz, 4H) 
 
13
C NMR: (75.4 MHz, CDCl3) δ= 157.8, 155.1, 143.7, 136.5, 130.4, 129.1, 128.8, 125.8, 116.3, 
115.7, 66.2, 48.9 
 
FT-IR: (NaCl, thin film) ν = 1594, 1533, 1496, 1450, 1413, 115, 953, 859, 769, 700 cm-1 
 
HRMS Calc (C16H16N4O)Na
+
: 303.1216, Found: 303.1213 
 
MP: 129-132 ºC  
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7.5 TOTAL SYNTHESIS OF PENTOSIDINE 
2-chloro-1-(2,4-dimethoxybenzyl)-1H-imidazo[4,5-b]pyridine (49a) 
To a flame-dried 50 mL round-bottom flask equipped with a stirbar 
was added 14.9 mL THF and diisopropylamine (1.07 mL, 7.64 mmol). 
The reaction was cooled to -78 °C (CO2/acetone) and, n-BuLi (3.82 
mL, 1.95M in hexanes, 7.46 mmol) was added slowly, the reaction stirred for 1h and 1-(4-
methoxybenzyl)-1H-imidazo[4,5-b]pyridine (25c) (1.0 g, 3.73 mmol) was added as a solution in 
7.5 mL THF. The reaction mixture was stirred for 1 h at which time hexachloroethane (1.77 g, 
7.46 mmol) was added at -78°C as a solution in 4 mL THF. The reaction was stirred 2 h at -78 
°C, warmed to RT and stirred for an additional 0.5 h. At this time the reaction was quenched 
with 2 mL of NH4Cl(aq), diluted with 10 mL of H2O and poured into 20 mL of EtOAc. The layers 
were separated, and the aqueous layer was extracted with EtOAc (3 x 15 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. 
The crude product was purified on a silica gel column (4.5 cm x 12 cm) eluting with 3% MeOH / 
CH2Cl2 to give 920 mg of an oil that solidified to a brown solid when triturated with 5 mL of 
MeCN. (81%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (dd, J = 4.8 Hz, 1.5 Hz, 1H), 7.59 (dd, J = 8.1 Hz, 1.5 Hz, 
1H), 7.14 (dd, J = 8.1 Hz, 4.8 Hz, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.45 – 6.39 (m, 2H), 5.33 (s, 
2H), 3.79 (s, 3H), 3.78 (s, 3H) 
  
178 
 
 
13
C NMR (75.4 MHz, CDCl3) δ = 161.2, 158.1, 153.9, 144.9, 144.3, 129.9, 128.0, 118.5, 118.2, 
114.8, 104.2, 98.5, 55.4, 55.3, 43.8 
 
FT-IR: (NaCl, thin film) ν = 2939, 2837, 1612, 1589, 1509, 1463, 1410, 1371, 1278, 1210, 
1033, 834, 781 cm
-1
. 
 
HRMS (ESI) Calc (C15H14ClN3O2)Na+:, 326.0667 Found: 326.0671 
 
MP: 92 – 93 °C 
 
Rf (4% MeOH / CH2Cl2): 0.24 
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Boc-Orn(H)-OtBu-HCl (83)
209,210
 
To a flame-dried 100mL RBF equipped with a stirbar was added 20 mL 
CH2Cl2 and 20 mL t-BuOH followed by Boc-Orn(Z)-OH (3.66 g, 10 mmol).  N,N’-diisopropyl-
t-butylisourea (12 mL, 50 mmol) was added and the reaction was placed in a 50 °C pre-heated 
oil-bath. A precipitate quickly formed, and the reaction was stirred for 24h then cooled to RT. 
The reaction was filtered through a Celite plug and concentrated in vacuo. The crude product 
was passed through a silica gel plug (150 mL coarse fritted funnel) to remove diisopropyl urea, 
eluting with 30% EtOAc / hexanes to give Boc-Orn(Z)-OtBu in quantitative yield.  This material 
was taken on without further purification. 
The Boc-Orn(Z)-OtBu prepared above was dissolved in 38 mL EtOH and added to a 100 
mL RBF equipped with a stirbar. 1N HCl(aq) (11 mL) was added followed by 5 % palladium on 
carbon (717 mg). H2(g) was bubbled through the reaction for 5 min before a H2(g) balloon was 
equipped. The reaction mixture was stirred for 24h at which point TLC analysis indicated 
consumption of the Cbz protected amine. The reaction was filtered through a Celite plug eluting 
with EtOH. The filtrate was concentrated in vacuo, giving a sticky oil, which was triturated with 
methyl tert-butyl ether (50 mL), and concentrated in vacuo to give 83 as a white fluffy solid (3.2 
g, 98%). 
 
1
H NMR (300 MHz, CD3OD) δ= 3.97 (m, 1H), 2.94 (t, J = 7.2, 2H), 1.92 – 1.65 (m, 4H), 1.48 
(s, 9H), 1.45 (s, 9H). 
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 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-5-(1-(2,4-
dimethoxybenzyl)-1H-imidazo[4,5-b]pyridin-2-
ylamino)pentanoate (82) 
To an oven-dried 50 mL Schlenk tube equipped with a stirbar 
was sequentially added Boc-Orn(H)-OtBu·HCl 83 (2.14 g, 6.58 mmol) followed by chloro-azole 
49a (1.0 g, 3.29 mmol) and 6.6 mL n-BuOH. Diisopropylethylamine (2.87 mL, 16.45 mmol) was 
added and the reaction vessel was then equipped with a cold-finger under a positive pressure of 
Ar(g) and immersed in a 120°C pre-heated oil-bath. After 18 h TLC analysis indicated complete 
consumption of chloro-azole 83. The reaction mixture was cooled to RT, diluted with 15 mL of 
EtOAc and, concentrated in vacuo to give a purple semi-solid which was purified on a silica gel 
column, eluted with 4% MeOH / CH2Cl2 to give a 3:1 mixture of the desired product with 
cyclized Orn 88. The product was further purified on a silica gel column eluted with 3% EtOH / 
CH2Cl2 to give 1.6 g of 82 as a yellow solid (87%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.18 (dd, J = 5.1 Hz, 1.5 Hz, 1H), 7.31 (d, J = 7.5 Hz, 1H), 7.01 
(d, J = 8.1 Hz, 1H), 6.87 (dd, J = 7.8 Hz, 5.1 Hz, 1H), 6.48 (d, J = 2.4 Hz, 1H), 6.42 (dd, J = 8.4 
Hz, 2.1 Hz, 1H), 5.34 (brs, 1H), 5.13 (brd, J = 8.1 Hz, 1H), 4.96 (s, 2H), 4.22 – 4.05 (m, 1H), 
3.86 (s, 3H), 3.78 (s, 3H), 3.66 – 3.55 (m, 2H), 1.90 – 1.60 (m, 4H), 1.43 (s, 9H), 1.41 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 171.8, 161.2, 157.7, 156.5, 156.2, 142.0, 130.0, 127.6, 115.7, 
114.4, 113.6, 104.9, 99.0, 82.1, 79.8, 55.7, 55.5, 53.7, 43.0, 40.7, 30.8, 28.4, 28.0, 25.6, 22.6 
 
FT-IR: (NaCl, thin film) ν = 2977, 2935, 1710, 1612, 1561, 1509, 1420, 1366, 1265, 1155, 
1042, 772 cm
-1
. 
 
HRMS (ESI) Calc (C29H41N5O6)Na+: 578.2949, Found: 578.2958 
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MP: 69 – 74 °C 
 
Rf (4% MeOH / CH2Cl2): 0.23 
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 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-6-iodohexanoate (63)
160
 
To a flame-dried 50 mL RBF equipped with a stirbar was added alcohol 
86
160
 (470 mg, 1.55 mmol) in 15.5 mL benzene, followed by imidazole (264 mg, 3.87 mmol), 
triphenylphosphine (1.02 g, 3.87 mmol) and iodine (787 mg, 3.1 mmol). After 0.5 h the alcohol 
was judged to be consumed by TLC analysis and the reaction was quenched by the addition of 5 
mL saturated aqueous sodium thiosulfate solution. The layers were separated, and the organic 
layer washed with saturated aqueous sodium thiosulfate solution (2 x 20 mL), water (20 mL) and 
brine (20 mL). The reaction was then dried over sodium sulfate, concentrated in vacuo and 
purified on a silica gel column (2.5 cm x 12 cm) eluting with 5% EtOAc / hexanes to give 583 
mg of a colorless oil (91%). 
 
1
H NMR (300 MHz, CDCl3) δ= 5.05 (br d, J = 7.8 Hz, 1H), 4.14 (q, J = 6.6 Hz, 1H), 3.15 (t, J = 
6.9 Hz, 1.93 – 1.45 (s, 9H), 1.41 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 171.8, 155.4, 82.0, 79.7, 55.7, 32.9, 31.9, 28.4, 28.1, 26.0, 6.6 
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Protected Pentosidine (89) 
To an oven-dried 25 mL Schlenk tube equipped with a 
stirbar was added 82 (250 mg, 0.45 mmol) as a solution in 
1.25 mL THF followed by iodide 63 (205 mg, 0.50 mmol) 
which was added as a solution in 1 mL THF. The reaction vessel was then equipped with a cold-
finger condenser under a positive pressure of Ar(g) and immersed in a 75 °C pre-heated oil-bath. 
The reaction was stirred for 72 h at which time TLC showed consumption of 82. The reaction 
was cooled to RT, diluted with 3 mL CH2Cl2 and concentrated in vacuo to give 390 mg of a 
brown solid. The crude product was purified on a silica gel column (4.5 cm x 12 cm) eluting with 
5% MeOH / CH2Cl2 to give 300 mg of a pale yellow semi-solid (69%). 
 
1
H NMR (300 MHz, CDCl3) δ= 8.15 – 7.85 (m, 2H), 7.61 (d, J = 7.5 Hz, 1H), 7.46 (d, J = 8.1 
Hz, 1H), 7.05 (t, J = 7.2 Hz, 1H), 6.30 (d, J = 8.1 Hz, 1H), 6.26 (s, 1H), 5.31 (br s, 2H), 5.15 (br 
d, J = 7.5 Hz, 1H), 5.08 (br d, J = 6.9 Hz, 1H), 4.44 (br s, 2H), 4.10 – 3.90 (m, 2H), 3.73 – 3.45 
(m, 2H), 3.65 (s, 3H), 3.62 (s, 3H), 2.00 – 1.32 (m, 10 H), 1.27 (br s, 36H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 171.4, 171.3, 161.2, 158.9, 157.9, 155.3, 155.2, 151.0, 132.6, 
131.7, 131.2, 118.5, 114.4, 113.8, 104.6, 98.4, 81.6, 79.3, 55.5, 55.2, 53.4, 52.6, 42.7, 42.5, 41.5, 
31.9, 29.7, 28.6, 28.0, 27.7, 25.2, 22.0 
 
FT-IR: (NaCl, thin film) ν = 2959, 1586, 1507, 1463, 1296, 1203, 1157, 1114, 1037, 814 cm-1. 
 
HRMS (ESI) Calc (C44H69N6IO10)Na+: 991.4035, Found: 991.4035 
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Pentosidine (18)
154
 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar 
was added protected pentosidine (89) (242 mg, 0.25 mmol) as a 
solution in 2.25 mL TFA & 0.25 mL H2O.  The reaction 
mixture was equipped with a cold-finger condenser and placed in a 75°C pre-heated oil-bath for 
48 h. The reaction mixture was then cooled to RT and concentrated in vacuo. The crude product 
was partitioned between H2O (2 mL) and CH2Cl2 (2 mL). The layers were separated and the 
aqueous layer was washed with CH2Cl2 (2 x 2 mL) and concentrated in vacuo to give a clear 
brown oil. This oil was dissolved in H2O (2 mL) and applied to a C18 silica-gel plug, eluting 
with H2O. The eluent was concentrated in vacuo to give 112 mg of a white solid. (91%) 
 
1
H NMR (300 MHz, D2O) δ= 8.69 (br s, 1H, NH) 7.93 (d, J = 6 Hz, 1H), 7.74 (d, J = 7.2 Hz, 
1H), 7.49 (brs, 1H), 7.20 (t, J = 6.6 Hz, 1H), 4.51 (t, J = 6.3 Hz, 2H), 3.81, (m, 1H), 3.73 (m, 
1H), 3.54 (m, 2H), 2.12 – 1.65 (m, 8H), 1.60 – 1.30 (m, 2H) 
 
13
C NMR (150.9 MHz, D2O) δ = 174.6, 174.5, 162.9 (q, JC-F = 36.2), 159.6, 151.5, 132.1, 131.7, 
119.6, 116.4 (q, JC-F = 291 Hz), 115.2, 54.6, 54.5, 53.2, 42.1, 30.0, 28.3, 27.8, 24.6, 21.5 
 
αD
23
 λ 589 nm (c = 0.3, MeOH): 15.9° 
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7.6 IMIDAZO[4,5-C]PYRIDINES 
tert-Butyl 4-chloropyridin-3-ylcarbamate (92)
211, 212
 
To a flame-dried 1 L three-neck round-bottom flask equipped with a stirbar, 
internal temperature probe, and a gas-inlet adaptor was added tert-butyl pyridin-
3-ylcarbamate (91)
213
 (10.0 g, 51.5 mmol) and 258 mL Et2O (0.2 M). TMEDA (18.5 mL, 123.6 
mmol) was then added and the reaction cooled to -78 °C in a CO2 / acetone bath.  n-BuLi (55.7 
mL, 2.22 M in hexanes, 124 mmol) was added slowly over 20 min, and the reaction mixture was 
allowed to warm to -10 °C. The reaction was then stirred at -20 °C – -10°C for 2 hours; and then 
returned to -78 °C. Hexachloroethane (17.1 g, 72.1 mmol) was added as a solution in 72 mL 
Et2O (1 M) via addition funnel over 20 min, and the reaction mixture was allowed to warm to 
room temperature overnight. Upon consumption of the starting material as indicated by TLC the 
reaction was quenched with saturated NH4Cl (aq) (250 mL) and diluted with EtOAc (200 mL). 
The layers were separated, and the organic washing with 0.1 M HCl (aq) (200 mL), followed by 
brine (250 mL). The organic layer was then dried over MgSO4, filtered, concentrated in vacuo, 
and purified on a silica gel column (6 cm x 15 cm) eluting with 30% EtOAc / hexanes to give 7.7 
g of a light brown solid. (65%). 
 
1
H NMR (300 MHz, CDCl3) δ= 9.36 (s, 1H), 8.20 (d, J = 5.4 Hz, 1H), 7.28 (d, J = 5.1 Hz, 1H), 
6.83 (br s, 1H), 1.55 (s, 9H) 
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 4-chloro-N-propylpyridin-3-amine (94g) 
To an oven-dried 100 mL round-bottom flask equipped with a stirbar was added 3-
amino-4-chloropyridine (2.0 g, 15.56 mmol), EtOAc (24 mL), propionaldehyde 
(1.23 mL, 17.1 mmol) and trifluoroacetic acid (2.31 mL, 31.1 mmol). The reaction mixture was 
stirred for 5 min at which time sodium triacetoxyborohydride (3.95 g, 18.7 mmol) was added in 
three portions over 2 min. The reaction mixture was stirred for 15 min, at which time TLC 
indicated consumption of the starting material. The reaction mixture was poured into 100 mL 
saturated NaHCO3(aq) and diluted with EtOAc (25 mL). The layers were separated and the 
aqueuous layer was extracted with EtOAc (25 mL). The combined organic layers were washed 
with brine (25 mL), dried over MgSO4, filtered, and concentrated in vacuo to give a yellow oil 
which was purified on a silica gel column (2.5 cm x 12 cm) eluting with 30% EtOAc / hexanes to 
give 2.05 g of 94g as a yellow oil. (77%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.01 (s, 1H), 7.84 (d, J = 5.1 Hz, 1H), 7.15 (d, J = 5.1 Hz, 1H), 
4.18 (br s, 1H), 3.19 (m, 2H), 1.69 (sext, J = 7.5 Hz, 2H), 1.02 (t, J = 7.5 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 140.7, 138.3, 133.4, 127.4, 123.8, 45.2, 22.6, 11.6 
 
FT-IR: (NaCl, thin film) ν = 2992, 2938, 1543, 1471, 973, 855, 691 cm-1. 
 
EA: Calculated: C8H11ClN2, C; 56.31; H, 6.50; N, 16.42; found C, 56.66; H, 6.39; N, 16.65 
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General Procedure F: Copper Coupling 
To an oven-dried Schlenk tube equipped with a stirbar was added copper (I) iodide (10 
mol %), potassium phosphate (2 eq.) and tert-butyl 4-chloropyridin-3-ylcarbamate (1 eq). The 
reaction tube was evacuated and refilled with Ar(g). trans-1,2-diaminocyclohexane (L2) (20 
mol%) was added, followed by 1,4-dioxane (0.5 M), and the haloarene (1.1 eq). The reaction 
mixture was degassed with three vacuum / Ar(g) purge cycles, equipped with a cold-finger 
condenser and placed in a pre-heated 110 °C oil-bath. The reaction is stirred overnight, cooled to 
RT and diluted with EtOAc. The reaction mixture was then filtered through a Celite plug, 
concentrated in vacuo and purified by silica gel column chromatography using the indicated 
solvent system to give the desired product. 
 
General Procedure G: Deprotection 
To an oven-dried round-bottom flask equipped with a stirbar was added the Boc-
protected compound (1 eq) followed by dichloromethane (0.5 M). The reaction was cooled to 0 
°C and trifluoroacetic acid (0.17 M) was added. The reaction mixture was allowed to warm to 
RT and stirred overnight until TLC indicated consumption of the starting material. The reaction 
was then poured into sat. NaHCO3 (aq), diluted with dichloromethane and the layers were 
separated. The aqueous layer was extracted with dichloromethane. The combined organic layers 
were dried over sodium sulfate, decanted and concentrated in vacuo to give the product. 
Purification, if needed was performed as indicated. 
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tert-Butyl 4-chloropyridin-3-yl(phenyl)carbamate (95h) 
Following general procedure F, Copper (I) Iodide (83 mg, 0.44 mmol), 
potassium phosphate (1.86 g, 8.74 mmol) and tert-butyl 4-chloropyridin-3-ylcarbamate (94) (1.0 
g, 4.37 mmol),  L2 (0.11 mL, 0.87 mmol), and iodobenzene (0.54 mL, 4.81 mmol) were 
combined in an oven-dried 50 mL Schlenk tube. The reaction was stirred at 110 °C for 18h, 
cooled to RT, diluted with EtOAc and filtered through a Celite plug. The crude mixture was 
purified on a silica gel column, eluting with 30% EtOAc / hexanes to give 1.28 g of a light 
yellow solid. (96%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (s, 1H), 8.39 (d, J = 5.4 Hz, 1H), 7.39 (d, J = 5.1 Hz, 1H), 
7.33 – 7.21 (m, 4H), 7.18 – 7.11 (m, 1H), 1.42 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 152.8, 151.6, 148.9, 143.0, 141.3, 137.3, 128.9, 126.0, 125.6, 
125.0, 82.1, 28.1 
 
FT-IR: (NaCl, thin film) ν = 2977, 2932, 1719, 1559, 1319, 1160, 691 cm-1. 
 
EA: Calculated: C16H17ClN2O2, C; 63.05; H, 5.62; N, 9.19; found C, 63.29; H, 5.45; N, 9.39 
 
MP: 85 – 87 °C 
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tert-butyl 4-chloropyridin-3-yl(pyridin-2-yl)carbamate (SI5) 
Following general procedure F, Copper (I) Iodide (83 mg, 0.44 mmol), 
potassium phosphate (1.86 g, 8.74 mmol) and tert-butyl 4-chloropyridin-3-ylcarbamate (94) (1.0 
g, 4.37 mmol),  L2 (0.11 mL, 0.87 mmol), and 2-bromopyridine (0.46 mL, 4.81 mmol) were 
combined in an oven-dried 50 mL Schlenk tube. The reaction was stirred at 110 °C for 22h, 
cooled to RT, diluted with EtOAc and filtered through a Celite plug. The crude mixture was 
purified on a silica gel column, eluting with 20% EtOAc / hexanes to give 1.33 g of a white 
crystalline solid. (97%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.50 (s, 1H), 8.44 (d, J = 5.1 Hz, 1H), 8.19 (ddd, J = 0.9 Hz, 1.8 
Hz, 4.8 Hz, 1H), 7.89 (td, J = 0.9 Hz, 8.4 Hz, 1H), 7.69 (ddd, J = 2.1 Hz, 7.2 Hz, 8.4 Hz, 1H), 
7.41 (d, J = 5.4 Hz, 1H), 6.99 (ddd, J = 0.9 Hz, 4.8 Hz, 7.5 Hz, 1H), 1.41 (s, 9H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 153.7, 152.5, 152.0, 149.0, 147.9, 143.2, 137.6, 136.2, 124.7, 
120.0, 118.2, 82.7, 28.0 
 
FT-IR: (NaCl, thin film) ν = 2979, 2934, 1721, 1588, 1467, 1436, 1158, 1111, 845, 781 cm-1. 
 
EA: Calculated: C15H16ClN3O2, C; 58.92; H, 5.27; N, 13.74; found C, 58.61; H, 5.31; N, 13.86 
 
MP: 92 – 94 °C 
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4-chloro-N-phenylpyridin-3-amine (94h) 
Following general procedure G, tert-Butyl 4-chloropyridin-3-
yl(phenyl)carbamate (95h) (1.12 g, 3.67 mmol) was combined with dichloromethane (7.3 mL) 
and TFA (2.45 mL), and stirred 24h. The reaction mixture was poured into sat. NaHCO3 (aq), 
diluted with dichloromethane and the layers were separated. The aqueous layer was extracted 
with dichloromethane. The combined organic layers were dried over sodium sulfate, decanted 
and concentrated in vacuo to give the product as a tan microcrystalline solid. (732 mg, 97%) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.56 (s, 1H), 8.02 (d, J = 5.1 Hz, 1H), 7.39 – 7.31 (m, 2H), 7.28 
(d, J = 5.1 Hz, 1H), 7.21 – 7.17 (m, 2H), 7.15 – 6.95 (m, 1H), 5.98 (br s, 1H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 141.2, 140.5, 138.0, 137.6, 130.0, 129.8, 124.4, 123.7, 120.6 
 
FT-IR: (NaCl, thin film) ν = 3106, 3031, 1596, 1560, 1496, 1406, 1328, 1233, 1075, 816, 755, 
696 cm
-1
. 
 
EA: Calculated: C11H9ClN2, C; 64.56; H, 4.43; N, 13.69; found C, 64.86; H, 4.66; N, 13.86 
 
MP: 107 – 109°C 
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 N-(4-chloropyridin-3-yl)pyridin-2-amine (SI6) 
Following general procedure G, tert-butyl 4-chloropyridin-3-yl(pyridin-2-
yl)carbamate (SI5) (1.0 g, 3.27 mmol) was combined with dichloromethane (6.5 mL) and TFA 
(2.2 mL), and stirred 8h. The reaction mixture was poured into sat. NaHCO3 (aq), diluted with 
dichloromethane and the layers were separated. The aqueous layer was extracted with 
dichloromethane. The combined organic layers were dried over sodium sulfate, decanted and 
concentrated in vacuo to give the product as an off-white microcrystalline solid. (645 mg, 96%) 
 
1
H NMR (300 MHz, CDCl3) δ= 9.46 (s, 1H), 8.30 – 8.25 (m, 1H), 8.14 (d, J = 5.1 Hz, 1H), 7.57 
(ddd, J = 1.8 Hz, 7.2 Hz, 8.1 Hz, 1H), 7.31 (d, J = 5.1 Hz, 1H), 6.89 – 6.83 (m, 2H), 6.75 (br s, 
1H) 
 
13
C NMR (75.4 MHz, CDCl3) δ = 154.2, 148.3, 143.0, 142.0, 138.1, 134.8, 131.7, 124.2, 116.8, 
110.4 
 
FT-IR: (NaCl, thin film) ν = 3057, 1609, 1558, 1520, 1482, 1421, 1334, 1310, 771 cm-1. 
 
EA: Calculated: C10H8ClN3, C; 58.41; H, 3.92; N, 20.43; found C, 58.57; H, 3.98; N, 20.19 
 
MP: 122 – 123°C 
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4-chloro-N-(thiophen-3-yl)pyridin-3-amine (SI7) 
Following general procedure F, Copper (I) Iodide (83 mg, 0.44 mmol), 
potassium phosphate (1.86 g, 8.74 mmol) and tert-butyl 4-chloropyridin-3-ylcarbamate (94) (1.0 
g, 4.37 mmol),  L2 (0.11 mL, 0.87 mmol), and 3-bromothiophene (0.45 mL, 4.81 mmol) were 
combined in an oven-dried 50 mL Schlenk tube. The reaction was stirred at 110 °C for 22h, 
cooled to RT, diluted with EtOAc (10 mL) and filtered through a Celite plug to give the crude 
product which was purified on a silica gel column eluted with 20% EtOAc / Hexanes. 800 mg of 
the product was isolated as a mixture with tert-butyl 4-chloropyridin-3-ylcarbamate. This 
mixture was taken on as is to the next step. 
Following general procedure G, the crude coupled product was combined with dichloromethane 
(5.1 mL) and TFA (1.7 mL), and stirred 7h. The reaction was poured into sat. NaHCO3 (aq), 
diluted with dichloromethane and the layers were separated. The aqueous layer was extracted 
with dichloromethane. The combined organic layers were dried over sodium sulfate, decanted 
and concentrated in vacuo. This mixture was purified on a silica gel column, eluting with 20% 
EtOAc / hexanes to give the product as a white microcrystalline solid. (495 mg, 54% over two 
steps) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.41 (s, 1H), 7.97 (d, J = 5.1 Hz, 1H), 7.32 (dd, J = 3.0 Hz, 5.1 
Hz, 1H), 7.24 (d, J = 5.1 Hz, 1H), 6.98 (dd, J = 1.5 Hz, 5.1 Hz, 1H), 6.95 – 6.90 (m, 1H), 6.06 
(br s, 1H) 
13
C NMR (75.4 MHz, CDCl3) δ = 140.5, 138.6, 138.5, 136.6, 128.4, 126.1, 124.1, 123.7, 111.9 
FT-IR: (NaCl, thin film) ν = 3027, 1580, 1523, 1459, 1415, 1324, 1238, 1074, 825, 763 cm-1. 
EA: Calculated: C9H7ClN2S, C; 51.31; H, 3.35; N, 13.30; found C, 51.35; H, 3.50; N, 13.35 
MP: 110 – 111°C 
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 4-chloro-N-(thiophen-2-yl)pyridin-3-amine (SI8) 
Following general procedure F, Copper (I) Iodide (83 mg, 0.44 mmol), 
potassium phosphate (1.86 g, 8.74 mmol) and tert-butyl 4-chloropyridin-3-ylcarbamate (94) (1.0 
g, 4.37 mmol),  L2 (0.11 mL, 0.87 mmol), and 2-bromothiophene (0.47 mL, 4.81 mmol) were 
combined in an oven-dried 50 mL Schlenk tube. The reaction was stirred at 110 °C for 24h, 
cooled to RT, diluted with EtOAc and filtered through a Celite plug to give the crude product 
which was purified on a silica gel column eluted with 30% EtOAc / hexanes. 1.12 g of the 
product was isolated as a mixture with tert-butyl 4-chloropyridin-3-ylcarbamate. This mixture 
was taken on as is to the next step. 
Following general procedure G, the crude coupled product was combined with dichloromethane 
(7.2 mL) and TFA (2.4 mL), and stirred for18h. The reaction was poured into sat. NaHCO3 (aq), 
diluted with dichloromethane and the layers were separated. The aqueous layer was extracted 
with dichloromethane. The combined organic layers were dried over sodium sulfate, decanted 
and concentrated in vacuo. This mixture was purified on a silica gel column, eluting with 20% 
EtOAc / hexanes to give the product as a brown microcrystalline solid. (530 mg, 58% over two 
steps) 
 
1
H NMR (300 MHz, CDCl3) δ= 8.22 (s, 1H), 7.96 (d, J = 5.1 Hz, 1H), 7.20 (d, J = 5.1 Hz, 1H), 
7.07 (dd, J = 1.2 Hz, 5.7 Hz, 1H), 6.92 (dd, J = 3.9 Hz, 5.7 Hz), 6.88 – 6.82 (m, 1H), 6.11 (br s, 
1H) 
13
C NMR (75.4 MHz, CDCl3) δ = 142.3, 140.6, 139.6, 136.3, 127.8, 126.2, 123.8, 122.6, 122.1 
FT-IR: (NaCl, thin film) ν = 1574, 1543, 1496, 1438, 1408, 1320, 1159, 1073, 814, 696 cm-1. 
EA: Calculated: C9H7ClN2S, C; 51.31; H, 3.35; N, 13.30; found C, 51.36; H, 3.55; N, 13.25 
MP: 105 – 107°C 
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General Procedure H: Cyclization of 3-amino-4-chloropyridines 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was added Pd2(dba)3·CHCl3 (1 mol 
%), Me3(OMe)t-BuXPhos (5 mol %), K3PO4 (1.5 eq.) and the pyridine (1 eq.). The reaction 
vessel was evacuated under vacuum and refilled with Ar(g). t-BuOH (0.2 M) & formamide (1.5 
eq.) were then added via syringe and the reaction mixture was degassed by three vacuum/Ar(g) 
purge cycles. The reaction vessel was then equipped with a cold-finger condenser, and placed in 
a pre-heated 110 °C oil-bath and stirred for the specified time. Upon consumption of the pyridine 
(as judged by TLC analysis) the reaction was allowed to cool to RT, diluted with methanol, and 
passed through a Celite plug, washing with additional methanol. The crude product was 
concentrated in vacuo, and applied to a silica gel column, eluting with the specified eluent. 
 
3-benzyl-3H-imidazo[4,5-c]pyridine (96a)
214
 
4-Chloro-N-benzylpyridin-3-amine (88 mg, 0.4 mmol) was reacted 
following general procedure H for 4 h. The crude material was purified by 
flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a beige solid (70 
mg, 84%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.70 (d, J = 0.9 Hz, 1H), 8.43 (d, J = 5.4 Hz, 1H), 8.04 (s, 1H), 
7.70 (dd, J = 0.9 Hz, 5.4 Hz, 1H), 7.39 – 7.28 (m, 3H), 7.25 – 7.17 (m, 2H), 5.40 (s, 2H) 
 
MP: 134 - 135 °C 
  
195 
 
3-(2,5-dimethoxybenzyl)-3H-imidazo[4,5-c]pyridine (96b) 
4-chloro-N-(2,5-dimethoxybenzyl)pyridin-3-amine (112 mg, 0.4 
mmol) was reacted following general procedure H for 6.5 h. The crude 
product was purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the 
product as a beige solid (92 mg, 85%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.83 (d, J = 0.6 Hz, 1H), 8.38 (d, J = 5.4 Hz, 1H), 8.06 (s, 1H), 
7.65 (dd, J = 5.7 Hz, 0.9 Hz, 1H), 6.79 (app d, J = 1.5 Hz, 2H), 6.73 (app t, J = 1.5 Hz, 1H), 5.32 
(s, 2H), 3.75 (s, 3H), 3.68 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 153.6, 151.5, 138.8, 146.3, 141.8, 133.9, 131.8, 123.7, 116.2, 
115.0, 114.1, 111.7, 55.8, 55.8, 45.0 
 
FT-IR (NaCl, thin film) ν = 2968, 2936, 2878, 1650, 1610, 1492, 1461, 1383, 1309, 1264, 1211, 
907, 826 cm
-1
. 
 
EA: Calculated: C15H15N3O2, C; 66.90; H, 5.61; N, 15.60; found C, 66.79; H, 5.24; N, 15.59 
 
MP: 125 °C (decomposition) 
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3-Propyl-3H-imidazo[4,5-c]pyridine (96g) 
4-Chloro-N-propylpyridin-3-amine (68 mg, 0.4 mmol) was reacted following 
general procedure H for 6.5 h. The crude product was purified by flash column chromatography 
(3% MeOH in CH2Cl2) to yield the product as a beige solid (55 mg, 85%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.85 (s, 1H), 8.43 (d, J = 5.7 Hz, 1H), 7.98 (s, 1H), 7.69 (dd, J = 
5.4 Hz, 0.9 Hz, 1H), 4.21 (t, J = 6.9 Hz, 2H), 1.95 (sext, J = 7.2 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 149.0, 145.8, 141.9, 133.5, 131.7, 115.2, 47.4, 23.4, 11.4 
 
FT-IR (NaCl, thin film) ν = 2969, 2880, 1655, 1609, 1492, 1460, 1383, 1309, 1264, 1211, 1166, 
1126, 1027, 906, 825 cm
-1
. 
 
EA: Calculated: C9H11N3, C; 67.06; H, 6.88; N, 26.07; found C, 67.10; H, 6.99; N, 26.06 
 
MP: 75 - 78 °C 
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3-phenyl-3H-imidazo[4,5-c]pyridine (96h) 
4-Chloro-N-phenylpyridin-3-amine (82 mg, 0.4 mmol) was reacted following 
general procedure H for 6.5 h. The crude product was purified by flash column 
chromatography (3% MeOH in CH2Cl2) to yield the product as a beige solid (70 mg, 85%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.91 (s, 1H), 8.46 (d, J = 5.7 Hz, 1H), 8.19 (s, 1H), 7.72 (dd, J = 
0.6 Hz, 5.4 Hz, 1H), 7.61 – 7.41 (m, 5H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 149.1, 144.8, 142.5, 135.4, 134.2, 131.4, 130.3, 128.7, 123.8, 
115.2 
 
FT-IR (NaCl, thin film) ν = 3177, 1597, 1503, 1480, 1304, 1233, 761, 696 cm-1. 
 
EA: Calculated: C12H9N3, C; 73.83; H, 4.65; N, 21.52; found C, 73.80; H, 4.90; N, 21.28 
 
MP: 149 – 150 °C 
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7.7 REGIOSELECTIVE AMIDATION OF POLYCHLORINATED 
AMINOPYRIDINES 
2,5-Dichloro-N-(4-methoxybenzyl)pyridin-3-amine (101) 
To a flame-dried 50 mL RBF was added 3-amino-2,5-
dichloropyridine (1.0 g, 6.13 mmol), 10 mL ethyl acetate, p-
methoxybenzaldehyde (0.82 mL, 6.75 mmol). The mixture was 
allowed to stir until complete dissolution at which time trifluoroacetic acid (0.94 mL, 12.3 
mmol) was added as a single portion. After stirring for 2 min sodium triacetoxyborohydride 
(1.56 g, 7.4 mmol) was added portionwise. The reaction was stirred for 30 minutes at which time 
the chloropyridine was consumed by TLC; the reaction was quenched with 20% NaOH and the 
pH was adjusted to ~8 with NaOH(s). The layers were separated, the organic layer washed with 
brine, dried over MgSO4, filtered and concentrated in vacuo to give 1.87 g crude material which 
was recrystalized from 60 mL 2:1 Hexanes:Ethyl acetate to give 101 as a purple crystalline solid 
(1.68 g, 97%) 
1
H NMR (300 MHz, CDCl3) δ = 7.67 (d, J = 2.1 Hz, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 
8.7 Hz, 2H), 6.84 (d, J = 2.4 Hz, 1H). 4.79 (br s, 1H), 4.29 (d, J = 5.1 Hz, 2H), 3.82 (s, 3H) 
13
C NMR (75.4 MHz, CDCl3) δ = 159.7, 141.4, 135.3, 134.9, 132.0, 129.2, 129.0, 117.6, 114.8, 
55.7, 47.3 
FT-IR: (NaCl, thin film) ν = 3308, 1610, 1577, 1512, 1499, 1358, 1252, 1120, 1035 cm-1. 
HRMS (ESI) Calc (C13H12Cl2N2O): 283.0327, Found: 282.0327 
MP: 115 – 117 °C 
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2,6-Dichloro-N-(4-methoxybenzyl)pyridin-3-amine (102) 
To a flame-dried 100 mL RBF was added 3-amino,2,6-
dichloropyridine (2.5 g, 15.6 mmol), 24 mL of ethyl acetate, p-
methoxybenzaldehyde (2.08 mL, 17.1 mmol). The mixture was 
allowed to stir until complete dissolution at which time trifluoroacetic acid (2.31 mL, 31.1 
mmol) was added as a single portion. After stirring for 2 min sodium triacetoxyborohydride 
(3.96 g, 18.7 mmol) was added portionwise. The reaction was stirred for 30 minutes at which 
time the chloropyridine was consumed by TLC; the reaction was quenched with 20% NaOH and 
the pH was adjusted to ~8 with NaOH(s). The layers were separated, the organic layer was 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give 1.87 g crude 
material which was recrystalized from 20 mL 2:1 hexanes:EtOAc to give 102 as a white 
crystalline solid (2.93 g, 66%) 
 
1
H NMR (300 MHz, CDCl3) δ = 7.25 (d, J= 8.4 Hz, 2H), 7.05 (d, J= 8.4 Hz, 1H), 6.89 (d, J= 8.4 
Hz, 2H), 6.84 (d, J= 8.4 Hz, 1H), 4.31 (s, 2H), 3.81 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ =159.4, 139.9, 135.9, 134.9, 129.3, 128.5, 123.6, 120.7, 114.5, 
55.5, 47.3 
 
FT-IR: (NaCl, thin film) ν = 3366, 1584, 1487, 1095 cm-1. 
 
EA: Calc: C; 55.14, H: 4.27, N: 9.89. Found: C: 55.44, H: 4.34, N: 9.63 
 
MP: 60-63 C 
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6-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine 
(103) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was 
added Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (11.6 
mg, 0.02 mmol) K3PO4 (128 mg, 0.6 mmol) and the 2,5-Dichloro-N-(4-methoxybenzyl)pyridin-
3-amine (101) (113 mg, 0.4 mmol). The reaction vessel was evacuated under vacuum and 
refilled with Ar(g). 1,4-Dioxane and t-AmOH (10:1, 0.2 M) were then added via syringe and the 
reaction mixture was degassed by three vacuum/Ar(g) purge cycles. The reaction vessel was then 
equipped with a cold-finger, and placed in a pre-heated 110 °C oil-bath and stirred for 6.5 h. The 
reaction mixture was allowed to cool to RT, diluted with methanol, and passed through a Celite 
plug, washing with additional methanol. The crude material was concentrated in vacuo, and was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a beige 
solid (105 mg, 96%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.43 (d, J = 2.4 Hz, 1H), 8.11 (s, 1H), 7.52 (d, J = 2.4 Hz, 1H), 
7.10 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.24 (s, 2H), 3.76 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 159.9, 154.9, 146.1, 144.0, 128.8, 126.4, 126.2, 126.0, 118.2, 
114.7, 55.4, 49.3 
 
FT-IR (NaCl, thin film) ν = 3041, 3003, 2934, 2837, 1611, 1514, 1491, 1406, 1250, 1177, 1032, 
917 cm
-1
. 
 
EA: Calculated: C14H12ClN3O, C; 61.43; H, 4.42; N, 15.35; found C, 61.60; H, 4.72; N, 14.95 
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MP: 108 – 109 °C 
5-chloro-1-(4-methoxybenzyl)-1H-imidazo[4,5-b]pyridine 
(104) 
To an oven-dried 25 mL Schlenk tube equipped with a stirbar was 
added Pd2(dba)3·CHCl3 (4.1 mg, 0.004 mmol), XantPhos (11.6 mg, 0.02 mmol) K3PO4 (128 mg, 
0.6 mmol) and the 2,6-dichloro-N-(4-methoxybenzyl)pyridin-3-amine (102) (113mg, 0.4 mmol). 
The reaction vessel was evacuated under vacuum and refilled with Ar(g). 1,4-Dioxane and t-
AmOH (10:1, 0.2 M) were then added via syringe and the reaction mixture was degassed by 
three vacuum/Ar(g) purge cycles. The reaction vessel was then equipped with a cold-finger 
condenser, and placed in a pre-heated 110 °C oil-bath and stirred for the 6.5 h. The reaction 
mixture was allowed to cool to RT, diluted with methanol, and passed through a Celite plug, 
washing with additional methanol. The crude product was concentrated in vacuo, and was 
purified by flash column chromatography (3% MeOH in CH2Cl2) to yield the product as a brown 
solid (78 mg, 72%).  
 
1
H NMR (300 MHz, CDCl3) δ= 8.12 (s, 1H), 7.49 (d, J = 8.4 Hz, 1H), 7.15 – 7.10 (m, 3H), 6.85 
(d, J = 8.7 Hz, 2H), 5.29 (s, 2H), 3.78 (s, 3H) 
 
13
C NMR (75.4 MHz, CDCl3) δ= 160.0, 156.0, 146.0, 146.0, 128.9, 126.2, 125.1, 121.0, 118.6, 
114.7, 55.4, 49.6 
 
FT-IR (NaCl, thin film) ν = 2935, 2837, 1611, 1514, 1485, 1406, 1352, 1250, 1114, 1031, 920, 
807 cm
-1
. 
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EA: Calculated: C14H12ClN3O, C; 61.43; H, 4.42; N, 15.35; found C, 61.39; H, 4.43; N, 15.02 
 
MP: 98 – 100 °C 
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RESEARCH & LEADERSHIP SKILLS 
  Extensive experience in preparing and derivatizing heterocycles. 
 Experienced in keeping laboratory notebooks and in good laboratory practices. 
 Supervised and trained multiple undergraduate researchers. 
 Experienced with milligram to 100 gram multi-step organic lab synthesis. 
 Excellent in handling of air and moisture sensitive reactions, utilizing Schlenk techniques as well 
as glove box experience. 
 Experienced in high-throughput parallel reaction and purification techniques.  
 Analytical techniques: MS, TLC, LC/MS, GC/MS, NMR, IR, Elemental Analysis. 
 Purification techniques: TLC, HPLC, flash chromatography, distillation, recrystallization. 
 Experienced in maintaining laboratory instrumentation including: GC, Glove Box and Solvent 
purification systems. 
 Literature searching using Scifinder Scholar, Reaxys, and Web of Science. 
 Computer skills, including: Chemdraw, CaCHE, Spartan, Microsoft Office 
 Trained in chemical safety procedures 
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